var title_f16_55_17264="Bacterial tracheitis";
var content_f16_55_17264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bacterial tracheitis: Endoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 352px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFgAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5coooqhhRRRQAUUUUAFFFFABRRRSbsIKUUAE9ATRgj+E/lU3ASg9aDnvTkXLdCR3prTcdhtO2e9S+UuPmGD2Fa+l+HdS1Ir9js3dW6M3FJzjHdlQpyqfCrmEVPbmpDHjHOB6mu/t/h1eRAf2hcxQ8ZKryf0rZ0/wTpcJHnrJOfXtWE8VCOzO2nltWdm9DylYdw4JLduKsR2FzKB5VtKfcLmvZ00WyhP7i0hXHHIpk0ZiyEUKf9kVj9ctqjthlS2kzymDw5qc7AJZuc9yMVoReCtdlGVsRj1zXoUMsgJ3O3FaVrdvgAu2PrWX1yTepqsqpR6s8wPgXXQObHJ+tQSeD9ajJBsmOPSvcreTKBS/HXBNLsBbO4D05qXiph/ZlHzPAJ/DeqxklrCUj1C1Qk067hJEsEi49VNfR0lq+3duIyOKzprDzAS6qwHqtaxxkkhPKqTXuyaPntlKcMMEdajbc59AK91uNG064X9/ZQsfUcE1j6h4J0m5Uvbo8D+ucirWKj1OaeUSXwO54+VIIHrTvK967+6+Hd4xzZ3Ecx67OhrnNX8O6ppblbyzdMd15GK2VWD2ZxVsHWp7xMAA7tuaVlCnnn6VO0agnbww6huoqOUEAZGc9Ditlpqcj03Ivp0opdp/unP0oIx1GKOYYlFFFUIKKKM0xhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUhBTgvApACegzUgBwBjmjRjCMYVuacp35HPFPgR2cAJkN7Zru/Cvw81HVUW5uyLOzz0b75/CsqlSEPiNKVCdV2ivmcPb2ss8nlxRNLKegUda7XQPh3ql2BPef6LBnksecfSvWNH8PadoShNKgBcdZZAGY+/tVyaMu7EkkD17mvPqY1vSKPXw+AjDWT1OS0nwvo+lYK24uZAfvyjj8q3icIFjjWNcYAUYFRXLIrYYdT2q5DgpuYggdM1yc0pPc9SNKMVojPaF2YBmPIOTVV3VG+9trRuLmJeAd3fiufuWaW5wAcZ6U72OiEbluaUhc5LCqTuWlJPIzVpkyhTjOODVaSMIcdj3qWWoiOqmZQnQ84qeBWAPHTio7cAPwMn1rSigYJyDuP5UJjtYqyuyn5Rz65qa1uZCwMjHg9Kc1sQQCTnqKFtizAD6mmHKjbsrpS4DncO1W12uHYBSe+axre0cKOQCv51fs2AVlcEt0BpNmUoroU7uMCVlIGfaozbN5H19ulX2i7uBn1q0IQ3yKMgildrUNlYyYbQlRgcg4yB1qSVAE2TYkjHVWANaEQ8oBWbBB4pHsxKSxOSelJSuHkcfqPhXR9XkPmwtbyE8PGK47XfhrqVnul00LeQAn5U+/j1xXr32MBgrHpU8Vu0LBlLAr0wa2hiZQ2OSvhqdVao+YpbWaG4MM0bRuOqsORVWRGZxgZX+9X0lrvh/T9bRl1CBDIfuyRja4+pry3xZ8PNQ0gCaxJu7PrhOoHuK76WLhLSWh41fLJw1p6nnrJtGc0yrcsTBmVlYMv3lI6VEAnXaMV1pt6o8yzvYhxRTipwTjjNJVJgJRRQBTAKKWkpjCiiigAooooAKKRs44pVzjmgAooooAKKKWk3YQlFLnntUkadmABI4zSuh2YsaMOTtAPTJ61r+H9CvdavBHYReYCPmbHyr9TW54L8G3OvlJ5wbawU/NI3X6L9a9n0XTbTTLb7LpsapBjBPdj61x1sV7K8Y7nfhME6j5p7GF4R8D6foSQzSIl1fAZLHlUPt71225mIDOWJ65HWlii2hWPYcVNJ8sW7OAB0ryHVc5O7PZhTjCyiiDC7ScYY8CligVt4PpVN333C/NhQeMVuW0I27s9fbrU83Y25eU5LW7JxCzpgBefc1jwXzbDGzYIHNeg3MIeNgVHzcYx0riL/AExo55CpwS3HuKqE9TopSUtGVZCXh3Ade9UGiCMWBOfWtHd5Sqr4P4VWkGSc4wemK0bOiKFQ5K8ZzUgQM/3QRTrVASvt1FaENorDg8deKQPQZYRxRy/Oo2/SppruEkqq9OOBUd0qqu1N/wCAqFE3LlgVHXApbha+o4zrnAz9cdKcv3v3fTuTTRgnABNTeQ7AbScU+gmWIGAJXPQVpWsMbplx78VUtLQO5VsAY61et08sbWb5c8N1qTKROlvG2RjjtntVuKzjLA5HA7VlXErQcpKCuO561VbV5kXcseB0qNTPlky9qVptHyPjHOcVQEjBBhyMcVYMpnUMz/Meg/rTDZyRgksCo5FS7l+TLEKgY3MGJ9auvHuGVAPGTisC+aRI0ZTgd8d61tNu98eMYkxgGk30M5Re5KkGWU7cH6Vbgh2OSpOO47GpQQy8kcd/WnB/lIwB7002jKTOL8ZeAtL8QwGWLy7LUcZEicK59GrwjxBoN/oF61tqkJUg4EijKtX07eTHYyr8wrldYs4NWhe01GHzLcg/VD6g110MRKm+VvQ5sRgoV1fZnzjIrFcDpURBU4Ndx4z8GXXh8rJGfPspAWWVBynsa4x8EIx5A4JNexSaqL3T56rRlRkoyRB3pe1O2tnpxTSCDzVt3MhKKDRTiO4UUUVQBRRRQAUUUGgA70UgINLSEFHbjr6UAZ6VKqAhWJ+opSGhyqqJuY5b0967zwP4ON+Uv9UXZagjbG3VvYVX8FeFlvGF/qKbYM/KnTdXqtp87rGqhY1ACgdhXn4jEcr5Y7nrYLA29+ZqWsax26RxIqQJgLGOgrXs4lZ/lTaB696y1bYoCgk54NbVgGbAcZY+navMnLVu561rIvKg2j5BxWTqjujFcDpwO1dDFGNnIrO1SzEjBjnA9Kxj3YU2r+8YFohmmUDjHoK6uEMkK8L8oHOaq21gsSh40BB65qcZBwRgU3oOc+Z6EV5KCTz0rnbkJJIwJ6Vpag2S6A8ms9rYtIqMCfWiEnc2pK2rMSa3yWwGb8KpeS24BsjANddeWojhIiXkH7xNYtvYS3F4Sd2wfeIFa3Z0wmilY28kk2ApC46mt1IlRQoOCfarHkbBhBlV4zjFCR7mBGeKd7dQcrlKW3JfG2kWDcNuQcD0xV64KLxzu9RUWHxkfN7UX7E8zI7awhXuOtXDDCo4bj2FVEBAYMME9BQGIXGwjHOT3pIWrZLcMCiqo+U8g1VuPOyAjEKBnFOO9gCw2jtzTLrz44NwVm57U07vUqxQnuWQgPEWx1NS22oW5G2WMqCOh71lySymTdKjAVGbhMj5OfcUuuhpy3R0UF1bZBi6+hrRe4XAz0I6elcZHIAgKsUbPNbVi0t0gQNkDv60nFsznBLU2BbLOoIVSOvWrltbLHjaATj8qr6ejxj5geeDWtbKpH/1qye+hyzlZ2GBW2lQM5quIJGfkn6VrCLGGAo28Zxx600u5ncx5bMg5AOah+yqh+cYB56VuvHI44xiqdzbtszIfpiqsHN5nO30O6KSEr5sL5yjDg57CvHfHngiTSXk1DTFM1ix+dVGTD9a9pnRlkJGfao2TdG0bqzROCrxkfK4PrW9CtKm9Nia1CGIhyzPlosA2MNgfeJ7VHLkPzg5GRj0r0X4i+D102Z9S0pC1jISHT+KI/4V566BenSvbpTjVjzQPmsRQlQnySRCaKOV7UE55NaowDvRSAg0tABRRRTGFFFFIQgXFLRR3pNgPhGW9QOuOtdd4G8MtrVwk9ypS2hbkHjd7VleGdGm1vVILSEfITl26YXvmvctK06CyhWC2hCwxjAJ7+9c2KrqnG0dz0cFhfaPnlsJHaLhVWMLEgAVR0ArT0+2CvvXAXv61ZhgBjBz8p6DFX7C2GenGa8Vy11PdTsrDbeDPHlnb2OK2rOEDjGMjNEEagYB5WrUZYn5fvdqxbu7kt3BX2Z3A7fUVIQzBMxgqeCT1FPTaibmHJ655yajlmRjjdhh29aCLagwCgxjt0qrdPsRgOuKlQtkyDq3Bz2rOupSx6fKDjNTcuK1M6VizZPIByTVhCc+YxAT+lU7mbB+YBVA/OmfbvN+VcbeM1UTp5GzRWF7pyEzt9T0xUl3FFbWwCrt3e/SprO4UxRqq7UH3iPWnXECzXB3YKjtnitloibtOzKMCp5BBJ6Va8mP7KCMbgpxjvT50iiiOVAPTANYTX72sjBPmHYZzSsy4rm2LTWjBAZcDPPvSKjKQUHA7mqf2u5uzyNq1r2MbMgRzn2xQtC5LlWpRaKUybmQbT3pZmXyWQDcF4FbEloSQGyBjtVSa1iSJ9pyxOKZEZps5q7djGqjnB6U6DW5bNQkkWY+mCelbH9k+cSXx9cVzuq28cN4Y87gO3rTWhtdPQg1PUo548rHtbvWahDgNz+NXZbNZWHlIVHenDT2C438fSquappIoqpcZ6c9q1NDvktrhElHyk9aa+msqqNwIqubVWypyNp4I7UpPsTJpqx6PYtDPCHQrjNai24jQKwGevFeZ6bf3OnylFYtGecYrvdK1JLsKGJJ2854xU8tjgrU3Fk07lQVxwD1qaHB27iAoqaaCIhHX73bnrVaY+WVDY60mrGCd9C0CiAkYNZl26kjJ9sU4TOzMMcCozgygMmSfepbHy2KkkAZ/T6VVubc8EZP44rc8s5O4YBqhcqgUqQS2aSuncpSsctfRht8dwivA4w6nvXinjrw22hXTT248yymJKkfwn0Ne66grbORyK5zU7S3v7SW1vhmOQY+h7GujD1fZSstmGIw8a9Ple58+SqFQcfjUf41t+ItJl0bU3t5VHlK3yuf4hWRJuUvwMA4r3lNNXifKTpypPkaIgMUtFJVCFoowdue1FMYUUuKSkK4H7pPoKlWEyFVjVmZiFAHcmmRkKct0rsfAGkm6vvtsuPKhb5cjqaiq+VXNaNJ1aigj0HwVoQ0XTEV1DXNxhpGxyo7Cu2tLJVmJIzuGRzVHTIs5YoXzjIzXS28a4Q4IdegxXhVp802fRRjyRUUEVqnl9cY6ZqxaQlc5xhuhFHyiQBzgVrWkCsm7jk1zNts0bsiOOLC8nH8zSRhgpccYqa4xCPl+96VAysNh7detS9CY6g8w8sgsSQc81CMO+/ALdqftBDMelRu6rGdo5HIqbs0VguZAoEecZBrlLq9m80oCQq+netyeZnJXjOfxrGvIcyDZgjvQtWdFOMb6lCbzpkO8tj3p+mW75IHzZPQ1oxwrKEIJ461fgthCNzAAE8bRW/KkbOdlZE9rEI4gvY8kVVvJi23y22gc8d6suzkbccetQ3dsGSPHQDqKDJavUx57iVnBdmCnipWe3SMZHzHuamS1HzA/hUFxaZjLMMcYqk9NTb3ehAb2NZ41U4HtXQWuqwQrt/iHoK5qHSn/wBdI3A6E1ftYxu4HUY5ouugppM1v7XLz54AIxir1tZG4jLkjnkE1zuoeTb5JkUEdR3rJn8T/Z1MSyvtHTBoUXJnM4a+6dxeD7NETLKo4x1rnZrezdi7zB2znFcRqfiGS5JRXYj1LVSg1OWL5hKc+mc5rXkLXu9T0ETWcSFSAB+tV0Mcr7oipHYE1xh1XzT87Djk81LHrFsm3LkEH1o9mWpo7H7M/wA7l1J6bapSQMsRbketZEXiC35aOQ+YeOelSf22WQCRgwpOCjuCnclacLKGyc9DWrY3LPIGiO1x6Vz813BON2CD6Zp9ldscBPlIPNKye5crSWx39trc5jCSpkjjpVkXW9A+Pu881i2EgZVEi4YrgHrmta2iTaHZuMY5rNrU5nCKexZhIYFl78mpU2+Yueuai8tVIVGxnvVuOHHzE5I6GpMZbFnYGJ29BWTeId4wBuNbKyBlYsOfQVQu15DAYA5NNkR31Oev4WfO0cVzl/CoT7hY9M12MyHll+7jpXPakjsxKsNtQt9TphKzOG8VaMms6Y0KgG7gUtGTzkeleNvGyNJHKCDk5/2T6GvoJA8c/mKMFeeR1rzb4naGtldR6lZp+5uQTJkcK/cV6uErK/s29zzMywvMnVhujz4UYoK4O3uKWvS1PBD+HHaik60U0IdTT1pCcClU5GapK7sTYns4HubmOCPO5zjivZdDtBY2ttaIPlQAtx1PvXn3gazzdvdsSfLwFPqa9M04ZwW5Ytk152LqNvlie5gaVvfZ2mjRZjzjJ6V00UQQcDjFc5pDMixnGATzmuit2DJIVIOOleVN3dz0mtSGdSrrsz171tWTMFG9TtPcVlom50J65rdtyNhUgjI6VCjfUio7IqXcJkdWXOAac0WSOwHSrbx5U+lMHyxjHOOKTRlzaIpXEQSFssKw7u5SAkyntxitbUGHltvAPPrXK6s/nzbcHCnH4VLidlCKe5Wn1IRiSVBuY+vaorG4e6ClMcnmo7iFSxTnkdBU1hGtpIMhhgelWo9Dr5VbQ3FVIUQAc9/etO1A8vkA9650XSfMGHLYI3cVoWt584PzBW4FUtDJxNGeLEoLkBT2qvL+9KiJSEHrTjFLcMA2Qgq9bxIidTmmYSlbQrpaEgnAziqd5ZyyqvOFrYMjBsLge4rLvb+OKN2klUAdgaNGSpu5A+xLYozhivrWJqmpw2sZO5V47GsrXfE0cUrLF0Letef6tq0t7MwPIzwM1vTotu5o6iitWbuq+JULyEfPk+tctdalNcyluRntTWtmKBpAVB7GgtGGxGuTXVGmk7HNLEdiFDcMcnPrSl5QMnNSM0qAFkIBp3nLsAdCCO9acvLsYuq31K4uZBwSRSGYueGOaslrdl+dfmNReQDzGR649KVkNVX3BDIvQk1PDfvEw3Fvp2qrJIVJz6YpVCPjJ59aThFmkKrT3N2C/E5AztPp61qWsvllcHrXIrmKTI6etbtlchkQ7hkdM1hKlY6oVtD0TSroOgLOu4DA56Vu2GVhZXzLuOfpXmthemKXqeeetdTp2skSgMCVI6A1zSg9yn3OzV0fvgj34qdJ8DDKfwNYKXqzISgCDvTo7rY+Sdw9BWdmjNwN63n+c5+7n5aWUlpCf73askXARt27GRx7VObrdGP3vQelJkOLRHOx3N27cVk3iLygGD1q5LNngGqt04OCe1TctGFcL+9Lk/J3FVNU0uHVtKnsrgApL9w/3W7Gta5ChjiqrvtXI61snZ8y3CSumj501OzltL2WGZdskZKtnvVI9a9H+LOkqtxBqkA/dzjbIQOA1ecsQH+XJHHNe/QqKdM+YxVJ0qrj0AUUrMCKK0OawwjI5p8ag7VHUmm1oaFbrcajErDIByaTdkaU488kjvPD9obaygjAAONzY967PS4D56471h6Opd92Co6AV2WjW+ZkJweO1eRV0d0fR0U1FpGxbIzIq55B/Ste1dxlQAM8YAp0NtH5SjZtwKsW0e3k4xXFJHTdW1LttDhVd+W7L6VfRgMEna39081Xh2+WNvWmSNg5INGxzy1NLORjPXrUc4CoQOlV4pORj9aZd3QCAbhnsDRYhQbdjM1tSkeN+49cjpXOESMzYX73GSK6ZytxuVzkDpis/kSYCAkHgetS0dtJ8uhmyWhjVZWHzZqSQhoQzRj61oSFmd5ZwQOyis9iZ9wwdvQ5po25rmXOTLMgGML/ACrcsFXyhuAIz3qCK2jRdsihiKjnuRDJxjb70rajbvodHCRjcSwX1zUc19DGDlufaudn13ZEQoDNjjBrmdY1+O3Qsn+sbnGe9aRpt6HNKOup1Os+IILGEkyZYjKjOOa871PxDPfyNsOE7sDWLPcT6jKWmLMufWopQIuUIC/3a64QsrGcpcj0G38sgdWBLbjzmqi4hYyuBnqBVhyxbfKPujIBqlDiZmeQjZngV0wVrHHUk5MV7yWYnzDtXtmp4by1thnAkf64rKupdz/uwAo4xUYTA3HGapxRlvobF5rr3EaokSRqOmKzjduX6cVXOCaF2/xUo6FWsWTcktnGBTo5wwyCc+xqm2Odnem7WU54p6AaIlVzhuB/Ojodyk4qoGyBgDPrU0T7SM9KTHF2ZoZBRSvXpSIWQ8HikhIPIzV1I/MTGOaiV2zaMiayuGYgkHIGAa3rC7MbZJHTFcs8bwS5Un2rWtZDLCCMBgO9c9VW2OyD7nZWepIgVBht3fPSr8d6u/5fvelcfbSbRjv6VcScqQwPIrma01OhRTZ1sly+3dtKse1Sx3aNEN0nWsK0v8jMpqO81FYpNwOB64rN2Q+Q6J5S3K9Kjly6kE4I71gQak2/D5K5zxWp5/nAYOVqLCcLFV5CWYse9V5ZcLgZ69atzRY5HI9qpXRx7D3q4vQTgmZmu2q6toN9ayf63bvQ4z8w/wAa8MdNjFWQqyDDA9jXvBd1kz0XOfrXkvjSwSw8RXXlhhHN86rjsa9TAT5bp9TxM0pe6qq6HOEDYCOuaKWTh2HpRXpXueIthuCeBXR+EoMLLKcZziudcjzAe1df4ejEdjHxyxyayquysdWEjeodvpAKxoSfvHIrt9IYIAfxJrg9IfPlhOMetdPBLh1Xr+NeVNWPo6UTvrKUTYJbAxVyFSQ3OV57Vz+mXA8sY4NXRfOrhSQRmuVqyuXyNm7b8EAdKu7VKcjtWVaXq7R92tCC5XeOQMdqa1MZwaYwQnzN38NUdRtzJA+ztWx5okOQABVaZ1ZiDnB4o5SYyaZzsBaJuM575qS4Yh1YcHFXjCrS5THJ71FfWzE4AG4Co20OhSIXJNvknJNVuEGFxg9asJFmAbuo7etOtIFmJzx6ZoLTS3KN3GY4i/dhWFcn5NzHmuh1qBhbZZsAdT2rib66xKpLcDvVRjdlxd9jK1q/NsMKPmY8Vy0rSXMg8wk5PNaWsTrc3W1T+NPsbQqrZXPB5IrqjHaxhUbuVRiMBUXj2NV4IjPM7MRsTkCrF7NHDDgYyD3rNiuCiOSetbxVzlqsNWud6BAAprHknJAVTjHFJdzCVuex4qtwxJrbVI5Wx4fyye5pHfcKZkc0gFFieYcDge1SKVwM5/OoqUEDrRyhzFjAz8tQu7Z/+tTVbDEr3pxcd6fKPmQKxyKsrzVYHcePTFTxcGlawJ9TTsGBcK3at21jzwOM8iuagcK+cHIrpNHkafapOT3qJmkWE8TEDj5s+lJGWgGTjH0q9KF+0GInkelVdRcGMxgDIPWufdnXBkEt0XcbWAx6GtOCcvB8nLgZPNcy2VywFaGmXBVjlc54zWc4p6nZTbsaTXzAhQpGeMVc3maNVccismWXN4u08Z710KEbFGwc1z1Eoq51rU29LsxcWWPLAKd6j2SW7FSBjNaugSRrCm44bpmm6pCPPO3BB+bIqFvZmDl71jPlaTHPAx2qgjg7jyT71emDGNAO3WqkqgsD8qgdqqwrlW5RiGx261wnxJgMtva3ygFoyUb2r0KZQ8Z25HHWuN8VRmXR7qJjlgN/5V0YeTjNI5cXSU6UonlTfeNFOfOMnuaK94+SemgijcQg7niu602PEMS4+6oFcXbL5l6h6c5rt9NYnr2rlrN6I9DAw3mdFpIGU9q6GP8A1y1z2nsVOfpW5bt5hzjFefUPoKOp0GnzHyvoauxSgyHntWTZqSmOfwq7aqV359awex1NF60l5dlPHAAzWtBPtkG48NWVpduHeRR97rmtPyCF+bG6osZztc3rSUGPGRx0qG6kA3Z5B6VXtlxEFzz7UojJOGGRTb0OXkV9yaxiBG5iR6VX1dzCxO/r3q/BGfoAKytcT5Omfas5aIdP40iC3lztBbHB4NacRK7RgflWNaQNK6rjKj+LuK2ApVOf4e9SmyqiSe5jeJZxHCydWIyBXmOsTHydqDkda9F8RMTu6HcOK801hx5bgAgE1vR1ZpDSN0QaBpr3dz5jg7FHJrcvnSzhZCAWIqt4auHjsJUC8nGDVbWpDuLHGdvU10x0ehzVHq2zlL2QyyHB6n0qhdSHJAOKtoC0zMSoFZt2cTt3rogtUcVR3KjHIyfWgkY44pZKjPQVszFjlHpTjnjBoVSKmVcn1pAlcYEz3pDHnqTV6OJQMkUjxqCSMUXRXKjOk+U7RScirUqA5I4qu4YdD0pXJtYEfBOfSrURxy3fpVJODzVpHPGfwod2C3LakAZq9pF00c6jOATzWehBQ+9NUnPGfwpNLqaJ2O3ubiFGjdTuPc1m3jEyFlGd3PWseKZ2ADMT7mr6ykRgcE1hJWOmkyNyGTbg+9WrCPgbiAuetRZUxsM4NNiutkJBGTWMzup6rQvvAFvFCn5eua73TNGWW2DF+GArhLE+aUY8kV6/4ciWWzjzwAlceJlZI1qVHFKxHb6MISmx9yAetF/aORuHbjpXSRwj5Qq8CszUwwQqp4zWcdzBVHJnLyxOBz0+lVHQ7T0/KtW4bb2Jz6dqz5TuOcVaehqrlTYFBjLYA/WuW8QwKxdF/ijIz611U/G84zg81h6nGHjaQHJ7ZraD5ZJhJKSueJ3KlWwezEUVPq6eXfTIRjDmivfg7xTZ8bVjyzkn3I9KBbUIww4rtNMxg5FcfpX/ACEYvxrsNP54rDE6Tsehgl7rOjsTt28ZzxW/YR7mG716e1YFmDvzjnHSulsf9YueOK8+oe7R2Nu0iAQFDzVoBU4YdRzTLMbQB1B70y/f5tqnGP4h3rF7HQndl20nNsQ6AFe571dGoR3lwY1DKRzyMViRYki4OfpWnpixtIASQw4/Gs7hUj7tzpbGISoGHA9KtQ2pZWx/COtQ6aNgXPUdq3YVYRYwvzcmmkebVqcpjyOI8gEZArLvlM3JPA9av6goS5IxioZETHzdB1qJGlN2syhZxFQoB+XPatqWLNuwwAuOuarW0BUD5OD0rQeE+QFPQ1CYqk1zHF6/Bttw5J4z0ryzXXCI/HANex+IYilnKCpzj868b8RgmR1xyWrWg7uxvF+4WfD9yPs/3eMc1X8QfPbyFTx0pfDMalX8x8IB0B6mqmrhpZniT/V5rsjozCbMJ0KKNvFZN2CkmD1rWuQ0Myg5/Gsy+O6cnpxXTHQ4ZFQnPU0pAxTdvPWnNjHBzVp3M7DlPA5qzHxjHWqoHIPpU8b45Heh7AnbQsvIRgCoHdgxw1P3c80hVc5FQVcjyxqI5BNWDxUD8kihbibID14p+7gZprLtI5pSMgirJTtqXEY7eDxTomwSeuarRsen6Vbt14wahl9SZOWx61t2K4UFhnIxzWNbjdNzwM1sW7nZjBwD1rOfY6ae5DcphjjB/GiOBgAWGM1LhZHHHGea25zG1tGuF6Y4rmk7HfTdito8DtcKicgjv617D4ZheOwjDDDbcH3rzzwtAv2lWK8AgD3r1fSV3QKGGExxjvXFiJc+iCtLQ0IfliYhSDjvXPamxMu0ZGf1rpMbYt2OSOlc/fjJJIJYdMdqlaq5hSd3cwbgbC5PIPHSs1mBX5eBWtPJ94FcY9aypMksAAKuOx1JlO553H5jxjpise7YGJsEE56CtyUevp0rBvCkZbjGTWkJasb7nkniwAa1NgY5oqTxj/yG5scj1or36XwI+RxStWmvMz9J/wCQjF+NdjpxAI7+9cZpjBL9Seg4rsNP4cDqPWssRrI68F8DOtsMfITXQ28eeR2rmrWRREvP0rpNJkDnB53CuCp2PcoPQ3rJw8AX+Id6beQsImIGcd6rlDAy7CRu55q4jtImxjn1rnex1Lcr2IKpg4TJ/Ot/TlAIIILdT6mqEFllsL1Pc1e0retxtJGBx0qOoVGuU6m3Td5bZ544rorcBkOR90fnWHZrgKPTBzWzGHjiLBs5HpWyR41Zq9jmtaVmuty42iljiDABsZPapru1L3imTP3c/WprSIF8njHArGS9425rItQW2xc45pLhAYz39qvkgxlQMEDrVTBwT60ONjn5ryOW8RoTC/BHy8c14t4lRjMwJ53dq9t8Rwxna2PnAOG9K8c8UJsnbPOSaVLSZ6FHWDMDSGMN8kLucMfWtK/2QGQg5bPFc+0hju0lHGD+VaOpSK9ukiNksOtdxnUMfVpd84HcVl3AzIT2xirl0xdtxqq4yTXUtjhmVDgLTafMnPXFR0LQzHg8U9CM1GOnWlXrTbQifOe9KMimCn7xgA1A07h1NRuMNxzTiwDZzTCcnNUlbUTZE3XmgdRSvy+32zSxDd1GMU7oEOi4er0fSqyoN+auxY6YpWKvqTQxZYHNX45WSMrjg96hiXEDvjgcfWgvgJXPPY66e5cYeVGhP8XarcDCbyx3zjGaz53aXy1RSx6cV0vhTw3fXk8c0qbI1P8AFXNWlGKszshors6rw5p6lA7Eqg549a9H02IIIW/hArJ0zThAERIwAR17V0tsrJHsYKCP1rz+e7uYVp3GT8jI4HTFYGogoSwBPaulmAMYAX5gOa569VlJLdK0uiaDOdu4ju245z0qhOhUccGtmUchmHOaztSZMfLyaFsdsdTOuIshXcYz61zeqQ7z1zk8V1l0T5Kkr1FYTQl7ngcZxzVqVncdzxfxeNutTA9sUU/xx/yMl4o6K2OtFfRUdYI+SxWteb82ZNrhbqIk9W5rsLE7W4Hfg1xUbFJozjIDCuztGA2YOcis6y1ubYN2TizrLPLRLweBW7pJIeNug3Vi6OQ6dcnH3a6mztQ0KOF+bO4ivPqnuUJdDTlYTshVQMDFSQ/un3N0zzmorYgSqGUY9auzQttY7cr6+1c7O6Mk3YtwSKUD889M1NpLbrliV+XsRVCFsrtU8DtWzZWUi24lHA9KnqRUaS1OmtTlV2c5XkitwgG2VVOCOPrXPaS+UA/KultlzAAwwTyK6Ejx6/xFC+tyoV/QYBrPtZAbkK3TPat69UfZ8Hr2rnLkeTdKQenNY1VZphRfMrM15JMSkDBB6VEQefT0qvbSGR9xOTxVxwBz94d6m9xPR2Oe1dS0b8cjpXkvimy3SOWGCGPBr2fUIt6uR34FefeJ7IsG+TJas1Jxmd9CWljxi+hMUpJzinROGtipOcdB6Vt65Ysh5U/lWXZWxZmUg12qaaQVItmNLyxXp6VA/BzXQX+jyuu6IEMO3rWRJp95u2iBj+FdKqK25x1IMz5huXINQYwdo5PtW9a+HL65cho9v1re0zwZJPKq7Wbn73alKtCK3MlTkzh0jdgAq5/CphZzH7sbGvZbHwTDCgDKpwOpq1D4VRlOIxx7VzyxkEzWNBvW54iLWdWIaJsCmmCQE5VgK9zPhWE5LIob0qjceE4m4Crx68ULGQb0RX1dvZnizQtyR/Kkwy/er1ufwlH2Cn2Haqkvggyr8q1q8VCxP1WXc8t6nIHNSLhRwMV30vgO5JwgIPvWNqXg6+syW2Fx7U1Xp9GR7GadrHOoec1agJ9cnNRTWs1u5WRCp7AipLcc5JxW109hKDT1NbzgloEAHJpkEL3MqRoMyE4AFQwZnnVEyc8YxXsvw68IJbLFe30Q3kZUda469dUU5dTqj7mrKvg7wPiKO4vAGc4IWvS4NLjiRVSMAAYxjrWjaxJswAfbjAFWoo8HmvIlUlUfNLcznWd7FBLcBhuHAqaZNhO0du1XfLwcg1WML+ZuUE/0pRVkRz33IwNsB+bDHr61iauhIODxW1dMobaOOax9WkwoG059K3ZrRdmczcO5l2AgjHIFY8zfvXDDp+ldBGirIXOSenIrN1CApuZUzuNJbHowetivNG72ylTxwQT6VSs7ZnmYnkDJrcWAG1DNwyjpVS6KwaTqd0ML5UBOenOKfxNJBzW3PmjxFL9o1i9nPVpmGfaiqt0+/LHqWJ+tFfUxVopeR8fVd5yfmyBvuBucg811mlsWs4WI54Brk8/IV9e9dB4clMlvJFnLKQRWVRNo2wsnztHdeH5cSJj3r0PSHDQ5IXpXmGkSbZhgmu90l1LRZY8rXDUj1Z7FGTudGtqpCsMEGtK3jEsLI+BxgVWthvhXB6VpW0BAJyeK5LW3OuM1cyFi8sYQruDenaugsrkfY8NggDn0rIm2xsxYDmr1gFkiKnlGqVuaTfNG5u6WpYIyc98Cuit5SUBY9DjPpWNpUawqqKTtx0q6iqoAXIy2T71umeZWV2aFyN8W/PPp6Vz+qLiZSehHWt1CzRbXGDnFUL2AYySDis6uuxFF2ZUtFKHGetaKHhlDAMfWqiIBkgkVI4xG7R/6zadv1qUVLe5Vu2CZCrwD19a5u/hF05JOAK6Yo7hPMwWCjOPWsudV3Fto4zxWbWtzakzznxBpAk6KCc8Gubi0ow3WMHOfSvVrq1WVAdoOTWJdWSSSlFJDrycCjmtudXOmrMoadpiPIE2ZP5Vrx+GrcHIUfhWnpdmqBN+dxHU1vQwFGGFzTk3LY5JztocidCQjbHCCfTvW7pujrbW/GCTzt6YrRWIGcH5etWZImJypAXpUOnJbkcxleQC5LKMdgKRonxhVIP0rVEIOcckU4RjO47h7ZrL2bKVSxgmxkYkMDn19aYdIJG92ABOOneuh/dnO4nkdKYWAmXGBFsJx70rWKjVZiLoowAcVftdPQIyugU54x6VNPPiIOOGrJ1PVDHGFVjk9x2p2sVFSm9CXUbdUGOADx9K5zUAodkKZB9BWzb3Iu4/mft3qvdmAZLFSR+tKS1ubRUo/Eec+JtLtrjl12t6iuGm0eQOwhBZa92h0uLUSQY+D6itnSvCFnEjO0Az6iuilWktias6aW2p5d8MPBMs10t5eoQinIVh1r3SGzCIgVNoFXbLTo4YQkagAcjjFTLDnucYpVrz1ZwTruUisi4UhevpSp1BY4z0qUgYYN1pkKhVxjDnpXPymYvzKG2Lu56mm5ZSQVHPXHapMMchRnPU03OFYkZpxaQGTOmbv5hx2NVrtFJOcZ961GbbP5gXGB35rI1Z3fcw6nuKb0Oyk7sxPIMsuQcRhulQ6soVAEAJ9MVs2cZO0/d/DrWXr68qM8+tJJ2OuEvesZKOxyrNn2rA+Il9/Z3gDUSMZuSIlGfzxXVW8IEBbH3edteX/AB9vdiaXpiMMFTOwrow9NyrxSFXmo0pS8jxaXGwDOSDg0U2Q5ZvrRX0jSWiPk076jK1PDs3lagEH/LTissdRT4S0c4kUkFTwamSuioS5XzHodmTHNgc813OhShmUMQCDgVwVtMs0MU0eMFRnHrXUeH7gCQDdk5yK4am2p7NOTVpdGenaa4MPON3qO9bFscx9TzxXO6XIWRFQbnPQV01ohdVBwpPJGelcU01udaktzJ10hWUBQR6inaNcEPggEdB6Ve1fTneMlAMN0I5rMtYmQohU5yASKztrc6oyi4WOxtG3gHdj6GtFcBUwM4zWPp6ZRFT7w61sxcH1wK0R51UusOFbPPpVW5CMmTncTVkv+5LEcn07VnSOM4JOBzSkYU9yB5QqZz8/92pYydgLfWq8sQ80Hcduadev5YUrk+1Skb2TEnmCBsE5I7VmcuoAyQTkmrMrt5TEMo4zWSlyBIEz8xNDSNqcGW50Lx7VG0D04qjs/eNgZJ6+9ahKugwQD6U6C3CNyFbPvzUyiOTF0yDC/OMn37Vrqi/eB3DpVS3BRjwNoPWtW0CkYIyK0hFHJVlYzvICSfMvU5BIqaUBEJZBirNzLHEj5PA9R0rj9V1oLE5QkAZpzSQ6NOU3oat5qEVqoAKqT2qsdXUQkswAHPWvPb3VDLcedJISB71nXWvTTEIp2r3yK5m3uerDBbHoEuuq8oVGGfUd6bDqkjkh8HHTmuAivC8gMbFdvoOtXYJ7gv8AIrNnnpUvuzV4ZROyuNQO0NuyT2J6VjTT+ZKxY8HtWPML9xgRuPSlWC7QfOjZIrL5jjSUSe8nlWUG3Y4PvVm23SyAyvnjpWXIZYTtdTjGea09MdSwJzk9AamXcqUVynY6IqIIsDdxyDXV2D/LhsAZ4A9K5HS5AjqPXFdNBMsbAYz0rowz1Z4teDub0QIAOOT0IpqxjcQGzntUcMm9RyRipwS6kKo3AV3yp30R5t2nqV5rYdQabFAzuBt/GrecLk8kDpToZgMblAB5zWDgg5mVxCYywxjHBqm8ewNgbu+K1ppQ64YAqOg9KpzbR90cNUOCNKcncwpsrzis+WMMxGchvxxWrcqc5cfMePwqqIkVlCjAznFc9rnbTdkVVhVduCRWDqsUjTgSsCM9q6mViq9etZMluTOvy5BNXbSxtSm07kFlaKcAjIznjsK+Xvipqzaz4zv5d4NvC/kxgHjaK+lvHmqr4e8G6peldsjRmOE5/iPAr46uS0sjs7lmY7ifU16OXUm25PoceYV24qC6kcpBbKgbT3opgPyhaK9Y8cYnWpBzxk801V+YD1pd5RyABxxQJ7HVeE7pnhktmA3DBUH0rqtNnMboQBuJIFeb6bdNb3ST8hQRux6V3kDb9kkZyrYII+lclWNtz0sLUcoOPU9R8P3Bk2ZOCMV3Wl8ohbqWyfpXkfhy+EbLuY8mvRtEvlYYGCuODmvPqR1ujvTvE66Nd6YBGM05NPjfcSo39ao2sjBMg5BrZtDlQG6HqahaicnHQjtLURAnoavIPk7Ag96bh1PzH912PpSz2/mwMrswVh8pFaJWMpScmW4eFwR8tY+pEDcV6A46VqWke2MKhOF4+Y9aqa0FW3yvDnripqbCp/FYzDPuHX5e5pk/zoAj5kxkA9KggIeI7toNSoF2q6FcgYwKzidduhDdyhUVWVVyBnFYLswuzgc54rQkkL3B39B6VSnkRrsN0U8DFJm9JWNG2lj3r5nJ7VsWgwRkVz0aEv8AKTkdPet2zkbILHI6YqkY1kaO0bie1WQ4ghZnHPUYquHG4KOprP8AEGpR2dnIZJFVgta7I5VTcmomPqur796qWAB9a5HU3eR9qvmPrmoobhrl5JZGIVjxmoZpvNk2RgbE5JrllJ7ns0qSg9ChNAjNs2nk5+ta2jeD7rVyrlPKiH610fhXQI74iWUcA4OR2r1HT7CC3to0jUJtHSnTvJaGOJx/s9InA6X4FtbQqCu5s85zWzHoFrCMLCo29Ca6mBC+48qAep70l3AzOu7hQOMd6meHstzy3jJzepy8mmxAA+WB9KpXWnxEH5cHscdK6i4iIcgAe1UZkHO4AEelcU4cpvTrOxxWo6SGA4ySOuOtZUdpsYDkMp44rtbu2EjfJGcjvmsJYQlyVI5JrHm5T0KVW6sxkE4ilUEgnH5VvR3pEQKnJxmsm4tE81GCjPSrMFvuUgEg44xXTSm2zCrGLNjR9ZEjOjsN4PTPNdGlzHtLqwB9M15TqlhcWUhvLeSQv3wKjsfFV5E4EoyvQ5rvp1b6HPUwSmrwPW2m3pgfe9KGkxEAcZrB0bVUvLZHUg564rVkZccM1XN31Rwyp8j1Hs2RwaY7N5fy8mqvmnzNp+52I60s8pjO1SCMZzWEmVCLuV7piXw1VJCwxjtTZ5cSZLfnUcU4eTkgj2rFPU6FFiTT8Dd0HWkiJllGATxmlvoM2+4cL1JrF1XW4fD2h3epXLBTGu1VzyWro3djanFSR5R+0Z4j82+tPD1s4MVuBJNzn5u2a8KcnJzwfStXWdUl1TVLu/umLSTOWJJ65rKfBY4r3MNS9nTSPExNb2lRvohp6UUjnAFFbHKgoxTQcmnUmMcvBwfung11PhS982IW0pwUPHvXJqSfyzVmznazukmBI2kEUqsUzajU9nNM9O0+YxzLt6bu9egaFfYbBxnHSvM7GaK7gjuYSR6iul0W8CMMmvPqQs+VnqUp6X6HsWlXCmFCRz3Ga6K0l6kdRwBXn3h+/BVNxHNdZZThpvMBPTArlejNpK7udFv4BPPtU4IZgG7rWfDKGHX8Ks+bjkjGRgU+YycdbIfPKI1GSwweNtUdVuC0WG79OKkeQsT3wKz2YjJk5Hapk7mlOGpnSuyOUjOExk8VPBxbjJ6+lUNRk2sXHep9OlR4CrE9KzWjOxxXKUdSYowJ4UiseW48+7ijjOAp57Vo+JWH2M+WeR271yNm8n2pXZsHNLds6aUFKJ6TGqJFG6Y5H50CTJ6hcc1gxaqIYER8cHI9xVWDVfNu8E46jiqckjm9i7s7RLpPIMgOD0zXn3jPU/tEjxK5J6GtLV9QlhtNkQyT271w1w/n3RLKwJPOKUp3VjfDYe0udmzC4S12Kc5X071c0DS5Lu4QMuFY8571mQbsqoVto6nvXfeEYSV80Z+U4rNm2IqezjodbotuLaPyVVQF44rdUsMKSAB361n28O0lk781bVWYZLAVcNFofO1NydWZGwcEZzmmzyFuvSmgkcEg/SmSODwOlOUnsZ26kM5yM9qpTrtJ+nNXihyOVxjOKheI7T9a5akbo1i7GWzAK2c4HFYF8i/ag3OOeldXc2oaIgZ644rIurZWbkgMvrXLKHc66M0zNJBjUrz2qS3aNWHzjPf2qylqpy2VzjHFQzWBGHVRnNODcdjZyi9zS8pZoQhUFT1z0rz7xXpDW03mxsMMcgDpXX/aJEcISQOhz0FUfELJc6a428jjNdadwoN0p36MqeEZHgtEM8q7c/dzXbQypIo2nt0rxYSywOcs4C9Dmu18M6y8qeWUO4dTW0ZO1mXisNf3lsdRczmNhs55qlJesjNnOD070s7eY25AwH+1VCQ7yRngVk22YQgkSu7tghtymrdlCGmx/DVWKJyQoAEY9K29NT5BtA60QhzMVWSjG5I1uzJ5S4J449a+cP2gfEiS6jHoNq4EVsS0xU/eb0r3f4leJYfBfhW41Jir3bjy7dN2CWPf8K+LdTvLi8u57q4kLyzOzOeuSa9PCUry5n0OCvX5KdlvIz5CC3y9KTNIOlFeolY8sU0UlFMBCcUA5pSMjmmZwcCgBzDIoU4xnrSAkmlxlhQBu+F9TW0vBFcY8hyevrXbxTGM7lIZexFeXBiBgY45B711nh3VPtFuLW5bbJ1V8da5q0ObU7MPW+zI9U0LUgoQlu3pXc6bqO9lw3DdK8e0+5MEgV5Np9Mdq7PR78MI3EmcHA4rinHoejSlrqeoWl0I8F2GCO3NXkuN6A547Vx2nXuUUA9etbUE6suOa5ldaGzS6GwJDkMOnNZ99/q8qec9qDMEiIHQ+tZ9zdYnQA8Ghs0grizhzbcvz9OlJYgx/IOT3NJcklZJMdqxtP1MJdMrsce9Q3ZnTGLcdDS1sKYk4Oe+BXNGNYF3/wAQNdFfussHySY5rnLoP5jqxG0nmnuzanorFW9u2LMG64wKTR2d7oA4A65qjqR23GEbI6E1dt2EKqykfMMdKa1ubdDS1JzuIU7u2axGgcSEqgB61oyy/db+dViWLFgTjFK1k0OOiJrJVPHOa9I8HIEtT2ye9eb6a2Zwr5PNegaZeiAQxqPbFQ1ZpnNjE3CyO3hO0knpipFkQgkHis6K581Rt4NaCplByeaqSueE4KI5CM9R9KV+3FIkO5jJj5lGBVhAOBjc3fBpWZm5Ir+XlcjrjIpiKeSepq6ygE4GCBjFRlCfSlyC5kQvHlfvfUVmXcPXjqa1wreYBxUFxGW9MipnC61LhKz0MZ4/LPFNPTGK0ZYvlDEck1G9u20MBwOtc8Iu5uptvUw7pAAMjJHUGsm7iYwOTzzxW7dKPNfPIFZV0dykjsK2Ssjsps4LV18q4BXknoT2q3olyYbqMr3IpfEMPmIrJ1rGs5TGwU/fDAirhFpHoyXNA9TEwdclsEjtRFalmPmcjrVXS2SW2TJO4+9blqAEww//AFUcl9zypycWENv8sZXkHvWhuttPtZ7u+dY7WBfMdzxj2oto944IWMc89Bivnz9oD4iJqMg8P6NMfscLEXMqNxI3936V0Qg5NJHJOpaPNLocT8YPHM3jPxI8kLY0y2YpbR9AB3P415zKWWQgdKfJkHZzgc9elRPwa9iFNQVonkTm5y5mNpM84paTAzmtE7ki0UUVQwpCcHFN3GkJJOT1oESUDrTQTnmnUgFwv8WfwqSKVomHldQcjPrUVLUvQDt9G1RL+MROAtyMderV02n3pgfy2wAMcEd68mhkkSUSRsRKuMEHFdjouqpfIElO25XH4+9c1am37x6FGu5K0j1bStU2hMsMGuq067XylIcZ615DY37xyqrOMD3rrNN1QkKN5x7VxVYWPQpy0O7lvtoIbj8KybjVVNxjdnHBxWdLeiaHgnIrJkOCzDJJrFwO2ios9BguRLANpJyOc1zGqRNBfFwvyN1plnfhYQvmEetTajMJrbOScjHWly2djemrMbb35aIDPy5/Go5bjzp+Pu9zWTC/ksFyevNWI5P30pJ2hRkD1p2SZtYqXwJumVMYB4qym5EAYjJ7VVhAd3djtycirEAUPmQkk+9JIsnJVCrFNw9KQMCz784bpipVX5hxww+WmMmHQHr1pMpDLYGO43L29TXWaZeYjCg7ie9csqszkds1v6YiKw5zjHSoktLk1lzRZ6L4fkaWNcfjmt+M4OB+Nc1okqxKI4wQxHGea66yhLIoIJ4ralByR85iPdkPjiG/p6VcSBd2G7irVvaM3zYq3HFhsyLnA4rvhQPNnO70M8Wi/wAI/Gj7Lu64POAK1cDHykBuwxTUDgEMgbv6YrV0EjL2hkG1OWXG3DZwx61VvLZSzEg5XpXRFAxBdTkep6VRuYgxfjk9axq0E1oaU5u5zskeAQNpcjOKzbiSSIN6+mOldLPCocbFAIXkmsu5hDIcj5jmvNqUnHY7IVbnNThCq+p5rHvGw7FASBya2tStniYFeV9hWDfrJChbDEN7YrlUpbM9WjZnN37iS5f0PrWJLA5ukSMcsw59q13RZZC7EryeKv6fZ7nErL9K1hPmVkeg3ZGzZR7UiQrtVVGWHPNdFp5MxRUHfHPAFcs0sjSgKxEY6sDgD61wfxO+Ka6bZy6P4ck82eRSk9zkYX2U+tdFODnLlSPMrcsYucnoX/jZ8TYdNSXw14emDXDDbc3C/wDLP1UGvmy6fe+4/fBz9frT7q6eUmR3LzE5LNyT71UJOfrXsUaPs4ps8GvWdZ7WSEJGMf5HtSUUVsYC0lIxI6Um40JJAOopFYGimMRQQaUgls09QDnPpUZJzQA6ikUknmloAbupRyKTaKMkHA6UhDqekhjwY8rIOjA0ygHBB9KAOp0fWEnVYbshJF/jPeuls75oh8+SB0PrXmLFgAwxjORxW1p+sPbMY7gs8Z6VzVKabvE7aWJ6TPUrTUwwHzY4471bW6ydu4HP61wlteo6LJFIcdxnpWlp98fNLFvzrknE9OlU0utjqVk2Y2421PBevnYTgHisVbsMBUhk7qPm7VjOHVHZTqmpJnfuj4Gep7VMJd0RK8+tZ8F0CgDctU0UhEjhiNp7Clrax1Kpcs28RlPGQB0qSNGD/wBTUCThThScelSW+4tlicZ/SpUTaLNENs27uTjtSSZeZRnBxSFkLKAPl6HmnwYJIPGD1qZIa3JIkJZGbAQ1r2CbbkFASgbrWdbLuljQHI3YzjtW9FBidIYDu3Hk1HKKclFXZ23hqEzHzG+Yg4GO1d5YpiJQvWuX0WP7JbIvG4gYNdRYtiME8134Vcr1Pl8Y7ybNcjcijPIx1qRMLk5BqqjAu5zjjufakWVsELGcY5avTZ5aWo9ZgrPgEkninSOildz7XbrioCqH+LOe+cVJGoJG4A46ZrNsYsjKy7Um+YdB61BJDK4y2C+eeasiNTJuCjOc8VKpHOf5VFrhcy7qJiNrY5rNuYP3m7Axit+dE3Bu+eeazrhSc4wBXJVgmzaE2YEyqHAdAfQntWZfWkcqEMv0Arcuoi2d1UpYmx5bEFjwDXnVIqO53U5PucNqGhKZWdUIOD9ais7Ywwt9rYRWka7mlY4ArofFGqaZ4b083mt3AhQcBSfmkPoBXzB8SfiZeeKZ3gsmax0wEhYe8g7E4qqWHnWdo7Hd9aUYe+dF8VfiRDcsdK8MyFYBkSXKjGfpXjLyZkZmJkY9fSommJj+TjB71ErsOhr2aVKNJWSPEr4mddtSei2HSMCMCo/WkJJ60VslZWOcPSiiiqSGFFIxI6Uo6c0wGv0FFD9BRSEOopm405TkUxi0UUUAFFGfeigApKWikIUn5APSljby23AZPpTaTI9aVkBatLiSEl1bkHOO1bWnauJBiXbGw71znb2pSd3X6UnTUtDWlVlSd+h38F5hlO4Y9qvLfNj7wrz21vJ4m4kG3/arXtdVjfiX5W7H1rlqUXE9OjjYydjtI7pShz1+tTW94WckmubjuA4+RiVqxFcAKeuaw5O56EaiZ1kUy7i2etXFlIBO4kH8q5aCfPfir1vdttwGOKycbM6ITOhjlcn5TxVy2mwxBOc1gwzjcuSfersdyo5HWs5RerOmNRM6K2lzKpHNdV4cthbv5rO7mZgfn/h+lcNpUxM4LHdXb2OoRmNFwNwHXNZ36mda7id9asSqgE/jW5p87AbTnjvXLaXepJAuc78cehrobW4UBFGD34rppSPCxEWb0Z+YM3frVgMSdqthPes+KYNzn5Rxip/MUJwQM8HnrXfCbseY9y2fLEm0Ak5xmlf5Md81UMgCrj8x3pykueDjHqaUpPcmxZim+SQKCpA4J6U9bhflDZJPeqrgiEknkHr7VWDtvIG18enasXVCxcuZEdiCCMHoO9U7hxGXY5OOgHpTbueK2i86+lS2RedznAryvxx8dPDnh+R4tLRtVvQCoZCNgPuaylUcvhV2axpt7HpdxH+78932R4yS/AxXjfxH+NelaAklj4djS+1FSV8zkonv714d48+KviPxXPItzezWtoT8ttA2FA9yK8/uJSxHzE8etVDCuT5p/caSrKC5Y6s2fFnibVvEV89zqt9JOznIXoqj2HauekZQCh3FDzQTjzADwFGOaiJJCk9cV3RSjHljojlnUlUd5MQsx6nj0pM0uM8ZxSYx3zVJEi4pKWg1QkNDZNLQAB0oplCA5paAAOlFACMM0UpooAYVwKcv3aXIPcUD2oAKKKKAEUYpaKKACiiigApu3nOadQOPekIKKM57YooAKVn4GRnHakoPP0oCxLBcyxYMTsMds8VpW+tNGR5iADuQayASBx0pQSDUyhGWpvCvOGzOutdWt2Q7ZCAeu6taG4DKNsgb6V52ST1OakhuJ4hiKVlHWsZYdM7IZjJW5keoQXDKATnFXoJzwM5+leZWus3kI3JICR2IrTsvF1zCxEkMcmPwrnnh5dEdsMwpS62PT7CcKpO8gk9BXRWkrlkySOO1eTW3jsRttlsY9vsxrbsfiPYxOu+xkyPQ1zuhLsdMMZTt8R7dodyyKgDtnb36V1ulzs0a8/MDXgFj8XNLgfc1ncccAAcVuW/x00mJSRpNw7emcVkqFRPRGFapTnf3kfQaT7UwPvnrVsTuQgRRtI5zXzs37QsMa5t9ByfR5MVnXn7RWtMCLPSrO3GOGZicV0RhVeiiebL2ae59RWu6Q4UEAeoqzPdRWMRe5mghT1kcDivivWfjX4y1NSo1FLde3kJtP51xGp+I9V1EH+0NRuZ/Z5mraFOstHoYVPZ73ufZ3iX4v+DtGLedqMdzMox5dv8AMa8k8TftG3rCSHw3pMFvCSQJpj82PXFfO32pRnAG4d+uKhlm3HO/k9eapYaPNeTv+BDrJaRj+J1fibx1r3iOR31nUZpx2TeQmPpXKvcBFwmOeOtQOwKnkfnULDIGa6IQhHSCsRKcp7stSOdjAnI9qg3j0NIS23HO2m1olYgWkoooSGFFFFUAUUUUAIGzS0AAdKKACkLYOKTLUnJPIoAGOaKdtHpRQI//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the adherent mucopurulent membranes within the trachea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17264=[""].join("\n");
var outline_f16_55_17264=null;
var title_f16_55_17265="Slit lamp beam width";
var content_f16_55_17265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Slit lamp beam width",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 490px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHqAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDRNL1J70dqOlUQIaaTzTzTD+tIBp4pCaD6UxqBgTUbGlJ59Kjc+lIoa9XIsto92OuOaosea0dPXfpt4uD92qhuRV+EcoLeGpCOMA/0rB0Y8zBvb8q3YYy3h+dCSAAefwFYGk5WR+eCo5qphT3NgGnqeahzxT0b/OayNrFlTUqc/Wq6mp056GkIsR/eFfNvjdMeK9VAPJmb+dfSMR+YCvnLx18vjDVR/wBNW/mKaEzSv1z8NNKYHI+0TD6ciuk+AAH9o6sAD/qk/mawLvH/AAq3TDj/AJe51H44rf8AgAcarqi/9MV/nTYke0gc04L1pQDmnhRzQhkUkKzRPFIMo4KsPrXyR4vsZNG8S6hYyDAimIH+72r6+Vfmr5h+O8kD/ES8+zlW2xRq+P72Of6UMTOG87+7wSfwxWnoV7sv41J4Y44rCqSKQxSpIv3lORj1osB9V/D/AFVdR0RIHbNxbjaR3I7GulIxzXiHgTW2Mcd3ZsPOQBXUnr9a9e0nXLTUkVd4jnxyjevtS2GmXSKjIzVh19BUZHPSquOxXYV5x8a32aHZLnG6c/8AoNelsOteV/HViNP0xB3kdv0pegnsVvgkh8vUWPYIP5mvTnGa85+CUf8AxKtRfk/vFH6f/Xr0dx6/pUoFsQsCe1Rt3qZhUZH/AOunsMruMVCwz1qyR+VV34NG4Faf7h96ztpygA960bg4jbjBqhgh1HHC0ABGD2pp7e9PwRgfpSEHHNHUNxp6c1t+DIfN16H0Xn6VjYrpvh+g/tWWQ9ESqhuY1naDLXiSUPq0x9OKKoapL5moXB/2qKU37zCmrRRcPI96THrTsZoxTGMPGaa36VIwx0ppFG4yBv1prVLjpTGFAyE1E5yKnIqKQUhk+ixRzapbxzgmIv8AMPUV6FNeabChSHTLdQRg4HWvPtFO3VLf/erq7nrRdrYmSuWDNZPE8X2OMRt1UDg1WjtLGNmMVnEmeDxTE9KnTFS2+5SSRy+rIkV84iXap5Aqsp9Kva8Nt8D6rWevUUJlonU9KnQ5IqqhqxHTAtxn5hXz7r9s2rePdRghILSySBB64/8A1V7+hIGeelfNniK5e08SNcwSMkyTFldT0bNNEs6GUhvCdpoxR1e3uZJnb2IHH6V1HwRtzaa7fK2MyQcfgwrjrnxPb3kLzT2my8HLsh+R/wAPWun+E/iCzvvFsFvBFKs7K2SemMUPfQlHtV3PHZ2k91O2IYUMjnHQAZNecD40aDk4s7srkAHjn9a7rxZz4U1n/r0l/wDQTXyDtURKTkNx06miw2fQF38YNIuYHS3tryP1bAyeOgryPWn0DUdRkvJJ79pZnMj5285rl0xg5c/yFIrEdMEmjYVjX+zaGVIR7s/7RxxUQh0cqAv2otnk8VnByY1GR9MZpFTPOeQOc5ANFxnV6JqGm6LeBrf7S2MFuRzxXd6X4m0bVpsyie1ZWG1gwyTz0x2GP5V44G+6uS3AAOK2/C4b+0IiD03U02Kx73pni3TrKAxzXU86ggKzjkV1GmX0Gp2S3VqcxMSBnsa8QdVCDHT6V6F8LLvdZ3lkx5RxIo9j/wDXFSUjs2XNeIfHHVIrjWLbT4XVjaxEy47M2OPrgfrXX/E3x9L4avI9KsbcNeTReZ5zniMHI4Hc8V4I88t3NPPM5kmkYs7sclie9ANnrfwPvIxbX9izASkrKoPcYxXqLDmvmHTtWuNE1GK9snIkj7HoR6GvobwlrY1/Q4r4RmNm+VlPqOtGzGn0NRhjvULj8qsN0FQsKNxkB6VA/wBKsMM/WoWHPrQgKN3/AKs81VA/eH2FW7wfKO+TVYAbnNAMYw496OfY07HT0o6D3pksY2M9TXW+AVxFfTHjaCK5JuhNdZ4YYwaFdyDjdV09zCv8JkTPvuJj6uaKbAjPayTYOA/J+tFROOupcNjb/Sil7UZ70xiGmMOeKkPpTTQMhYUxhzUrD0pjA4oGQOOvFRPn0qVqifGKQ0S6Wcanb/71dXcnniuT0441C34/jFdZOPmpMUtxsQzzVlBVePrVpRxUsaOb8SDFyh9qy17Vs+Jl5iP1FYqnrTRaJkqePrVdKnjPSmkBZj9DXzR4wXbrc/GR5rHHoM19MRda+avGoK67c5HHnEfrTSIkUYkBWf6E10fwNc/8LEsuRyjg/wDfNc7Fw0g4GVP8q3/gex/4WPYD1WTp/ummxI+jfFY/4pTWQP8An1l/9BNfH0gO3ODtPOc5r7C8Vf8AIrazj/n0l/8AQTXx4ZCqhcjnkZGMUhsaRuX26E4po+/z90d+lJkspznPX60FhycY3YHNAhQQHyF7enen4yMENuJJIPpURYFhgfjU2dqKQT5hPPHOKYBtbAPPHpW94UUSahHk8YY4BrnhjgHcFGT7Guk8HKXvcD5hsPPrSaA7GbkDjjH/AOqug+Hl4LXxRCpPyTqYjn16j+VYkgXZtwOnUCm2cxtbyGdesbqwI9jmkxlH47Nu+IiqP4LRP/Zq88gGY3PYn8q7f4y3SXXxAllQ/KbWLB/4Dn+tcPCCYivIG7PNNiZJddt3THSvoX4WReX4KtOMZZj+tfP10q/L2yeAO9fRnw6Qp4L08H+6T+ppPccTebp7VE+amPf1qFqCyGSoHBFTtyc1C/rRYCjdclQPXNVkGQfrVq4OHX2zVZRhaYmxMZ6daaaf2pjUCGP0JrsNOi2eD8/3jyfWuOk+6a7ef9z4St0HcZxWlLc56/Qbo1kX8JagxXLbgQ3piite1H2XwDK3A8wn8aKuSWg6exh0d6D1o9qxNA9z1ph75p5phPtRoAxqY1Ob9aYaGMieoX96mcioHPvSuMdYnF9B/viuun+9XH2h/wBMh/3xXZTcmkwluJGKtIOBVWKriVIIwvE6/uoz71gL7V0nicf6ID6MK5paaLRMnNTR9c1AlTx1QFmEnd0r5t8dr/xP7rAxiZuPxr6Rj+8PrXzj49G3xBfEHnzW/wDQqNyJGbARmQ9eOMfSt/4J/L8SNP44xJjP+6awLdt28gfw4PpW78FCB8RdO47Pj/vk0xH0j4pP/FL6x2zaS/8AoJr45kYnGeQDye5r7C8VN/xS2s/9esv/AKCa+PGxk4+XHQdzQthsM7cAKMn05pH5IAHPv1pCACcDjHOaaM5Hzc9RzQIdyxJ7nnnvS5KqDxz36kULgKBu+8ec9BSPzknPJ6mgBSQuCGAPHSuo8EH/AEpySQRGfx5rls/MAB9Peuv8CrmeQkYxGR+tAHXyrhQ+Kh25ZhgemRVycKqKN2X6+wqn8xyN3XrSYHB+IZ5Z/EF6zsWZUVB9AoxWXbH90M4xnitDWw413UA3y9M5HbAqjDGfLjA3ZJzjpigCzMCzxBueB/OvpPwanl+E9NUf88gcV85MN13Dgc8V9K+Gl2eG9NXuIF/lSe5US85qFjmpX/XtUDn3oKIm61E571I1RMaaApXH3s+gquoIUelTXB+ZvpgVEegx2pCYh+7yOKaeAKce1NPbvTEMbnaMdSBXba7+70W0i9hXHW677mFcclxXZeIxxaRd8DitaZzVfiRp+If9E8BWiZPzrk0Uz4kN5Hh2yh/uxD+VFWyobGLQM5oxRmsDQQnimnmlI4pp6UDGtTDTyfamMeO9ICFveoX6d6mYVC4xQUNtv+PmI/7Y/nXZS9TXHQcTx/7wrrpOlJikSQ84q5F2qlCauRVLBGd4jXNg59Oa5Na7LXlzp8o9q45aEWiVamTrjFQp1qYVWwE8X3x9a+d/iDEW8QXwX5j5znH419DRn5hXz18RMDxFfjBP71v50IhoxrU/ORjjH9K3PgxgfETTj0A3/wDoJrBtjtlIbPSt/wCDrA/ELTyBj7/8jVCR9FeKW/4pfWf+vWX/ANBNfILeobntivrjxW3/ABS+sf8AXrJ/6Ca+R1zlcDgdDSQ2B4U9M54GMUHBRCc9CKDxnPBH4dqs6famcuShYxjJUDJNMRUzk4OcHr3peB1yO/rmpdgZuBgH+HvTNv7xlGMe4xigBnUBsjnjGea67wMNs0hzxs6kdea5Ns49M56niut8E4zKT2UfzpAdbIenbPep9Iszfara2idZZFU/TufyzUDkjAPTmut+Gtp5usS3jAbYE2j/AHm/+tn86B2PI/iAEPjvxAkQ+VZtq/gAP6VgwE7UyCO/Wtbxs5fxf4gf1unGc+5rItWAEee3f1pvcRcjyb6MZzgA5r6Z0kbNJsk9IUH6Cvmm3XfqSbfQCvpq3+W1hX0RR+lS9yojnNQOc1Ix96hdvegoYx9fyqJjkc05z27VGxxRcZSuBy31qM9h6UTHpnuaCelCJYhNN7UmRSAnPFNMRZ0pfM1a1T/bzXY6uPN1y0ixnkCuX8ML5uvQf7PNddEvn+MIFHIDCtIbHNU+Mi+LcvEEQ7KBiik8eWz6n4iWAcIhBY+gFFVUkk7FxWhRzTM0A0Z55rIsM0hoOOwzSHmgY001ulO7000DImzUL1O3rUMg4qRjE/1qfUV1p6D6VyQ4cZ9RXVg/KO/FJikTQ9e1XYu1UIiKvRdBSYIh1dc2Mo/2TXELwOtd5fjdaSD/AGa4QcE0kWiRTmpV69KhU1Ih56UwLEZ+YelfPvxGH/FTahz0lJr39D8w+teBfEhR/wAJNfgjnzT2qokyMK2OXHQcc1ufCHC+PrEjoGb+RrFtly4JGQTt6V0fwvjSPxvaEDDeYR+hqiUe7+KGA8M6v1P+jScf8BNfKDYCjjt0719XazC95pN9axkCSaJ4wT6kYrwmT4a+JF6WsbEdCsg6UkrjZwrqSg5GMZxnrW14X1++8N3VzcWBQSTwm3ZnUEhTjOPQ8da15fAHiRAcac5+jA1RuvCmuWsZmuNMuEjQZZtvC+5qtVqIyL+dLl08mBIY1BG0c7j3JPrVYr1Cnt+NXTZXScGJ/f5etNa1mLcQSE5z905pAUghL5OeOxFdb4MxmbGR8oHAx3rnHt5lLloGBPqDXV+CrSaQzLDDI74AAVSSaLAdBJgA56dTXpngS1Fn4fgZlIe4Yytn0PT9BXHWnhPUrraZ0S2iP3i5+bHsK9EjIjRI0GEQBQPQClJW0KifMXiR/N8QazJn711IP/HjWfCCCvoOnarmsxn+0dTdwfmuZD+bGoIVG4bc44pvck0NJXfqsQ4yXRf1r6U3bVUdgK+dNATPiC1XAGZUB9+a+hnb5jzxUsqIrsRULNzQ7Y6VGzUkWDEVC5+WlLY+npUUjYU9qEBVlOWFIxzzTGPzjjpQSPyoJYuflzTf5UhOen5UhOOaYjofBEe/WC5/hFdV4bXzfFzP1CZNc54D4nnkwTgHpXT+DT/xNL+4PRFJreGxyy+Jlq8vYLNtRu5Y1eQk4z7dBRXK67ceZAVdjtd849aKhyu2zVIZil59abRmoLFP1pKO9J3oAQ02lPWkJoYyNh16VE9TN196iakMYBhlrpwfkU+1cx3/ABrpUOY0x6CkxSJouTV+Gs+LrV+HpUjRJdDMDD2rgnyJGHoa9AmGYT9K4C5G25lHoxoRSEz609TUQ96fGNzqOmT1qkgJ0bLYHJ9BXhfxHjI8UX+4FSZO456CvsLSL7S7G0ijt9MhO1QDIRlmPqTWdq2i+ENameXU/D9tLM5yz9CapONyG2z4utxiVcH0PFdN8O12+NrLHzMZfx6GvplPAHw/Y8aGI/ox/wAau/8ACCeEdJSO70zTI0nxlHA5X8ar3bbi1OQdWUksrAepFNLn1NQ65JNHdFVZlTPAzTQ9ZlosF5CQsbhWPRmBIFN1Twhr+sadNbRa/pqwzLtZDEVbH1zTbc7p0GK6nT+oxTvZ7CZwSfCjXAhRZrB1P8SS4PT6VlW/wy8W6Bqj6njT5jggKZNwH4Yr3S0Pyirk0QlgZSO1O67BY8Js7i7e+EGqadaKD1dR3rbjWOAMII0jB67FxmtzxDoaW6S3eORyPaub35Gc0rsaLJkJ60gkxz6VXL981YfT9QNo84tZvL2kg7TzxTS7DPm/XxuvJ2x9+Zz9fmNVIQS6he+DWz4i066iuT5tpOhyT80ZFZ0MDGTlT+VU0zM1/CqeZ4ksh/03TP4Gvd2f5jXjPgHT57zxZZRW8LyOZfTjuc17dfaVqFnG0tzbssYPL9RUuLuVEpO1RO3rSM1Rs3rUlDicj0qGZvloZuahlbCnBoGRbvnPqKCwqEMGc04n1oJFJ6/zoJxgGo92CMUE8U9xHa+CQVsLmT2PNb3hkiPSdVnx2IzWL4YXyvD07+tbOn4h8F3Td5X2iuiJy7tnKaxJ5jRgDhQTRVbUXxJg9gKKw1sbmnRRzSUDA0hJzRnI46UmaBh9KQmikNK6GNOeajNSGmN19qQDCPauiiOYk6/dFc4eK6G3OYYznsKTCRYi+9xV+CqMI5q9DSBFqQZjNcDqQ230w/2q9AP+qNcHrS7dSmHqaFuUimO9PQ4dfrUY605eo6UwO7tGHkoenFWM981Usjm3Q+1WR+lBI5TitmXmxhyaxRgcVsThjpibepUgfXFAzyi71A6nqN+giVY4H2owOcjOOaXdxU2i6VJa6RczXKss0srD5hycE8/SqZahAXdPbN0tdVp55HNcjppzdj6V1lhjIoYnudLZ9BWkg+Ssyy5ArVX7lMZy3jc7dIm59P515urH1r0Tx8caNLj1H86803UwNTRNrarB5ih1U7ip6HFeqx6xIwG5YyOmMV5NoJzqaD2NegJ90cVPUTNaS7t5v+PiytpM/wB5AagEGiE5fR7I+4jFUiaCfwFNSa2YrHTabZaItu0ttZQwzKeiqB+Nc34qvTNpV2gAEQQ4FX9PJEMh9q5zxLJt0i6PT5MU029xpWPPmbjmmFqaW460wtSLHM+arzt8oz1pxb86r3DZAHFGoDVbJ60u7BqBGz0xSlu2cUxMkLcZ9aQtniot2ckjnFOQ7nUDuelC1JZ6Lpo8nwqMdWrVuB5XhOzj/vvk1QkTy/DttHjkgcVf1r93p2nQ+ibsVtf3TngtTg9Vb/TXHYYFFR3rb7uX/eorJmxvZ49qT2pOtA9KAA0n4UHoaTNIYZpCaX60lAxGHHHSo260+mN0pDQw10Fqf9Hjz6Vz5+tb9lzbx/SkxSLkNXYR0qnCOlXoe1Jgi4PuVw3iBcam/uBXcL9w1xnicY1AH1FJblIyBTh1FMpRyRVgd1YqfsycHoKsgGrdjakWsXHO0VObb2pWJuZwraHOnw8VTNtjtWlJGUsYRQNHJeIh94CuGbgmu68RDAJ7VmweBNeuokmhtk8qQblJcdDTimwuluYOk/8AH3z6Gus0/qKpz+ENV0OMXeoJGkROwbXycn/9VXNN5xRKNmK6Z01l0FaafcrNsuSPWtQD5KBnGfEJv+JRIuedwP615sgaQgRozt6KM17bp1jaap4iFtqEKzQCJn2P0JBGM121rZ6fZKFtbWCIDp5cYFXFXJcrHzzoenX8NyLieznigxje8ZAye2TXar90fSuw+IU4bRoY1H351/QGuPC4FTJWYJ3HZpvekye+aTofWpGaVodtrKeOlcn4skxo0/PXA/Wuni+WxlPtTPD+mWWs6k1rqUXmW/lltucc8Ypoex44X4xmmMw6Zr3aT4UaHJOzxy3AQ9EDdKivPhJpD2rraT3Ec+PlZmyM1p7PzJ5zwtj61VnPJ5rpvEnhLV9CvDDcW0kiE4SSNchqyI/D+sXb4t9PuGz3K4FQ4tPUpSTMtTgUpauv0/4b69cAeasVuP8AbOTXR2PwoHBvdQZvaNcULQVzyzcPWrOmR+dfQovPzV7NB8NtGhUYR3Yd3OaxdR8PHTtViW308iFTnzUGc0JEyehJqceLa0hHXAFP8RttuYo+yRAVNORPqtvHtPBHBFVfEZ36ncA8ADGfTitW/dM4Hn8jZuHPvRXUSeEWmt1nsrjfkZwRRWVr6muxBniiikJoYC5pe9N7UvWgYfzpD7UGkoAQ8A0w0401jRsM0NC0ibWLswwkKqjLsewroptHnssR7HZF4DY61i+GL+WwuJHhPUDI9a7i28WDYBPbK1Q2Q73OejiZTypz9KtwxnjitxvEGnS/6y1wfUUDV9JYdGX8KWg7mcqnHANVJbOCRibiFJCeme1bf2vS5TxcY+tIwsH5W5j/ABpDuYJ0jTpOtqoPtSf8I7p7EFY3U54AauhWC3b7s8Z/GrVlZo91EFdW+bPB9KpNhcnjtQsajHQYpTbD0rZNv7Uw2/tVCMY2wz0qxc2xfyo/QVofZ/mUe9W5LXdO7D7vQUDTOO1Pw+LsFQxye9aunXmoafpcNtHbpN5KBFZmI3AdzWu0O6XylHyAZc/yFSeTjtQnYTs9zz3xf4gvb+GKwvbNIMv5gdWJzgdP1rJ05eRXpWqaPa6lDsuE+Ycq46qa5weFbq2cmF0lXPHODSeoKyEsRjFaqr8lMs9KuUPzooH1rUSwITDP2/hoKuc7pEsUPidmmkRB5LAbjjuK65biGT7k0bfRhWRJolqcnygSerHkmuI8S6FLqGoNY6U7QxxDfczRnBHog96uMmkTJXOt8ajzIbGMHrKW/IVhm3x0FZ/hi2uRJJbXE00kdt8qCRi2M9eTXRmEDtzSbuwWhkNB1OKaYMdO9ajQ9ajMNIZSnHl6fJip/A3OtS+0J/mKj1keXZKp4yRTfA8mNddT/FCf5ihbg9j0RCR3qdJj/FzVZWzxTxzWxBZkSOZMOqsvuOlZlzp20F7flfSr6Ng8VMrrjpihq+gvQ5plYEg0nNaOszQxum4ckdu9ZZvYx92P86wlo7FpXJBmnojFslePeqrXz4wqgVC11M38X5Ur2DlNEQQLN5skceR3xXDXKw3fjWYOFMKkkjHBwK6MyMx+Zia5XS/3mtXcv1/nTcnYfKkdKXtoxtjjGB044oqoaKzbHY8xBJNKTTB/kU4VsxDhSGjNIaAFpM0tIexoAT+lNPFLTTSGi5pfEzD2rYXpxWDZzCKXLdDxW3FKjAFWBqdhPclJ70w9OafkGmnvQAw5yaYxNSNxURNJjDzG6bj+ddn8O1JuLm4kJIUBFzXFfWu48HkQ6WD3di1CCWx3PnIaPMQ96xluBUgn461dyLGn8pNTCQYxnA9ayUn7ZqO+uStjNg8uBGCPVjt/rRcdjUs5Fe3EneU+Z+B6fpiptwrNWYKABwAMCnif3ouKxeOKacVU873pfO560AWaKg82k833pARatepp+m3F1IfliQt+Paq2gWTWumRm4H+lTfvps/3m5x+AwPwrP8TyfarrR9N4K3Nz5ko/6Zx/Mf1AFb7y7mJ9aYzIOnLb3Vw4UASNu/SkaMelaMh3Hk5qFlHagRQaOovKyavMgp1tEHuYwfu5yfpQM5Dx5dR6fGzSZKRLkgdSQOg/GuY+FniM6p4lWOaD7PIAw27s8Ecc1R+L+pmbVFtEbgfvHA/QVyngm4mt/EkL2rbZipVSegNElbUfkfUSkDvTxIo6sBXl+7xBN/rNSCD/AGRQNOvpf+PjVLhvocVXtfIOQ9Pa8t4/vzRr9WqpP4j0uA4kvIs+gbJrz9NCt2OZpZpT/tOau2+lWUBBjgTcO5GaXtGP2Z0Oq3qXsqvFnYBxVIU1aUsAOSB9TUN31ZVraD6KoXWr2FoM3F1EmPVhXPal8QtEs1OyVp2zjEa5pNiOtkO1GJ7Amub8PLmS5c9SRWdB4sl1W2LW0PlRP8uW64rntf1a6sZUt7WUxqybmI6+1O10K+p6Ld3UFtEzTSqgA7mivG5biac/vpJHOOdzZyaKFETZsA880oPSmCnA89asB9HSm59KUHjmgBe1BFAo70hiGmH8qe1Mb2oGhp5GKVFkLYhZgfUUnGeTXVrpMiWEUlnF5sbAEsoyc0WJlLlOWMmox9JCR7imtqF/H97afqK6KRFC/vFCnuDxUcthFLC7me3jUDPzvinyJkc5zja9cIP3kQP04qW01v7ShYJjBxjPNc54huxDK0cCmXHUqDisazmuJbkEK0ajsKjlNEz0Uah/eRhXdeH7v/iXQ4OOM15fYy+dbKxPtXX6NehbVFz0GKdrDep24u/epUuveuaW9HrUq3YHegVjpku/eo7+5GLNM8PcAn/gKk1greeppl1ef6Vpyk9GkP8A47QFjqxc570/7RXPLd571ILrB60Csb4uPenCfjrXOS3d0uTFCpjAyWd8Z+gp1nqS3CErwwOGU9QaQWOjE/vS+fWKLv6U4XOcc0wsVzcG48dNzlbKyCj2aRs/yWug+0ZriNEuBJ4o8QzekyQ59lQf410i3AIoCxpGc0hmz3rONwOxpPP560CNDzh61NFKEtbmUnkLsH1P/wBasczehqO/uxBply5P3VLfkKaCx4X4wvPtniK/mzx5hRfoOKZ4MA/4SK3YkBV+Ymsudy7s7fxMTVnw6HF/eP8AwJbH8yactgW57Q+r2EX+su4h/wACqtL4p0iHrdBj/sjNeTtzz1pjCs+U1PTLnx9pcIJjSaT04xWPc/EpiStpZY9C7Vwc33c/pVdRyark8xXOsu/HmtT5Ebxwqf7q1jXWvard58+9mOewbA/Ss/Gc0BfT9aTghXCRnf5nZmPqxzUUsWREv941Ptz+PerLQ5u7VcZ6VcVoyGemaNpyWnhi2bA3ua5DxMwfV3H91Qpr0WdBFo+nRf7OTXmmst5mr3LHpvwPwqnsJFYDIxRUgHtRUpdx3NQUtNB9qX0pFEn0pQajBp4psB/U0mOPWkFLSCwh601j6d6c1Mb3oGhmCSAMk1d07VtQ0x2W3nePacFScj8qqwzfZ5Ulxu2ENiupS00bxCPOhu1tbpuWV+ATTJn5lRfFt7OQtzDby+5QZrTstXhxltLsnb1Zc1VPgq8iO6Ge3mX1VxVmLw3qAwoCAd/mFNXRFokGs3wvYWT7NaxJ6RxgVweqwLGG2KB9BXpE3h94Yybm6t4h3y4rktZtbeRykUwfHUr0pO99TRbHO6JKGgaLBBU1s21wYWxng1QWIQXKov3dpqWQZTjqKncteZtLejH3qlS9OeDxXPKzYpyysvriouU4nSrenPJqO4viLuxJPAdh+a1hLcH1Ipl1OSisCSY2DCmmS42OxF771It76GuWW7JGQalW7PrRcVj0e1ntrnTI3UgXC/KwzWPNIIr2RgQMgDFcrHfMp4Yj6GpVvMnJNAWOnF2fWpYrvMiDPU1zK3fvU0N3+8Q56EUxWH+HLorqmulj96+kx+GBXSJdZHX9a4DTJzHq2tx9xeufzANb0V2fXmn1Cx0RuaT7V05rDF3x1oNz70BY3VuuazfF93LF4W1CWEqNsLEgjk8cAfjVRblsDjJ9jVXxZdFvDN1D5TskifM/8K8ihbiPJLcyfZYvPOZCoLfWtvQxjT76TuxWMfnn+lZEpz1/IVv2UZh0O3UjBmdpT9Ogp+QluQsKjYHFT44qNxxmmWVLjOOOKhQDJJ/SrE4qJBzkjAoBiY5+lLjvg08gAd6UDigQ1BlgPU1rWsO/WrZOvSs+BN0yDvmug8OQ+f4qjXspFPVIze56JqnyG3j7JGK8unbfeSvjILk/rXp/iBws1yw/gj/pXlufnyachxJOn0opplGaKkZoj3pRSHp1pwFAC9x3pw96QfrSigYoPSne3Wk+ooyaBgetRtT8/nTGo6DI5PuH6VBaNjH1qweQaqW/GcetLcTNVJ5VX5ZHH0Y017ucnHnyf99GolPA9Kifjp/npUisK0rMfmdmz6k1JEw6VWB6VIvDgVLKEul/0hCOmKQHNSTjIQ+lR/pVx2GSwwbk4oNsfStTSYfNgJxVp7T2qWtR8xzwtd3HeuX1HXl06R47mMjacZFeh/Zj5g471578QtL23sh2gBx1xRYTkzDuru61OUHRLiVZHGQobArX0R9XVDBd3PmTpwxxkVl+E4RbX0YZhhUYknjtXX6IEnuJpozlGfg+tDSBPqXLaz1ORQd0J+oIqzJZ6rANz2iuvrE/+NdHYR/dGK3oYgygECnZCuea/wBoCI7Z45oiP7y1Yi1GE8iVc122p6NBcocoMmuP1Lw2ULFVG2jltsBnxXKf8JRqJikVhMsc3Bzg4wf5Vrpc1w86vpGpi5VcqOGHqK2bXXLG7fEUoL9dvcUrtMLHSC5xzS/aBxzWVDKJVLI2R0qUbs5yaLsLGok47VY1dvtHhe9QddmfyrHViOa1bBhPaXED9GUimnZhY8uiiae4ihj5eRgoH1NdXqqLFcJbp9yCMRj8OtWPD+gtYXL3d2V3qSIVBz+JqjeNvupWPUsarqKKK5HpUbd6kIx9KYaaKKs/J6UxRhakn+8aaowo7UWEIRjrS444/ClH48Ue1DET2I3XiV1fgGDz/Ersfug1zOlj/SSx7DNdt8M48XdxMfc0+yM3uaviiTZa37jpggfyrzg9K7vxY/8AxK5exdwP1rhXQ+lEtSkQv+WaKSVXClvbNFRe2wG32+tO6Ug96X60xijpTh7UgpQKBijp70MOBSgDFHSmA00xqkIphp2GiPHrVaIbZGB6Zq2arXKtlWU4qbAyyvA4qN896rC5mU4Kqwq3HHLMM4UfWkwIe5FSxdelWk05z828D8KZc26wxEu/HucVNguQyshO0MC46gdqi74qG2i2l5OzdKmqkrDR03hgBrZ89jWy8Kmsfwp/qZB/tVvkUNiKi2wLDA71yXxEsQ0hOP4RXcRDMq/WuW+J0otraSQ9duB+VITOL8GeGf7VLzyEmNXKBR3x1zXptl4NjEY8lvLb6cVxnwt1FrTSRJjcrStuBr2XRdUsLlVBkEb+jU0JswI/D15b4IUMB3FXUs5k4aNgR6V2q+WUGxlYexpu0egpuwkzkfIfH3G/Kqt5ZM8ZHlNz6iu7UY6ACobuNpF5JNKxVzwjxXocjI7LGc/SvLZIn0q+aXBD5546V9TanYJKGDKK8l+IHhlBbTTKApUZyO9JhYzfC1ymoRuVPIAyK3/I9q434UoXmvwTkDAr0Ywe1C1AyhCa0NKjxL7YxTmh9qsafHicUBcpXRwG56Vx7nLE+pzXXahwsx9jXIE00xoacUxutPJ96ibqaoZWm5Y0nakl++T6mlz2NIQHkYpRjHGaQfpQTigRe03gTP8A7NegfDyPZplxKe4Nef2QxZTH14r03wlH5XhsseCwquqM+pleK2xaQJ/eYn8hXLMM9BzXReLm/wBIgXsEJrnjyfpSfYpEEyjYwwOlFPx1zzRQpIZcAzTx+dNFO60kA4c06m808YpjFAo7YpaPwpAhhFMapG9+lNPf8qdxkZpCAeDSmg0FGRcadf8Ams9nOu087HHAqW2PiCPAFrbv77yK6GzAKDP6VejAGMDFZtkpHP8AleJLhcA2duvryxp0egSBvO1O8ku5B0T7qA/SulLAJmork5iyKkpaHOOAGximdKlf7zfWo61WoHR+E/uS/WuixXOeEjxN35rpBUskWH/WAn1rg/jBLldoPAX+ld2vDDHWvPvi0cgnHYUCMr4e/wDIAB/6atXd2eQAP61xHw4TdoCDGP3rfzr0K0tW2A44oQGnY3E0Y+SRh9DWtDqN0B/rSfrWRaxlc5+tXlWhAacer3ach1/KnvrF3IuGkAHsKzDwKUGncYtxcyPncxrjPGxzpVxn+4a66XgVxvjhsaRdc/wGlqI4X4RJ8+ot6uAK9KK1558IlxaXzHvJj9K9Ez8tCAYVHSprVcSZ9Kiqa343H2psDB1UgW9wfY1yOcda6rWGxYTk9xXJscjmhbFIRhUbHrSkmo3PB7VQFZz+8FPGO+ahyN9OZu1ITHE49qaz8imHkc0g5YA+v5Uakm3bL/oagZ+Zq9V02PydAt0zjdjivLrJd4tUA6sDXrMihLOziA6LmqM0cN4pfdqhXsqAVk446dK0NdbzNWuD6Nj8qpFT6cipb1NCLGR7UVJnggUUn5isSjmnCmD9aUGmVYkBHSng1EDTwQKbAkBOKD0poNLnpSACeaYe+DQf0ppPpzTRQn0pppc//XpD0oGXrNsRjNXlOazLUkqccVahcA7R1rKW5PUtxs+0F8A+maS4b93xUL4DAs3Ipszh48g8VBRkyffaozT2zuNN44rdbAb/AITOHmFdLmuY8LnEsvHpXTVLJAH5hXAfFgYjPrtFd70NeffFmQCIc9VFITH/AAqt/M0KIdcyMf1r13T9OzGCRxXE/B7SGHh2xaRSC6lzn3Of5V7DaW8SIAeaaIbOe/s3ByKjksildNJEufl6U+KK3dSsgwT3qkhpnGyQlaj6Z9a3r+1QMdnSsiaLH1pMtFKc8GuG8fPt0e59dprubgYBrz/4hvjRbrntSEYfwkTGj3LY5Mp/kK709K4n4VLt8PsehMjGu0JxihAAqePiGQ/7JqAGpf8Al1lP+zTA5rXW26dJ7kD9a5Nmwa6bxI23T+vVwK5Qnk0LYpCs3pUUrcHihnx3qCeTCk0MCIPhsk0pb2qurZY0M9MklLU62bdMo5qo0owcGp9M+e59sUIT2Ox0OLzdUtIznIIr1K9AW4jT+4lee+D4g+uw8fdFd1qUuJbp/wC4v9KfchHnl43mXkz+rk/rUTMzHJP1pXbLZpDyckc0nqyxG5ziih22Rk9zx9KKL2FcUHin5FQBuaeDQhkqnnnrTgaiDUuaCiYZGKUmoc/nS7qAH55NMJppNJnjFMaHE0mabnj3pM0hlmA9R2zzV5CuQM81n2rfOatkAkFc5FZy8iepZMabeRk9ahchUHHP8qkDkL0xUUmSMk1JSM5id5pCaHI3mm5raOwG54XP+kS564FdOa5Xwuf9KkGe1dSTipe4mNZgK4Pxfp0viHxJYaVbgkzEbyP4UH3j+VdffXAiQnNaPhG3t9PlfUrpQbyYYGeqJ2H40Ihux22gaMLGzihgQKiKFA9hWyIGQfNXL3HipLdd22RgOPkXNLZ+NbCWURyzGN842yArz+NOxCOmdc1Xl+UVYtZ47pAYmBBqC8jaNsNQy0UZ+aoTqO9XJmxVGd8ZNIoytQIVDivMviS+NFn/ACr0TUX7CvM/iY+NFf3YUIGL8MAB4aQ46u3867DqM1yfw2XHhW392Y/rXVZ44pREKDzxUrnFnL+FRL1p8/8Ax5P7kU2ByHitttpEPV8/pXKs3vXobwRThknQMpHeuS8R6ObEefASYCeR/dprYafQxXbGTVW5kwuOopzsO/Sqd3JgAdTRqNhvOCM0xnznsagEmRz3phYE9+KLkku47q1dCUtPnisgcDBAPpW3oCjhveqXYT2PSPAMW7VXfsorc1mbZY30meuR/Ss74eptjupj0ANJ4qnEXh9mLY8yQD9c00QjmOn0pe/YiqkU54zzVkSK/QjNRcsiuWxEeaKj1EYhJB7UVT0EP3U4NUAP50u7vSKJweMU/dnpVfcc0u78qALG6gtUIamluaBomJ70m7NRbqN1MZKWHHPFN3fjUe7jk0maQFy1f5/SroY5rKjlKMD1q0L2FTiSRVPucVEkxGiDleTUbtlTUX2qAJuMqbcetVJNSg87yEbfJjOB6VLTGhrn52Ge9NzUbyZYnuabv561qlZDN7wuf9Nkx/drqJH/AIUG5j0Fcf4bfbeuc/wf1rT1LVGtsrAcStxu/uila7JeiOqtNOsrfbLqt7bwMxH+sYcD2FXwvh+VdsevQeaVxzwM5/wrySSR5ZC8jM7nqzHJNALGtEkjJwb1bPW5tBlZDJYzx3EXzHdGQSqgfzNc3dWwdfLmgwxGQjjG0f3mrndF1e80u4WW1meJgex4P1FeraVd6d40smhvEW31HC5dMZcD0J7dcijl7Bscjo2rT6I3mJO81lu5RvvD1ZfavR4tSW/tY5EYMrDIYdxXmWrWs+m3ktveKEmA+Ygg7VPQL9au+BL0wT3OnSMQo/fQgnJCk8j8D/OpaKidlcNgnNZt1LwcVbv5NoyT1rGuZSc1FyyhfycV5p8TmP8AZOPVhXod2ck5715t8T3/ANAjX1bpQgNr4fqB4Ws/cE/rXRduaw/BA2+GbEeqA1uN60lsIUdaluv+PPHq1RLU12P9GQepNNgZ8aZYnsKzvFMkcWhXBbGCMD3NbCRwx2xllk+bJAjHU1yfjNj/AGTLK5/iCqOw5qoysieW7ucK74HI6Cs+8lwwx3qWaQnrmqE7ZPPNSW2SI5wO4p3IB/nUSHgVID04pkkgODk9K6LQlAiHHY1g2VrcXswitYy7nrjoK6fSoGh3RyLhk4NERM9M8HqIfD1xJ61ifEWTy9K0+HOC0mfyH/166LTE8rwtEvQyMBXL/EeOSa+sYoukcbMfqTj+lWnovmSc7p0gIIY9atsnUqaoW1jcKB2NaEdvMPvHgVBRTvZWCBTnBNFR6iB5gUnn0HeinZdRXLW4UbhketdzYeDIUf8A0p2lYDoOBXSad4dsbcg/Zoyw7kZrneJitjsjhZPc8ysdLv70j7PbOVP8RGBW/beCbto91xOqn+6ozXpMduiDhQAOwFSKqA49KyliJPbQ6IYWK31PN5PBTqnFy27HdeKxbvw5qVux2xeao7rXsuEIwQOKcoiVSAoNSq80VLCxeyPBZ7a5g/10Eqe5Wq5lHeveLkW8vyyRIc+ozWVdeHNKuwd9rGCe4GK1WJ7ozlgpLY8cL+9Jv9a9EvvAdq5JtpZIvbORWBfeCNQhJ8iVJR78GtFXg+pjLD1I9DnN9ZetjfEf92te9069sSftMDoOmccVk353R/ga2i09jCaaVmS6ZEr6Rz2GajBCayh9YzU+k/8AIPcZ7VUmbGpWzeq4q2Zrc1tw65o3c8VBu4o3c9ag1NrQH2zzMey/1pLxi8rsc4JwKTRwUs55j3IUfzpXAaMkUo7sT2K54xilty0rusWDsGWyQMCnMh25AzXEyGSK9kMpb7xz+dW3YVmz0eyjDgCVdoI796lgvJdNule3lZdrbkYHBU1iR+Mpb3TrbSREq21sd0bEfPk9cmntMXXnk1adiLdz0/VdTi8TeH47zaqalaHEqqv384G76AZNYXh2RY9WibPLKQD3Oe5/KsPw1eNHe+WSTHMpjYZxmtbTRt1aEDr5nbmlLUSVjuL08Jn0rNmPWtC8OVT6VnTd6wZoZtz3ryz4py/uoF9816nd9CK8h+KTn7RCuc96aBnd+FV2eH7AdP3S1sVnaEmzRrJT2iX+VXwffiktgZLH97NSXnEcQ9jUcWM0+/P+qHotMRmTcOa5bx5IV0aNR/FKMfhXUT43muK+IkmLOyTsXZqiK94o4dieRVORsuw5zVnPOAKpsdz/ANaslkwIyB7ZNPVuuahU+3B7mnlsN7UxHrnwhitDZTJdoA87YV66PUPBkttM0sC+ZGxzxXGeGw1tpNttO1sbsivXfDOuxtpETXoZnztXHeoi7OwmrmebWRLOyh8p1CEM5Iqpr2jG+s3uIP8Aj4XO33FdZf6ml1B5UcDLnHzGo7e5VIET7OXI6n1qmwSPEpbqaGRo5F2uvUHtUL3cnY4rqPHUELa87RxhMgFgPWube3UKx9O9VZgZxPn3SKT8xYUVPo8Qm1AkjhAaKT1Yj31Igo96sRAY4xUBcLnJqGafZ908V5aVj6FRuXHkIbH61UublVOQeaqSXhYHJxWdd3KqCQc07GkYJFldVYXDqTT5tSJAxXI3N4I7kktjIqeO+DADNKzNLxudFHeOz5JFaFvcFutcvHeLkcirKX6hcA/jTKk0zoLi9jRG/vUizJKNynJPauS1HUMQN8+KdZaku1f3nHpmhO7KVJNHUT2kdwjJOisCOhFcJ4k8DJOrPprhGP8AAeldGurFeFBOaU3szZO3AzzW0ZcrvFnPUwsamkjy1dLvNOSSG6hZCAeexrHDR/2jaGblQcHFe1ymO6iKTKrg9utcZqPhyxF200CbWz9zPFdCr3+I8urgJQu4anM3cQhnwCdhGQahBP4Vf1tNjxgYyOCPSq+mQ+ffQofulsn6DmtIvS5xmzIBbWEEHR9u5vqeaTTWDs0THk8io9QYyTM/vVQMUcMpwwOc1EXrcpq6OgtrZRIY5cD0J71heI9Bhml3QsUb1Hetm21BLyIRT/LMOh9ahuDIpIf5h2NdGjRlqjmbLSBbPvchmHTArRPA9BVl29RUJUtmgC1ooJ1K3/3s11uhRGXU2mOdqk4z61g6HZsCZSMMwwuewPU12GkRLG6qowBSkwNy7/h9cVQlHrV65HI+lUpehrNlGVeDGcV418TWLarEntXst70NeK/EM7/EUSD1UfrR0Bnqmmrt062XpiNf5VYxgjHSo7MbbeJfRQP0qYikgZLD1p2oD96v+6KbB94c1Z1FPnQjutMRhTn9649K4b4jI2yxkBG1QQRXa6lKltIzOeWHA7mvP/Gc5u5LeAMA5JJBPSlFXdwbOQdgAee1VVbLHmuysPB09yivcyqsbcjZzx9a6O28E6QLby5FYuR9/dzVJMlyR5cp496mhG+VAO5AxV7xBo0mjag0BbfF1jf1FQ6QofUbcH+8M0O6GelWq7LeJAOigV3mjRhfsMf91TIa4SM7WXPQEV65ocVtd29pdRqvMew+xrJIEyCcETK5PGMbfercXyqOc1JqcKi8giUAZ/xqxNZFkYKcHtiqYLc8q8Tia41ycxRO+DjgVnro9/PGwS3cEjjIr1NdPSK+WZlB8zh+O9bi2SKPlQVfM2Jnh1l4d1awSSaWAFe+OoFFe5S2o8pgyggjGKKS8xHOSz714NU2uBlgzcVjPqyFThhisq81iNAcyDOOea81M+k2OhmulJwW49SaxdT1OOIMC4GPeuZv/EGV2wnJ9awZZ3u5P38pVTVag5lnXvEAE+YzlfujHc1WttZuIs7peCe9UruxglaMxykhT0IpklnMQMKCKuxCl3Ogh16QkZIYfWtCHWxj5ifzrj1tXXqMVU1JbgptgLZHJIPQUco1No6/WdWeSJVhPBOD9Kn0m/LMqseQK5LTt6W0YYkueuau2ssiNujOHLY9qOU3jJo9Ciu2BGGxVlbsyEAtkD3rgzf3KE8hsehqZNakRDnjNFjRSXU7ltQEOdpwKqSzAgStIMntmp/hzoo12Y3+qFv7OibCoDjzm9PoO9etX8uhWViXnsrcoowqCMEk+grSNGU1fY87FZlGjLkgrs+e9eZZWDKQWHpTvDsXzTzEfdXaPqa6rxhp8upyGS20yCzTOVVFwce9ZFhZPZWHlyjEjsWI9ugrWnBwhys8upWVWXMlYqzrnOapyrjJrTkQc55FVJk+XIpk3ILIf6ZHj1/pUwuJVdlJDL70lgv+nRD3q59hZ5CfeqTsxSIVcP8AwEn2q/p1kZHBMfv83NXtM04AgMOtbq2ghUbcY9avmZFivDCI1Ax9a09OGJM46CqgFX9NH72kxmhMchc56d6qS9Kv3XD/AIVQm696kZk33Q14n4yIk8XRKenmKP1r1/xRqVtpGnTXd24VEGQO7H0FfPsepy6z4tguZEZQ9wu1cfdGafQR7/FwqjtgU8mmKOKf0FCAlhPzj61pagmY42/CsuM4attgJrFW7igDltbhVVE5UF1BAb0rxjxRa3Wq6iXswzKpxkV7prsJk02cKPmC5rzSG5hs9MLvLHGzMxVQMsauD0JkR+A767jifTr0sXTlC3X6V2kSO5HWvNdCuJ5dfinlc4MgAHrXp5uI4huOFHqTTTWxJz3xC00Hw+Lo/ficc+xrzrS32X9ufRxXdeOtYN9Yrp1hvuJHYFxEpOAK5/RvBXiC/miaKzeJAwO6TipqNIpHYRK0mdo6DNd/8O74mOWxc4I+ZM0aD4TFnYN9qIe4dcH2rPtLKfS9didFIG7j0IrF9wO5d/O1qLP8KjP5Vriudsbn/TWnIyxzWn/aDk/KoFU9wJryHdExUfN1/GoEvmKDJ+YDFQXF9JsPbjrXmuo+M2hu5olBJRiM1SQbHp73vAy3NFeOP4wvLiTbEAPc0UWFdI49Lm6Zfnmc/jRhnPzEkj1NZwsddk1kaeYNkm/yykfPJ6DNWUtpYL+azumIljco3Pcdq4kk9j241eZ2C+LLbsIj81V7W6L4VlGR61vJpwEfPNZ81sifMincG4p6I1trYiO9sbR+FI3ngHnitaKAFgelTm1Q9ADR1KSSOble42HlulZ4mnWP7x9x611F5AkcLngYBrMt7ZHhDY7d6pI0VnoiCwv4yFR/lkHrWtEVYhlA4rFu9O3DK9aqwTXlkcKS6+jUWG7o6FkcOW9adaQy315BaQqTLM4RfqTVK21mNlAljZWHtxXb/CuCK/8AFaTY3LBG0oG3PPQcfjVRhd2IrVvZwcux6np1iumWMFnB8iQoFAPyk+/PetTTbHzZze3kTTLEQkMWOrnufpTQ8aKTuAA7B8f+Ot/SrttrtvEhUMFReK7Iq58vJuWpZ1yCyitJHZVM33VT1Y15Pqqb7qTndg4z612uq6gt6sk8hBC5CD3P+RXHyISxJ61FTexVJNamO8P+TVOeM4NbksXBrOuVABrO5qZdptS+iLcYbrXYQwIVDcY9a42UfNk1e0+W5lyvmkQAfMf6VUdxydlc3Lm8VW2QHCqfmb19hSabe/adTWPoAhPFYsswk5UYiH3ff3p+g3McGro0zbQQRk+4rR6KxmnfU6/HJyKv6aP3gqiJEk5VgfxrQ0z/AFgqSzQvPv1Q1u6g07S42fDTPyAOp9qq+L/EFroUAe5bdPJxFEOrn/CsuNBfwxy3zETMuSOy+wot1A838afbdZYSSxsqop+UdBXCaBayReIrKNx/y8L+Wa+gpdDjmXEbqw64NcfrPg+W11yw1CNB5azDfjtSlK+gktTrAvpRipdtNI/OgYxeDwK2dKffA8Z7Vjla0NKfbcKD0PFDAW8QFHUjggivNrj4c6pql95/mxwQgbU7kj1r1K+TBb0q3pM0TWgV5kVk4IJ5xU69APP9N+HlrpCrc398Ay9GPHNbNhpXhu4n2PcfaJfR24/KuQ+KPii3tPGsFnPK72SWwbah43Enmqg13TryDz/tMURACgbMNgDgcVfJoQ2z2iw0WxtlH2WzhUY6hRWqltsXkqi/lXAfD7X77VdALbykUcrRIxHzFR610e15DmSR3PuahWWxVjZe5sofvS729FrO1GcXibYIPLx/G3WokRVHyqBUuOKoLFexXAbHTgVbHAJqtYjasmeu7p6VNK2FpAtipfy7LaZj/CpP6V4deSmS6nPXcxP617F4hlEGi3Tk87SK8VaTc+RwWrSGwmWrQgsQM7scUVPpmn3d26tbxO4BwNozmik2upFxLm8vdN0ZbWIfOlyt55wHznC7dpPpg/rSGykuLg37qRvcAk8DOM/1rUuSX8ny2VTJhCW/u9Sf0qhaSTX+5rZGkXzWESseAvTP9a8yTu7roey4NTsluy1qVzFawFmdVVRljngCsGz8Q2dwQkVjdOP7+3rXVw+GfMCtfESsOdp6A/StW30eCNQFjAGOwrRSVtjplCcndPQ5T7bFtwlrPk9ttQyG/cAxW2xT/eNdpJYIvIAwKrXCDGQAPc0I3hA4ye1vHTExUZHQVRP2m342DaK7iPR7u8ceTGdp/ibgVop4KeZR9pm/BRVXSG+SJ5tHc+ZIEKYapHiVzyAfpXqtl4F02NizRl27ljW1HoOn20XFvEuPaqUrowk6jl7r0PCWsoyc7Wz6AV2nwxlW0vLxymxmjCgMO2a9BXRoJSHSJI09dvLUsvh+2kQvAojnUFdw6H61UZNO7Rz4iM5QabFu9TLWmFY9c4z/AI1yo1lZIZNkgfHUehq7LHLZXIguxgEHB7Gubnt4YzN5Y2tnn3reNRNXR5ipOLaZ1dldGW2gXP3uTVho+9c9pF1iWBWPA4rofPWiWruSlYglT5aybtCScCteVwQazrjBNQ1cRlpaCa4ijLqgdgpdui89TXR+J9DstPjgOn3hntWO3A7kDufxrnL6KWeGRIH8t2GA3pU2mQXcWlRQ3c3muJHIx2Bx/hWlNq1yZK7RBNtwTkYHasHV58RN5GQ54Bra1MLbR4PDGsCeB5PnI5xVR1DYzrTUdTtCDDPLj0JzXS6D4y1KO4WKTYxbgEjvXPNbuvzbiPenWtwq3MQlQFkYMD2bBqnsK52mqaB/wkk9rqb3MovAU3gnKlQRlQO1de1vt6DjtVO0RYLkiP8A1EgE0RA4KsM/4itpiGSoluUjOKkdOKHd2j2MxK+hqxIoqIrU3GQFKaVqwV9qTbxQMq7eamtTtmQ+hpSlOiXDigDTv8EZ7EZri9fma1vI5EYru4rtrwA26n2rh/F8ZNn5o48s5J9BRuI86+IduNc1q3k4jmSMJkDg0ukeBLprYzHUIsDOVAOR3oSQXeoxSocq3IPtXbW7GDR1PIMpY/nxVNE3dzqPA9ta2OgWtraybiF3PnqWPWukUVxEE/2SOMQrtZQMGuutNQhezjnlkWPcOcnGDS5OXYady6q08LXN6p400XTg3mXKuw7Kc1xurfFeP5k022LdgzdKfLYLnqTKIWMhIC4+YVXe6hkH7t1f6HNeCal431rUSd1wYkP8KccVjrqV4rFkurgE9SJCM0mkI9m8XTJNCYry/t7G277myx/AVxMmseHLDi0sptRmHAkm+RPyrii7yZaR3ds8sTk0LxzVNqwrXOlvvF+q3MZit5EsrftHbLs4+vWiucGeMg0UJsVjsItH1LUr/eshitFXywP7w7mu00rSYdOtwsQ+YdWNXdHhAs4cjqoNWLxkSPg15trH0SuMSRW+Urg02SREJUHms8meZttujMc8ntWna6UT887bmPbsKbkkO6RUdJJhthX6ntVvT9HSNd8p3kDO49K044FVVXGB0xVm7wlttXoxArJ1LhdvQrwKI4kJGAelXImy2BzgVTvsM+xeFXpUkUhKgNwfT3pJtlWVi+GBTjjNVpx500MAPDMN1Krlhz36e1VLm4W2kLMfukEGrTFDyOpntVtY/mAJAwPasS4nKOdoPNajXQuLOOVmzuwQKpXHllCXIHsK7Zu+xhB20kYmsGO6s2WZQdvSvLdTmuIb2SHzDtQ8fSvStRmjFvOcYHQZNeXalcLNfzODwTxWdNNSdjHGxjGmu9x9vqM0TKSA2Dn0rpLXVFnQFXGT2zzXIZUjORSg7cEHBrY82525uSaYXL+9crDfXEPAfco7NzWhb6wv/LVCvutAXOmtogSMitFIEWPJ9KwLPU4mxskU+3etE3wdMZxVWFY57XW8zUY1JwpYLU2pWTI5Xbx24qnrSNI+9OoORXUadcQ6tp6SjHnou11PUH1q4rmjZEy01OHvoymepHTFYlypDZAwRyK7nULMF3+Xn24rnrqxPmE4AWp1BM7LwxqDXen6fE/3oA0Wf9n7wH4ZNdZEflxXG+C7VhEZSCASdvv2rsk6c05O40B61Htyak70hH0qRkZGKCtPOcUlAEZFCqQQafjFCgZpgXrr/jxX1xXF+KJ4ZdMubeVSIipVnX8uK7HUSV01cEBm+UE9BnvXNahpn2m+tbVCHiRfPfHOR0X9cn8Ka7kydjyKDTNR0qSNPIeeBPuOvXHuK6W6Ot6pa29tp9g0IAC75GA/Gu5udNwhBXrV3wvYoks1wwGPuR5/U0WZNzKs7KaCzhiuvnkRQGbHU1xHxNivoZYJbTz1tNmJNh4Br2XUTFFZSylQSoOPrXP6RCb2wkW9RZPmI5Gcim04IE7nzuWLt8zE++aXvx1Nen+Mfhyw33ehL7tB/hXmbxSW87xzo0cqnDKwwRUXKHoQKkQdfzpmeBUgwQR+FMB6jsB7UoBPpSD0zinDGMHOe9MB6Y/HtRTVwBknjrRU3SEfQaWaxKEVjtAx17U8WcbYyBj3q15JP0p3lqhGTmvMu2e5qRwxKMBF49hxUoVgacZQpVR3/Sklm/eBY+WI/Kp5boobKNqkr26VDcZe23DOdw/Sm3LMq8sM5wQO2aiW4VoHU9+v1oUTVD7jLTtjsMr70olBYOWHI6ehqt9rQbHI524xWcJJC7sDwWyKpeZSXc2jOcnkkZBqjqDEhsc1ALjAPPoCacZVILOcj3NHLzaBF8rLen3khthDKTtTp7068vWWMk8IO54Fc/qPiK1s0KRkNJ/dWuU1DWLrUTtkcrF2QV2QjJqzOetXp0359jW1zWhcAwW33e7DvWB5a9wKRakB4reMFE8urVdV3Y3yU7ik8iP0p+fWlzxxVaGVhn2dO1AtU9TipFPFOzSsFiNbVRyCcirEMk0QwJSR6HmmbuaA3NFh2Ln2oMAJF49RRC5im86zm8uXuPX6iqeajemlbVBujcfU7t1w9ujt/eBqK2sJb6UPeMI4uuxO9c3Pe3FvcL5MpAx0NaWn6vMYl81QT7cUpTZHKkd7aSJBGiRqFRRgAVfjuVPWuMs9Qad9sYYtjpV8XzRnDgg0XXQZ1Syo3Q80v0rnYr8N/FVyK+6c0WEax6UneqaXmR2qZbhT3xRYCToOTQmc/WkVge9SRLll+tIZ0Oj28V1cxRTKrRxxs7BuQSeAP50uk2NrNqeovGgAaXykwONqDHH45rldR106VfXW04KIO/ouf5mpvCOutDbRB5WG0DcD0Ynk/qa2jHRGUtzd8T2SWltK4AARM/ieBXPWL+VboiEcdcHmk1TWLu/ijtrkgvNPkcgEhR29snj6VEwdWC4OTwBKuMn6ih6MEXNSbfpzO5ITdtzjvTdDixZZx95iab4sLQWOnWSIQ+7dJkg7fxH0NWNIuIpLWONGAZOD71E+gLYt7cVzHi3wdYeIIS5QQ3YHyyqP5+tdSRg9KSsxnzdr2g3+g3TQXyER/wAEg+61Z6jPfj0r6U1TT7XUrVre8hWWNuxHSvIvFvgK60svdaZuntRyV/iUf1ppjucUOtPPAye/NRr1+bIboRUmcL1IPtTAXuMn8KKTOOckjpRQB9FvcbR1GaYZuGJbmoGQ8459KRxhVwcjvXmadD6FIe9w3ygKfrQkgx945Jzmoflx9OlRzSHZ8vBpXBomnl3DseKrGUDGe9VzNtGCf/rVkaxr1hp0Za6nVSei9WP0FJRlJ6A5qK1NgOoLc9+4qvPcRRqcyc+lcJceK5LpXNnBKiZxvk4/SsqS9uZv9ZMxz74rqjh21qctTGRXw6ncXniC2gBBfe/91K5+9126u8qreXF/dX/GsReue/tUqnjiumNKMTkniJz0WhYVick9anQgH61VU4FTK30q7WOcsqfWnhsD3qure9P38daYEmevejd3zUW+m7u9L0AshqUN71W3evAp4bOPWgZPu96cD61Epp/pmmFx+TmmNS55oPI96BGRdnN2fardqP3SZ9Kzb2TF4wq9BKoVeccVlLVgdX4ZizNI/oMZrcnUMMEAmsnwvzZNIB95q1WPWiJlJ6mfJCoPTB9qjyynhjV6QBhyOaiKAUbBdkaXDr1PFWY709D2rOvXKDIrPFw+7gkVWpSZ1cV4PWtHT7rfcRjOeelcbb3Dk4PNaFrcGKVHGflOad7lFLxkztc6hLk4aTYP++gKh066eK3LMcDJNQeJtasl8+KfzIy0gcMV4PzZqtNcRvpwlsiJ0YYJRs4/CtOYzsdT4ala+1b5/mWGLpt3DJPpXUCHblo24HaN+n/AWrivCUv2czSsCplVSM8Ef1rqxfLLGVzuOP4sH/69EdRMydTv1e9uZGZi6J5SL2A7n/PrWNYahLbShlY4zk1XmkLzTOT95jUYFRN3ZaR6DpWsR3SBZGw3rWqRxnqPWvMraV4nDI2CK6vRtbyAk1SJo3mzUTEEEHkVYXZMgaJgQe1QyKR1pEnFeKPBFlqpee0xbXZ53KPlb6ivNbjwtrVvdPB9ikkI7pyDXvDHFMD7XDD7w70DueGr4Q1515sXH1Ior3+O9R12zKP94Cina/UV2ZNzMojIqok3HPcVFcSg8nI+tU3vFVjwcCvNSbPoeay0NF5gBz0qhdXioM7sVzuu+JYbFhGAXuG4WMf19KfCZLhVeY/MR07CtoUW9TkrYlQ0W5geKvFlxHcS2VlH5bDrKev4UvhuzW90qK4uF82clsu3JPNY3iq32+IJOOGQNXXeA4t2isndJCK6owSVkcFSpKerINQslSzlwoHFcqvAHFejatbf6JgDkmvOX+WRlPBBxVxIRItPU88VAG5/WnBqoosBvQmpFfjniqwb1NPVuOaALQf/APXTt/vzVXzAO9BkpAWGfPT9aTf6VCCzdAx/CpI7e4f7sMhA9qNAuPDE1Mp/yaWPTrs4Igb8atR6VdnqgH1NF0JshU9KmUmpxpU+OWUVKunOPvSfkKOZIXMiqD9aDjIz2q59gUHl2pPskQ65P40uZDckcTq8yrfv161Yt7jJ+VG/AV1P2W1D5MKE+pFWIkhB+VFH0FTv0FzGx4OCyaUBtw3OQa1pIsHpWR4alCX7IeA/Sutlt8k0IhmG0dV5EIHFbkltVWW346UCMOWPcuG71RezOcgcVvSW5z0oW3PcUxox4bcjFaMEPHSri2vTirEVuc5xxTsUmYer6NDqFsySIDnoa81vLG98M3zPBlrcnlexr20w8Vl6vpUN7AySIDkY6UDOO0rVkvrdXgfkfeU9RW5pl6VlbzmwNpxXA6xpF3oV79otSwXOfYj3ra0bVotRix9ycD5kJ/UUKdgsmaxPJ54NOHbFRj86euc1O4Eq1PGSp4NV169amQ8c0wNzTdUktmGSStdRaX0F3H1w1cEp4qzBO0bBkYg5pITR2s8HGRyKpyIRVGw1ojCTfnWsJop1ypHNNokz2crRVieHqcZFFGgji5rxnOQT9DXH614vdZHgsEXcpwZTz+Vbut/avsM4iBeXbtjVB3PeuHh8L6m/341Qf7RrCnTW7PQxFZx92JW0zzL3WIDKxkd5MsxPWvVLWE7BxXGeHtDltNTjkmZTtzwK9GtYcIOK6DhbucP40tNuo2kpHEiFc+4rY+H4xLc2553AOP5Va8bWRk0YXCrlrdw5+nQ1jeGLwWmq2s2fkJ2t9DRHctaxO01mDFvHx1avK72wun1G4WGCRh5hwQK9k8QqojtlAzvbjH0qlFAEUcDNNIi9jy2HQdUl6WzDPduKv2/hPUW+9sT8c16NtxSAc07MOZnEReDpTgy3AH0FXovCFuP9ZNI36V1W0k96dsosK7Ofi8Macg5jZvqatx6PYx/dt0z71q+XS+X3pcoXKAtIFxthQD2FBiUDhQPwq/5VMaKiwigydaicZ7VfaOoXjoAz3BzUL56VedMVA6VIFBwcnNQPmrsi/lUDpRYCkwp0fXrUrKM+9IBzxSHcs2chhuY5B2NelWoE9qkg54rzRhxXeeELn7Rp4Rj8ycU0irF54cVWkt/QVrvHntUZhzninYmxitac9KVbPJ6VsfZzk8U8QD8KLDMoWvHSklEcCZkIH9a1/KAz6VzqBrq4lmfoGKqPQCqjG7BuyFe4U/wNikV45OMgH0NT+SKikt/atPZolTM3VtMivIGSRQQfavK/EGgT6XdGe13Lg5BHavZogwIRsketVNU06O5iKuoIPqKxlGz1LTvqjzHQtbW6IguiI7gdPRq6ADBrm/E/hqS1laWFTjORjtTND11o2W21AnHRZD/WpKOqH5mpB25qNCGAK8g9CKeKBWJVPNSK3JqEHFOBpoCfdnvUsN3JCcoxqruxSFvegR0FprAYgTUVzpP4GinZE2LYTgkjk1XnUhc1pGOqV8uENO1lYlycndlDSovMviT2rsLeEBBmud8Px5ldsd66uJcKBQNEU9mlzazQSDKSKVI+teSrE9lez2UwIkhcr9fQ/lXsoOBXB/EbSzHLFq8C/wCxMB+hpddC4OzNrTNSXU7TTkY5nh3K4+g4Nabrg1574f1AWd7HcYymMMPavRFZZkV4yCjDINaeYSVmQkelPSPNShKnjjpElfy8LnFSCPNWlj9qlEeBQTco+Tx0p3k1c8ujZjpSApeX7VG8fNXzH1NROlAGe0Y9KryJ1rQkX0qtIOtAGfIvWqsoq9LjNUpuKkCpJ71XfrVhz+dV3pAREU0LyKc3elGc0DQ810Hgu58q+MTdG5rnc5zVnTJvs9/DJ2Dc0Is9bKZpNgos5BPbI688VMBmqEQ7eenFLtFS4puPWmBAy5rD+zG1uZEI+R2LKfr2roiM8VDJErjDDIqk7O4NXRleV6ikMPHArQ8po/uEEejUrs+zCqi+4HNae0RnyMzGttoywwT0prxA9qumMnljk+tMZPaspPmdzSKsjB1OwS4jKsucivNvE3hoxM8kSnHXFewvGD17Vn3tkkyEMAc1m0M8W0rU59NcQz7ng9D1Wuvtp47iISQsGQ1F4j8OYLPEtcvavcabN8mQAcFT0NTsVe52We4o3c1BYzm7tmlRG2oQHOOAalzwQKZI/OaM0ykJqkA4nmimE/lRTu0I6gxcVlaoNqkVvv8AcP0rn9XpszLXhyLKkjua6Jkxisbw5/qx9a3pKRRCWqC8ijureW3mUNFICpBqRqjbvQUjyq7s5ND1R7O4+aFuY2/vLXUeGtWFuy2tw+YW+4x7e1VPiUBi2bA3AcH05rBsyfJ6mnF6l7rU9cRQRntViNOOayfDjM2lQFiScdSa24utUzJjlXipAtHpUg+7RYRGV9qQrUp6CmHvSAiYVXkIHerEvSs+5J2mhgRTSKOc1Skl3NhQS3oKZcE+tXtCUFGYgE564pMaRS+x3Mo+WI/jUb6RdN1CrXYDpUEvepabKschJo0g+/IPwFVZdOC5JYmuquu9ZF11osKxhvbIuetVJgFBFalxWXc96WyuCRGnUc1Ifu8cUxOoqRvu/hRsWd54K1UTweRI3zrxzXXBcV5J4YYjVUwSPpXrdvzbqT1xV9BMMY602pKQ9KBDMZNNxmpP8KQ/40wIiKayZ7VMKRqAKrRdqieOrj9qjbpSC5TZKhdMirT9ajfpSC5l3losqEEDmuK17QAWLIvPtXob96zb8AxnIHSpaAx/hnZhLfU450DKzKCD9Kt674VKbptN5HUxE/yq34NABv8AAx+8H8q6c/dpxirAeQOrRsySKyuOCpGMU04x0rqvHEaB42CqGPUgc1yh70tgEzxRSN0FFUhH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The slit width should be adjusted to make the beam as narrow as possible without causing the illumination to decrease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17265=[""].join("\n");
var outline_f16_55_17265=null;
var title_f16_55_17266="Greenstick mechanism";
var content_f16_55_17266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Greenstick mechanism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 356px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFkAaIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poormtR8X21nrF1psWmavfXFsqNKbS28xU3jKgnI5xQB0tFcr/wmX/UueJP/AAB/+yra0DVrfXdHttSshKLe4UsolXawwSCCOxyDQBoUUUUAFFFGaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuX+J+s3nh7wDrWq6YyJeWsG+JnXcAdwHI79a+d/+FxeO/wDoKWX/AIAr/jWFbE06Fud7nrZbkmMzRSeFjfl31S39T6wor5P/AOFxeO/+gpZf+AK/416N8DPHviLxV4j1Ox1+6t54YLRZo/LgEZDF8Hp14qKWMpVZckHqb47hvMMBRdevBKK809z2qiiiuo8IKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzrU9fg8LX/xE1y7x5VjbW020/wAbCE7V/FsD8a9FrhNe8LapeaxrMkVt4e1DS9TEBktdVhaQbohgZXBU84PPcUAeXfs6+K/EEXi2bQ/GGpateS6zYJqlm2oxTx7JAT5kUfmgZXaQcr8vy8GvYvhb/wAiJpn/AG1/9GvVCbR/Es99Z3s2neDpLyyDLazvBKZIARghGxlcjg4xWv4ZspPDHhGzsr6WOa4gVgzRAhWZmLcZ5xzSbSV2NJt2Ru3E8cEZklYKornrzWZ5WIg/dR9j3NUry6lu5d8rfRR0FQV51XEuekdEehSwyjrLVj5JZJG3SO7H1JpmT6miiua502F3N/eP50okcdHYfiabRRcLDL9rqewnhgvLiCR0ISSNyCrY4PXsa3PAmtNrnh6GWcbb63Y212mc7ZU4b8+CPYisasWyvT4b8e2tw3y6brYFrOeyXCj92x+oyv4CuzC1HfkZx4qnpzo9UooorvOEKKKKACiiigAooooAKKKKACiiigAooooA4b44/wDJJ/Ev/Xt/7MtfJVfWvxx/5JP4l/69v/Zlr5Krxc23j8z9N8Pv4df1j+oV63+zH/yO2tf9g5P/AEZXklet/sx/8jtrX/YOT/0ZXNl38dfM9vjL/kU1PWP5o+k6KKK+jPxcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADxXKaxe/a7jCf6pOF9z61sa9dGC18tD88vH0HeuYrhxdX7CO3C0/tsKRyERnbhFBJPoBTLiJZ7eWF87ZFKHBwcEYrnvhdPImk3+kXDM0umXckA3DrGTuT9Ca4ZaQc10OqU+VpdzobeaO4gjmgdZIpFDKyngg9DUlc54S/wBCm1TRjkfYbg+Vk5Jif5l/IHFdHVSST02HCXNG4UUUUigrJ8U6X/bOg3dmrbJmXdC46pIpyjD6ECtainFuLuhSSkrM2fAOvf8ACR+FLHUHG25KmK4TukyHa6n8Qa6GvJvAF+dD+Jms+HpSVtNXi/tSzHbzRhZlHuflavWa9iMuZJo8iUeVtMKKKKokKKKKACiiigAooooAKKKKACiiuQ+J/gLSviD4dbTdUUJPG3m2l0EDNBJjg4P3lPQqeCPQgEA1a+pV+OP/ACSfxL/17f8Asy18lU7XfCbeGtcm0nW9KtLfUIMMCsS7JUzxLG2OVP5g8HBFNr53MK/tZqLVmj9i4RytYGhKrCopxqWaa8rhXrf7Mf8AyO2tf9g5P/RleSVG7LAWuPNkgKrhnSRk+XrgkEVhhKqo1VNq56uf5fPMcDPDwkot2d3to7n3lRXg3wS+GV8s1t4n8VTX8bDD2Omyzv8AKO0kyk/e7hO3U88L7zX08JOSTasfhuIpRpVJU4SUkuq2fpcKKKKoxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA838VSzad8RLUSyMbPVLUrGuBhZY+SP8Avk/rV6pfizpkl34YGoWaM1/pMq3sO0ZJC/fX8VzVOyuY7y0huYGDRSoHUg5yCK8/FwtJS7nfhJ3i49ieuX0sf2Z8SruLcRDqtoJlBPWWM4P/AI6f0rqK5jxoPsj6TrKBgbC6UyFf+eTfK2fzrmiua8O6/wCGNqq0v2Jdcf8Asrxzp10QBb6nCbSQ9MSJ8yE/UEiuirM8e6e994cme3/4+rNlvICP70Zzj8RkfjVvTrpL2wtrqI5SaNZB9CM1EJc1NPtp/kKm7ScfmWKKKKZsFFFFAHDfFNn0m00vxXbKTc6BdpcNj+KBiElX6bTn/gNe3WlxFd2kNzbuHgmRZI2HRlIyD+Vee63p8WraPe6dcDMV1C8LcdmUj+tcJ8MvjH4c8KfD210fxdfvFrmkSvp8lqkTySybGKqQAMdMDr2r0MJK8XHsefi42lfufQVFeRwfGK61QK3h/wAE6/dQt0muVW2U/TceRWrB458TP/rfB6xA9M6ihx9cKa6XOK3ZzqEnsj0eivPv+E18REHb4UTg9f7QTp9CoqyPGeqxgG48MTYxk+Tdxufy4pe0j3Dkl2O4orih8QrWPm70bWrdB95za71X6lSant/iP4TmkEZ1mCF/SdWix/30BVp3JtY66iqVjqun36hrG+tbhfWKVW/kau5B7igAooooAKKKKAOR+JPgbT/HOhG0usQX8OXsr1Vy9vJjr7qeAy9CPQgEfJOsaVqOg6vcaTrlt9m1G3+8oOUkU9JEP8SHHB+oOCCK+5K434neBNN8b6L5V24tdQtgXtL4DLQMeoP95Dgbl7+xAI48XhFiI/3kfRcPcQVMoq2etOW6/Vef5/db5AlkSKNnkYKo6mvdvgx8JZUnt/EnjG3CyriWw0yQf6k9RLMP7/cL/D1Pzfdp/CrwPo+gal/bXj3WNDGoWspFnZi9jaKIg4ExJI3Meqj+EHP3vu+nar8WPBOnSyRPr1tcTJ1jtMzkn0GwEVjgsD7L36nxfkepxNxS8ffDYR2pdXs5f8Dy69TuaK8z/wCFv6bLC0tj4e8T3kXAEkWnkKT9WIqeH4taOGT+0dK1/TIm4M11YkIPxUtXo3PibHotFUNF1nTtbtBdaTewXcB/iicNj2PofrV+mAUUVma5r2k6DbibWdRtbKM/d86QKW/3R1P4VUISqSUYK7fYTaSuzTorgV+MHgVpfLGvJuzjJtpgPz2Yrs9M1Gy1WzS70y6gu7Z/uywuHU/iO9b1sHiMOr1qcop901+ZMasJ/C0y3RRRXMWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2WNJonjkUNG6lWU9CD1FeP+Ho38PeIdU8K3AIigY3Wns38du5ztHrtbI+mK9irzz4w6Xc/2bZ+I9JiaTUtGkMpRRzLA3Eie/HI9xWdWn7SLiaUp8kkyzVDXbFdT0e8smGRNGVHOOe364qXTL6DUtOt720cSQToHRh3Bq1Xkq8X6Hq6SRmeFtYF7pelx3SYlngKlmIO6SM7XH6Z+lZ/g0PZRaho8nXTrlo48nkxN86H8m/SqNslx9o8QafZrtu7O6TUbRc/eDKMj6ZDce9T3V2ieINH122JFjqsX2Ocf3ZBkoT7/eX8KpQUZSitn+e6+9HLGVmm+n/DHVUUUVB1hRRTXZURnchVUEknoBQBn6/qY0vT2mVDLcORFBCvWWQ8KorH8LeDdM0hn1C4s7abXbmRri6vGQFzIxyQp7AZwMVfsbU6jqS6rdqRHGpWziYfdU9ZD/tHt6D61t1rKXIuRb9f8jJLnfM9ugUUUVkahRRRQAVBc2dtdJtureGZfSRAw/Wp6KE2tgaT3OdufBfh24fe+lQKe/lZjz/3yRVKTwDpXm77S71ayI6fZ76RcfmTXX0Voq1RdTN0YPocnL4SvggFr4x8UwYGOL7cP1FZ03grxAwxF8RPE0frtkXn9K72iq+sVO5P1en2POT4D8Ssct8SvFWR0IuMcVAfhtrbtuf4jeKixOSftNekzzRW8TSTyJFGoyWdgAPxrm7rxvo8c3kWTz6jcZx5dlEZf16frVxrVpbESpUY7nJaj8M7ny4/tHivxlqtyxIVPtqxxr7sx+tYr/BC51F92oeKNTt4SOYI5Wm/NmI5/A16Kmr+JtQT/iXeGja5PEl/OFGPdBz+tOXw14l1BB/a3iQ2wPPlafAEwPTceauWJcVaUkvxf4GPs6d7pNnIaT8D/BGkDzr+Ga+ZRlnvJyF+pAwPzrpYNa8D+GI/Js7jSrMBfuWkYYt7fuwST9auN4E8O2+Ztannvm6mS/uiR/MCmHXvAfh1SIJtKhYDpbRhm/8AHQaxdfn25pfgi/h2SRUPjyO6TGh6FrWoufulbfyoz/wJj/SuY8Y+OfHOk29u0PhewgkvJfItreadpp5W7gKuB05rY1L41+G7IOBaazJEBgSx2TBfwJrh9J8T6fq3i3TPFtvrGo63bWKzxz2DwYmsd4wJVQH5xjgke9a0qcnduFvxuRKq20uY9GtNOtNRnebRtQg0rxTYhFvTp0qsscpUEo6jh1zx/Wuq8PeP5rS+h0jxtDFY3shCQX0f/HtdH2J+43sfwr55+HuvjxP8VvEI8KQvZNcyNe288i4BIADrKvo5yfavbop7LxRp13pOt2axXQUx3NnL1Xj7yHuO4YVq5uk+67dUJRjV8n+ZteJPGOo6lrUvhvwFHDc6nGB9r1CTm3sQfX+8/tz+OCBa8O/DXR9PuDf6zv17Wn5kvdQ/ec/7CHIUDt1I9a8z8K+JZ/g7qEOg+Ibfz/Cd5Pi11mOPDwOx+7cY6/73XA/L6DikSWJJInV43AZWU5BB6EGvalmCjT9nhPdi939qXq+3ktO93qcHsHzXq6v8F/XcZJbwyW5gkijeAjaY2UFSPTHSvMPFehN8PbpvFnhCExWCsDq2lx/6qWLPMiL0Vl9uPwzn1Soby2ivLSe2uEDwTI0bqejKRgj8jWeExcsPPXWD+JdGv62fR6jqU1NefRiWV1DfWcF1ayLLbzossbr0ZWGQfyqeuA+CFxKfBH9nXDb5dJvJ9PZieTsfI/IMB+Fd/UYuh9XrzpXvZtfLoOnPngpdwooornLCiiigAooooAKKKKACiiigAooooAKKKKACiiigApGUMpVgCpGCD0IpaKAPHIYf+ER8dXfh+T5dL1Hde6YcYVCf9ZCPockD0NdTV/4j+FE8V6AYYyI9Ttm8+xn7xyjkfgcYNcv4X1j+17BjPG1vqFs5gvLZuGilXqPp3B7g1wYqlZ86O/C1brkZUlYad8Q7CYnEepWz2zHtvQhl/MZFUvFVp/YlvqEcjMuj3x82ORV5s7ocq3H8JIH4+nUv+I2+30/TtUjGTp17FOf93OD/ADrt7mCC+s5IZ0WW3mTaynkMprjqT5HGfR6P5DlG8pL+tTn/AAnqya34fs71T87ptkGfuuOGH5itevI7BNX+Gfiu4triznu/B96+8XkfzfZHPGXHXHr9M12Pib4g+F/DcEcmqavbqZV3RxxEyu49Qq5OPetZ07u9PVM0p1Vy+9o0dXUV5bRXVuiSl+JAzKPusoHQ/jXO+DvHfhzxgWTQdTinnQFmgYGOUAdTtbBI75Ga6eotKm9dGXeNRaaoKKKKksKKKKACiikJAGSQBQAtFc9qvjPw/pjbLjU4Hm7RQnzXPthc1Rj8R63qxA0Dw9cCI9LnUD5KY9dvU1fspWu9F5mbqwXU6+s7U9a03Sx/p97BC3XazfMfw61nL4a1vUeda11oozyYNPXyx9N55qyul+FfDUfm3AsYHHJmunDOT65bn8qjmpp2vd+RDqy6K3qZx8WyXjFdB0W/1H0kK+VF/wB9N/hTzpni7VADcX9npER6pbp5sg/4EePyqnqPxd8K2rNFYzXGpTLwI7KBnz+PSuevviX41vGUeHvh/flHPyy3bbR9cVolVfwwUfX/AIP+Ri6ie8r+h2lv4A0tpVm1aa81acfxXkxYf989K0LvVvD3hm38pprS0VRxDEBuP/ARzXlR0H4veJpW/tfU7LSLNukMB5x6cVfsvhKLEedrPiiRD1ZkCoT/AMCbmk4Rk/31S/kv6/Qnma+CJ1Fz46vbuJpNC0Ym2U4N1fzLbxj3weSK5bVPF00rFNT8YW0J722iQNMx9t+ODUd/F8J/DpzrGpwX9yOT51w07H8BxVzR/iV4XT9x4T8L6pdoB9600/aCPqa1jCMf4dNv5f5icm/if9fIz7e0g1SVZNO8J61rDtz9o1acxp9cHg1S8a/btA8OXUt1eaBomcRfYtMiTz2JPAZjnHrkV3qfEK7eLePB+vgZxhogOfzrjvEOtz3d1JdXPwqu70ucl3ZSx98CtISquXvRsvVP9RO1tH+BkfEK/wBbX4SaDqFt4rgkaxliF/LbOHWQnhQcdWXoR35rQ0G40jxmYjm20jxdEvm21/ZoI0uR/eXHDA917VwfijRvCXi2QrCt74E1ckeZaajCy2kx9QRwD717J4R+GOjRfDmx0aS7S8ljZpo9Rtm+ZJCc5jYdvarqVo04+9da/wBeTFGLk9NS94L1G0s9ak0/WtKtNL8RTDmeGMLHegfxK3r6iup1/QodV2To7W2oQg+RdR8MnsfUexrzbWp5tMSLRviFGZbHcBZ67CNu1h0L4+43v0NdL4e8S3GlXNvpPiSZZo5h/oWqr/qrhewY9A/8646tKV/a0nr/AFt/kaxkrcr2/r+rj47+DUJJPDfiyzhF1OuzypFzDeL6p7+3UHpXO6df6/8AB6VhDHc694EZ8mEHdc6aD/d/voPT+XWvStc0ax1uyNtqMAlj6q3RkPqp6g1x897qvg4hNa8zUtCztS/RcywD/pqv8Q/2hz9avDYlP4dH2/yCpG69/wC//M9V8L+ItK8U6PDqehXsV5ZS9HQ9D3BHUEehrWr57m8HzWN5/wAJT8K9Vi068n/ePbD5rK9Gedyj7p9x+ldX4Y+M+mzLc6f4xtn8PeIbWMu9rcH93cYGcwv0bPp1+tenSkqrtHfscs4Onq9jX+DvzReMZRykviW9dD6j5Of0r0KuD+CNpLb/AA50+e5GLm+eS9k9zI5IP/fO2u8r0c0aeLqJdHb7tP0ObD/w4hRRRXAbBRVDXNVtdE0i61LUJBHbWyF3Pc+gHuTgAeprynwx8Y7vXFFhaaA11rssj+TCk6xxGPkglm5yB1GOcZ4zgY1MRTpyUZPVnpYPKcVjaUq1GN4x3d0kvm7LTr2PZaK4H7V8SsCb+z/DGz/n386XzP8Avr7tW/D/AI4W51ZNG8R6dNoesv8A6qGZg0c//XOQcN9PyzQq8b2d16oU8rrKLlTcZ235ZJtedt7ea0OzooorY84KKKKACiiigAooooAKKKKACiiigArzX4kaPcaTqcfi/R4mk8pBFqltGuTNB/z0A7un6jivSqQgMCCAQeCDSaUlZjTad0eZXaWviLw5KkMiyWt9AQjryCGHBpPh7qDX/he2Sdgbu0JtLgDs6cfywfxqrqdgPA2ukFwnhrUZT5HHy2k5OSnsrHJHvWFqt7/wgniuTWJVkPh7VSFvWRdwtpxwshA/hI4Jry69B2dP5o7lUUkqnyZ6U6LIjI6hkYEFWGQR6Vw+ufDnRX02/fQrG30/VpR5kV1GgLBxyBzng+grVs/Hfha9uUt7bXtPknf7qCYAml8Y+J7PQrNollWXVZhstbSM7pHduF+XqB71w0lWpySjdNlScJK7PLvGthba38KrbxnbQW+neJdKX7Sl1axiPLofmU7cfKcHj3r0zwhrtt4k8N2Gq2cqSJcRKzbP4Xx8yn3B4rgfi3Mvg34IPpJCte3iC1Cqc5Zjlz7gDP6Vj+GP+Ej+HkOhaRHdWWpWmqQxyRK0ew27EDI46jpXpKPtYPXq7ehjCfs5a9tT22R1ijZ5GVEUEszHAA9Sa4fV/it4P02VohqbXsykhksYXm2n3IGPyJq7ceCdS1whPFWuG5sd2TY2kXkxuOwZs5Ye1byQ+GvDFuI0TTNNjUcD5UPH61zqdJaayfkbyqTe2i8zjbf4ueF7hAY/7UMh/wCWX2CTcf6VP/wmmsaluTw74R1OYY+W4viLdPyOSa0Lv4k+FIm/0ad76UdrW3Zz+eKgbxl4h1Tcvh7wpdbe01+whX8utaa7qnb1Zk6jenN9yGtafEHUwoeXRdGQjkxK07/rxSS+A7Zk8/xd4j1DUI15KTT+TCP+AjFD6R451WMnVdftNIhI5jso9zD/AIEawb7w74E0x2n8XeJn1OYDkXd5uB+iLSU5PRS/8BV/xJeu6+9muvif4eeFz5OnfY3nQcLZxea5/wCBDP8AOiXxx4l1n5PCfhS52N0utRPlJ9cdayrD4geDtPYQ+EvDV9fOOEay084P/AyM1bbxb8QdVQto/hCDT4ugfUrkBvrtHNHsXe7jfzk/0BS6J/ch/wDwiXjrXOdf8VjT4ic+RpseCP8AgRq9YfCnwtYt5+qCfU5hyZdQnLj8ulY7+HviRqzH+1fF9np0TciPTrbJHtlsVGnwfs7yQyeI/EWv6sxH3WufKX8hTtLZ1El5IpQb1Ub+p1V74r8C+E4ij3+k2e3/AJZw7d35LXJ33x0065byfCeiatrdwzbV8uAqmfrW9o/wu8G6S6SW2g2ryryJJwZST6/Nmuvt4IbaLy7eKOKMdEjUKB+AqOSind3k/M0VOo+qR5Ibn4v+KgNkWneFrNhgmRg8o/AZP6Ci3+CUN+/n+LvEur6xOw+dRJ5cefYcn+VewUVft3FWgkvQpYeO8tTkPD/w28I6AQ2n6Ja+aBjzJl81vzbNdaiqiBEUKq8AAYApWIVGZiFVRlmJwAPUnsK4HxL8W/COhs8P9o/2heglRbWC+cxb0yPl/WpSqVe7Lbp0/I7+kyM4zye1ePQar8UviCwXwtog8N6U/wDy+33+sK+oBH8hXRaZ8CNZivrfWL7x/qk2uxD/AFmwNEOMEbSelbxwcnuzCWLitkdvqFhaajbNb39tDcwN1SVAwP4GuLm8BS6RK914G1SbR5ycm1cmS1k9ip+7+H5Ulx4d+JHhHVrvV5r2LxXpMmPMsoY/KmjA/ijHTPqK3fDXi/R/EK7LK58u7XiS0uF8uZD6FT/TNTKnUpeaGp062+jMeLxrGP8AiS/ETSV095h5fnMPMtLj6N2+hrD17wjqfhzT7iXwki674ZuVLTaPK+4xg877d+xHUD/9denX1nbahaSWt9BHcW0gw8ci7lP4VxB8O6x4PZrnwTObnTgS0ui3Tkrjv5Ln7p68H8zUQsnenp5PZ/5CnTkt9fzOa+FHxcs59W/4RjW5J4ZUOy1lu12P/wBc3/2h6969xZVkQqwDIwwQeQRXjms+GvCHxajmcRyaT4mtxiUFdk8TD+8v8Qz3q14Q1/W/As9r4d+IMiS2zny7HV1+4/okh7H61lXoxqPmgrS6r/IinNxVparubOreC7/RrifUfAVylnK53zabNzbTn2H8DH1FcJ4z8RW3jO2svDd5oz2Xig3kaPFcxZ+zLnmRJO4Pt2zXvTSIkRkZ1EYXcWzwB614vZ+HI/inret65ez3VpYxEWumTW77HUociQHrx15/vY7V6eS1eWUsZX+Glrf+99leeur8kzLFLRUofa6eXVmhY6x42+FZWOVJvFng+MBV2gC8s0HbHR1H+cV7D4H8b6B430wX3h3UI7lf+WkRO2WI+jp1H8q+e7vxr4n+FmqW+n+PVOsaHOxS31SAATYGPvL/ABED6H3Na40Lw940kHib4ca4NG8QJ832uzyu4kfdni7g9zj8+lCrS+Kprfr/AJg6UX8H3H0jRXkfhf4j63o2j6n/AMLO0o2txYBDHeWC+bHfBuPkUdGz1Hv2xitCH4y6CwDXGmeI7WL/AJ6TaZIF/TNbp32MGrHNfFi51rx3rw8MeFraSexsZP8ATJwdsXnejP0wvp1zng4Fbfw/+Dtj4furfUdXunvdShYPGsRKRRMO47sfc4HtW/oPxG8D3Kpa6bren2wXhYZf9H/ABwOa7WN1kRXjZXRhkMpyCPWuRYSLn7Wpq/wR79TiCvDCrBYT93TS1tvLu2/PsvTVDqwfGfhq18UaJLY3PyTD57a4H3oJR91wevXr6it6iumUVJcr2PFo1p0Kiq03aS1TOV+G2uXGueGI21IbdUs5Xs7xfSWM4OfcjB/GuqrgvAQ8jx149s0z5a3cFwAOm6SMk/jxzXe1FBtwV/T7tDrzSnGniZcisnaSXbmSlb5XCiiitTzwooooAKKKKACiiigAooooAKKKKAKWs6Zaazpdzp+oxCa1uEKOh9PUeh968d0bVzo/iB/BHihi2oqGaymlXKX1v1BB6FgMgj2r2+vOvjb4Vu9e8NwalocSt4h0WYX1lgfM+378X/Ahxj6VnVpqorM0p1HTldHkWv8AgvSNV+Nsdjf2MEVjeaOxiMSBD5qucsCP4hxWtbeE/H2iai7aZN4f1Iqgihv76Am4RB0BPqBWnqYPjXwrpXiTw0QNYs83FqvffjEkDd+SNuPXFbvhr4h6HrPhaTWJblLUWwxeQyHD27jgqR161wVKtWKTgr9GvP8A4J0OEOZ39UcpqHwz1fWdH1O98TasNU8RS2zRWiqNlvbE84Uep6ZrlIdJ+Jniq90e2uNKtNBGjxiMXkx3+ZtwAQPwr0C3+LWlaoZP+Eb0vV9ZWNtjSW1uRGD6bjxS/wBueP8AUpCbHQtL0y3OCpvrgvJ+SVEJYhL3kl2vpYTjB/DcuR+DtdvQp1vxdfuCPmislECn8R/hUVx4V8D+GlNzrAgaU8+bfzGR2+gP9BUv9k+KL9lOqeJBbx9Gi06ER/k55qxpvg3RbGYzta/a7s9Z7s+c/wCbdPwqUpL45/KOn+Roqbe0fvKFp4y04qYfCXh66vQOFeG3EMOf940tynjrVSP9O07RID1WFDPIPxPGfpXYKoUAKAAOwpaV4J3Ufv1NVR7v9DhE+HFpdOJdf1bVtVmPLebcFEP/AAFcfzrW03wL4Y0199podiHHRpI/MI/Fs10tABPQVTrTfUpUYLoJGBHEscYCRr0ReAPwpahuLm3tv+Pm4hh4z+8cL/OsifxZocLFTqEbsO0StJ/6CDUqE5dBucI9Tdorm08VpcFhp2j61ekdPJszg/icVIkvjLUY1OneF1tAf+Wl/dKMe+0c1osNUfQh4imup0FIx2RtI52xr1Y8AfjWIPBPjbUlYaj4ntNORv4NPttzD/gTc1ZT4OaLdOkniDUtY1mUDn7VdsEP/ARito4N/aZjLFr7KMrXfH3hjRMre6vbNL2ht28529gFzWFb+LPGHipjH4I8I3EVs2QNR1f9zGB6hOp/OvXdD8EeGdCx/ZWh2FuwOQ4iDN/30cmuireGGhHzMJYmcvI8THwY1TxEQ/xA8XXt9HnJsdP/ANHtx7ep/KvQ/Cvw/wDC3haFU0TRLK3ZcfvTGGkJ9dx5rqaK6ErGDdwooooAKw9c8J6HrjeZqWm28s/aYLtkH0cYNblFAHnt54U1vSMtoV6NRtVHFpenEgHosn+NZ9prsLXP2PUIpdOvxx9nuRtLf7p6MPpXqVUdW0mw1e2MGp2kVzF2Ei5I+h6g/SsalCE/U2hXnA8v8VeE7XW3jvbeR7DWoBm3v4OHU+jf3l9jWQmswapE/hP4j2UUN3MNsc5H7i69GRv4W9v/ANVdnf8Ag7V9L+fwzqAnt1/5cb87gB6JJ1H0PFeffErxNp8Gg3OmeI9FlTVJAFhs7hcgsTgSJIvUA9xgk8VFLA1cRUjRirvo+q8/Rdeli516ai5vT9TjvFWr6x4SE3gS61eCXTrl444L+Vz5sEDnHlv+H/jv1r3DTLfTvC/haCKB1XT7OHIkyDu7lvcsTn6mvDZ9Jv8AwR4Z1668V6EuuQahajfPGd72pAxtcnkDJBLDuB6CsDTx4us/BPhjT9W1uystE1icfZjdy4lijOCNxPVQCCPw6VvmKpzhDC0Ze5F3b/nlbWXy2S7a7tmNHmi3UmtX07Lov8zqF0qX4wePfP1JGXw/pL5ZCeGbtGPX1P5V0ctpYaj8VdKm8F28dummho9VuoF2wyIVwsJxwzZ5z2qO0KXkQ8FeALjbptqAdV1hGByW6ojd3b1HQfSvTNC0bTND0EWVhCsUQGxI1PJ/vMx7k9OetcLlZ32VtF5d3+iOiEG9f6uRW0f2m5N7MDtA2WyHoqHGX+rdvRQOuau0d6K5pz5mdsIcqKOo6Tp2pxtHqNha3SMCCJolf+Yrmo/DeqeE3+2fD2+NuFy0ukXkhktLgdcLnJiY46g46dBXZ0VUK04PRkzpQnuij8Pvi3o/iq/n0i/trjQvEVu/lzafe4B3c/cfo3T2J7DvXpFePeLNFWWX+17a2hluI4jFdxlcNcQDn5T1EiEbkYEHjbzkCtGHx42jeGr4arcLNPDZm40+8OALwcBQf9sMy5Hoc16Ma8ZR5jhjhak6qpQV22kvnsaXwzP23XPGmqLkxz6obdD2YQqFyPzrvq5f4aaO+h+CdMtLgEXTR+fPnr5jncc+4zj8K6inQTVNX3/z1N80qRqYubg7xWi9IrlX4IKKKK1OAKKKKACiiigAooooAKKKKACiiigAooooA8a8TeGtT8EeJLzXvDltNf8Ah3UJDNqGmwDc9tIfvTRL3B6so+tc7f8AgXwP481OTW7dv31xj7WlrM0QmOf+WiZ4PrwK+h64zxf8NvDnim4ju7u3ms9QjOVvdPlNvN+LL978c1lKnd3i7M0jUsrSV0ZWjaTYaJp8VjpNpFaWkf3IohgD/Gr1Y8/ws1RF8qw8ea3FBnpPFFM//fWB/KqZ+EGryMPO+I/iTaP4YtkY/DFczwkm7uR0rFpKyR0ZIHU4rC1nxj4c0VS2qa3p9tg4KtMpb/vkZP6VSn/Z/wBDvSP7U8Q+J74H7wmvyQ34Yq9pX7P3w709gx0Vrts5zdTu+fwziqjg49WJ4t9EcLq3x48H2rNFpn9o6tcA4CW1uVVvozY/lUen+NfiN4sZl8J+AxZ2zfcutUkZQB/46D+Rr3rRPCmgaEgXR9GsLPAwDFAqn88ZrbraOHpx6GMq9SXU8V0/wJ8TNU2N4h8Y2GmRjnytLslLD/gZANdTYfDC0RE/tbXdd1NlHPnXZVSfoOleg0VqopbGTbe5zFl4C8MWkm+PSLeR/wC9NmQ/+PE1vWlhZ2abLS1ggT0jjCj9Ks0UxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWN4uvNSstCnbQrNrzVZP3VtGMBVc/wATk8BR1OeuMd6unB1JqC699hSfKrnivx9+JN3Za5a6J4cvHglsJFnuZoj1k/hj9wByRyDnB6GtP4Q6Zo3xBsdS17xRC+ra483lym5jxHbrzsWHsBjuOQfTqZ/BnwNs4Lg6l4zujqt/IxleBGIi3k5JZvvOc/QdeDXsdnawWVtHbWcEUFvENqRRKFVR6ADgV9NmOPwNHCLA4JXkt57X6td2m/RbbnBRpVZVPa1dF2PMPEPg3WtJtpk0Nl1rRpEKS6XePiQIeCscncYJ4Nec6Fp3w5gu2sdVtZLa+jXyY7TXmbMCf3Ig52gZPbmvpusTxT4V0TxVYNZ+INNt76BhgeYnzL7q3UH6V8lKmntp6HqRqNb6nIaHpunaVp0dro1vBb2Q+dUgACnPfjrn1rQryTXPgx4z8G3jXnwv8QSS2CneNLvJM4A/hGflI/I16T4c1JtW0W1vJUWOd0xNEuf3Ug4ZOeeDkVwV6Dh717ndRrKfu2saVFFFc50BRRRQAKSpBBII5BFeW+IreG+8VWPhD7bHbWgla8jIZd6sVOyNQepDEnb/AHSPSvRtWv4dL0y5vro4hgQu3vjoB7k8VxOg+DNP8QaP/aPiqwiur6+n+2/OPmiBGEVT1GFP+cChS15Hs9zuw0fY05Yvqvdj/ifX5LX1sdpZ/Ei00LUrXRfHF3bWV7cKTbXh+SG4AwDkn7jcjIPHNeh2tzDd20dxaypNBINySRsGVh7EV4vceD57a4juNMu4bsRp5aW+rR/aFRcjIST7y9OvzUukav8A8IxqC3F3p17oVqZQbk2y/arRx3YquCn1CjHfOK9SFZSst/67Hzs6Ljd7HtlFUtJ1Ww1ezju9Lu4Lu2kGVkhcMD09O/IyO1Xa3MQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArz/xTpMmg6pPrtipbTrkg6hAoyYm6eeoH/jw/HmvQKq3F5Zx3cNjc3EC3N0reVA7ANKFHzYU9cA81MkmrSLhzXvDc42N1kjSSNgyOAysDwQehFOrN1mwl8H3TzKGk8MytnjJNgxPPHeIk9ulaCOsiK8bK6MMqynIIPQg+leXVpOm/I9KlVVReY6s7xFrNl4d0h9S1IXLW69RbQGV/c4GBj8c+1aNYvizXhoGlNcRgyXkp8q1hXrJIeAPp61mpRjrJaHRTo1K81SpfE9jmLzU7Tx3q+n6dpE4uNFiC3l5KoIEgB+SPBAPJ5IP9K9B6VyGheEDZ6dHNJeTwa9IxnnvIWyWduSrKfldAccEduMZq7JqesaXGP7T037dCvH2jT+WPoWiY5z67SevSnCnze8nq+htjsRFONCHwQ0T7vrL5vbysdFTJZI4YmkmdY41GWdzwo9TWLp/izQ75mRNSt4ZlIBhuXEMmf918E/hWlqUIv9KvbaOQAzwtECDkfMMYPsQcfjmmoNSSlocbmmm46nnsHh+/1e3l1jTtMtdAvrgM9rNY3UkM5Q/cMwHyEkdRit/4AeO/EutSXvh/xzb41W0UtBdhQPtCK7RuGxxuVl68ZB6dzcu9fhsLNrWC1mbU0jCw2IUlnPQYPTb6t2HXniq3wk0+QeKJFSdLj+yoJEvZ1HytdXEhkdAe5X5c+meea9CjOTdpI4KsIpXiz2Wiiiug5wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuCvR5/xt01JPu22iyTR56bml2nHvj9K72vPfH8v/CP+MvDniiXI09N+n3r9o0k+4x/2Q3X8Kwr6RTeya/M9PKVzVZU18UoyS9bPT57fM9AljSWN45UV43BVlYZBB6givLte0+XwLMbm3WSfwtK3zxjLNp7E9R6xEnkfw9fr6kjK6K6MGVhkEHIIrK8Ta1pWh6XLc65cQw2hBUrJyZP9kL1Y+wrSoouL5tjhoxqSqKNNNyeyW5yF1qNpa6c9/PcRrZqnmGXOQR2x657Vyvhm1n8Q6uPE2qRNHbqCum2z/wACH/loR/eP+exri9Wgl0aSw1bW9O1Cy+HlzqBMVvNID9l3AbHkTGfKLZ4zxnjOefZoXSSJHhKtEyhkK9CD0I9q8edN3v8AZ6eZ9L7WOEpulFp1XpK2vKv5U+7+01tt3H0UUUHnlS902xv1C31lbXKjtNErj9RWSfB+kI7tax3FmHBDLa3DxKc/7KnH6V0NS2lu1zcJEnVjyfQetXGc1pFkShB6yRzmk+ALW91JftOq63LCqEFPtzr8p4IyCDg+lej6Doun6BpsdhpFrHa2ichEHUnqT6k+tWbK0itItkQ69WPU1Yr1KUZRjaW55lWUZSvHYKKKK0MwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq+oWdtqNlNaX0KT20ylJI3GQwqxRQ1fRjjJxalF2aPP4vh9e6apg8PeLdW07T+cWrhZxGPRC3Kir2jfD3SbHUV1LUZbvWtUXG251GXzSn+6vQY7ccdq7KisVQproehPNsXNNOe+7SSb9Wkm/mylrWmWetaTd6bqUCXFndRtFLG4yGUivnnTrrUvg/rP8AwjniszT+D5ZMaVrDAstuCeIZT2A9e306fSdVdU0+01XT57HUraK6s512SwyqGVx6EVpOCmrM4IycHdHGRSJNEksTrJE4DK6nIYHuD3FPqjZ/Cqy0JpW8H6ne6RE53GzZ/Pts+oR87fwIqWfTfFNjvL2VhqcY4U2spgk+pV8g/QMK4J4SS+HU7oYuL+Is10Wg2LQKZ5hh2GFB7CoNA05mghu7uGWGUjPkSgbkPvgkH86361w+HcXzTM6+IUlyxCiiiuw4wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+cLj49+IVurhItF0ny45njUtLJkhWI5/Kvo+vhOf/AI/Lz/r5m/8ARjVw4+vOjBOHc+q4SyvDZniZ08TG6Ub7ta3XY9Z/4X74k/6Auj/9/ZK1vCPxs1zWPFej6XeaRpkcF7crAzxSSFlyDyM8dq8OroPhz/yUfwr/ANhGP+Rrz6GOrTqRjJ6Nn12bcK5bhsFVrUoNSjFtavf7z7Oooor3j8nCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryTxs1na3fjzXNUhvr5dHtYJobaLUp7ZSPKJIGxsDJ74Net15F40l0a6v8Ax/4f1rW7bR21a1t4Y5pxnAMRBYLkbsfUUAYfwz1XQfGviN9K/sqRANMj1L7Tp/ii6vI497AeTJymyUZ5Xnoa9Q+F7u/gTSzLJLKwWRd8rl2IEjAZYkk8Ada828KR+GdM8T6NresePdGvptH0saTZx2lv9mUxjjdIWkkLtj02gdcV6N8KmD+AdJdTlXWRlPqDIxBoA6yiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvhOf/AI/Lz/r5m/8ARjV92V8Jz/8AH5ef9fM3/oxq8vNf4cfU+74B/wB8q/4f1Q2ug+HP/JR/Cv8A2EY/5GufroPhz/yUfwr/ANhGP+RrycL/ABoeqPv8/wD+RbX/AML/ACPs6iiivqj8FCiiigAooooAKKKKADpXnja/d6x4qmn064aPR9O326FDkXU5GGb3Veg9+a2PHmqzxWsekaXKY9SvwQJF6wRD78n1xwPc+1ZNhaQWFlBZ2ibLeFdiKTnA9/cnJPua5sRV5I2W7OjD0ud3eyLTzSuxLSuSe5Y0sdxNGcpNIp9mNR0V512ejZG/pOrNLIIbojceFfpk+hrbrha7DTLj7TZRSMfmxhvqK78LWcvdkcOJpKPvRLVFFFdZyBRRRQAUUUUAFFFFABRRRQAUUUUAFFI7KiM7sFVRkknAArzKa81H4lXs1ppNxPp/hCFjHPeRjbLfMOqRnsnv/PoM6lTk0WrfQ7MJg3iLyk+WEd5PZf5t9F19Ls3NX+Iuh2V81hY/a9Y1Bc7rbTITOy/Ujj9eKpv8SoLMh9b8O+INLtScG5ntMxp/vFSSPyrrdC0TTtBsEs9ItIrW3X+FByx9WPUn3NaDqroyOoZWGCCMgio5ar1crfL+v0Oh18BF8saTku7lZ/clZemvqyvp19a6nZRXen3EdxayjcksbZVhVmvMrmEfDrxbaT2X7vwtrMwgnt/4LS4P3XX+6rY57dfQCvTaunNyupbowxmFjRcZ0neE1dPr5p+a6/J7MKKKK0OIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqWt6euraTd2D3N3ai4jKefaTNDNGT0ZHXkEdf55HFXaKAPjzxnaeNPBWuHS9Z8TeJJQ+WtLxdWulS6jHcfvOHHG5e3UZBBrko0Ea7QWPJJLMWJJOSSTyT7mvtTxj4X0zxdoU2lazCZIH+ZJFOJIXH3ZEbsw/xByCRXyJ4v8Nan4O8QS6RrKbjy9rdquEu4gfvL6MONy9ie4IJ8XMMPUXvptx7dj9O4PzjCTaw1SnGFW1lJJLmXZ26/n6mRToZZre5gubSeW2uYJBLFLE2GRh0INNrqPh34G1Px5qxhsy9ro8D7b3UMD5e/lxZ+9IR+C9T2B86hTnUmlT3Psc2xmFweFlPGfA9Ld/K3U3/h2fiD471hrex8V6xbabbMPtl+XDBO/loMYaQj8FByewP1Faw/Z7WKESSSCNAm+VtztgYyT3PvVLw9omn+HdHttL0e2S2srddqRr+ZJPUknJJPJJya0q+npQcI2buz8Mx+Kjiq7qU4KEeiS2X6vuwooorQ4wooooAKralewadp9xeXbhIIEMjsfQCrNcH4xvP7Y1tNEiIazsttxf8AozHmKI/luI9AKUpKKuxxi5OyKWmefdPNqt+pW9vcOUPPkxjOyMfQHJ6ck1foJJJJOSaK8ec3OTkz14QUIqKCiiipKCtXQb0QSmCQ4jc8E9jWVRVQm4S5kTOCnHlZ3VFc9pOqmPEN02U6K57fWugBBGR0r1adVVFdHl1KbpuzFooorQzCiiigAooooAKKKKACiiszxLrFvoGh3up3ZHl20TSbc4LkDhR7k4H40m1FXZdOnKpJQgrt6I43x5c3HifXofBWlTNFCyCfV7hOscGeIwf7zfyI6jNd5p1lbabYwWdjCkNtAgSONBgKBXh/hB/GFqs91by6Va3urSm9uJJ1MkrAjgbcjCrngDoTXRNL476r4ksc56NYLj8uv61yUqsP4knq/wAF2PVzBSjbCUfgh/5NLrL9F5Jd2er0V5pF481fQyqeKtIa4tQPm1DS1Lqv+/GfmH1GRXdaJrema7aLc6RfQXcJHWJwSvsR1B9jXXGSkro8iUXF2ZxXx21W2sPA1xbXlhPcxX2YUljICwyj5kLE89R2HYjis74OfEHU/Ft/Jp99bQJFZ2Slpl3F5JAVXJOcc8nGPxr0HxVolt4j0C90q8H7q4jKhsZKN1Vh7g4P4V43+z3p1zpHjHxJp98hS5tohG6+4fqPY9RXBV9pHExafuv9D63AfVK+SV4Sj+9pu6/7eaV1+T+R71RRRXoHyIUUUUAFcd458Xy6PdWmjaFaDUfEl8Cbe1Jwkad5ZD2UYP1xXYMQoLMQABkk15x8IYv7Zk1rxndDdcavdPHbMRzHaxttRR6cqc+uAa78HTgozxFVXjC2neT2T8tG36W6mNWTuoR3f5DofBXirUEE+veOdRiumGfK0xFgijPoOMsPcgUyez+IPhj9/Yajb+K7FeWtLqNbe5C/7Djhj9fwFek1Vv8AUbPT4vMvruC2T+9LIFH61X9p1G7TjFx7cqS+Vkmvk0xewj0bT9WYvg3xjpniuCUWZkt763O25sbhdk0DdCGX0z3H8+K6SvEfiV4j8GXl4mp6B4iitfF1p/qLiyRpfNx/yzlCghlPTvj3HB0rb4l+JdQ0+0XS/B80l88QMs11J9ntw/cru+YiscVGhyqrRdk94vdP16rs/k+7unzt8sl8+565Qa8dmuPiTqio02t6Po8bfejs7YzSD8X4/I1FbeEbmZzJr/iXWdWYnJR5vLj/AO+FrzpYinHqdUaFSXQ9G1zxloOjblu7+Nph/wAsYcyOfbC/1ri7/wCIPifUTs8MeFzFGTxc6pJ5Yx67BzV7TtLsdOXbZW0cPGCVHJ+p6mrtc8sZ/KjeOE/mZx8mm+OtXYtrfjD7FF1EOk24T8C7c/zqVfBFmyg3Wq67dSnlmnvmO4/QAYrq6KxeJqPqbLD010MG18M21qALe91OMjut2+atxW2t2hY2HiS9A6hbpFnGfqcYFadFJYiouo3h6b6FL/hLfFGmNm+0i11O3HV7KQpIP+At1/CoPEGreDPiDosuja/JJp8+d8Yu18ia3kHR0Y8ZGfXBGQQQSK1Kq6jp9nqVuYL+2huIiCNsihhz6elbRxfSaMnhnF81N2aPGNA+D/iDUfFsuk38ixaNb4eXV7cgrcxEnaIRziQ4Oc/c685XP05oek2GhaTbaZpFtHa2NsmyKJBwB/Uk8knkkkmvFP8AhWNlY34vfDWr6to0w/5ZQ3DPCfbaTx+ddXp9lrdnbxf8VPdtNzuBjEi47fe71dF0KSfJob5hjMdmEovEy5uVWX9d31fU9PorzxdV8WQArHdaVdDs08Lxt/46cU7/AITHxHbRk3PhuG5C9Wtb1R+SsMmuhVYPZnmulNbo9Borztvitptrj+19H13T1P8AHJZlk/Nc1cs/ix4HuyFXxFZxP02zkxEfXcBWhmdxRWbpWvaTqybtM1Kzux1/czK38jWlQBi+Mdeh8NeHrvU513tGuIoh1lkPCoPqcVxXhuwmsdOzfMJNRuXa5u5Bj5pX5IHsOFH0qvr1+PFPxC+ywybtM8OsGfaeHu2HH12D8ia3a4cXU+wjtwtP7bCiiiuI7QooooAKKKKACug8O3RdGt3OSgyv09K5+rmjymLUYSP4jtP41rQnyTTMq0OaDR11FFFeseUFFFFABRRRQAUUUUARzyLDC8j/AHVBJrxT4qTahrmo6ToltLD/AKe5lcSKSEWP5sHnleh7EkV6h4x1OPTtKkeXdsCl32jJ2qMnivBJviDpE3xAhurbzrqWW1+xWEKxn55i+WJP8IHQk9q8/FuU2oRWn9P8j3MmUaUpYiW8Itr8k/8AwJo9B8NeG4tHknu57iW91S5OZ7qXqf8AZUDhVHYCt+orbzfs8f2gATbRvAbIz3wcDj/PPWpa5ZNt6mcUktArD1Dw1ZXFwbq0afTb/qLqyfynz744b8RW5RRGTi7pjlFSVmjDOp+OtHINpc6fr9uOsV2n2ebHs6/KT9RUGj+PtAs/F0174msLrw1qt9Cluxul3QS7ScETLxnBA5xwBXR1XvbO2v7doL23iuIG4aOVAyn8DXRHFPTnVzH2Lin7N2urPzW/6HfW88NzAk1tKksLjcskbBlYeoI61JXhNz4IvtGDz/D3XLrQLgtuNsT51q/1jbOPwrn7nT/Eur6tHpnjT4mqs7JvOnaWBA23OPmOByfSu2NaEldHDKjOLsz6F1HXdJ00E6hqdla4Gf306px+Jrlrj4q+E1fy7O/kv5s42WkDyH88Y/WvM9K8IeD9Pk3QaLfardI2DNcI87Mfq3FdnZSzRxKljoM0KD7qkJEB+FRPEKPT72kVGinu/wBSbxH8RDL4f1T7BoWrZFpKfNlQRhPkPPJ7dax/h7q/iFPAGiW+jW+l2kCW+BLdM7s5yckKowMnJ5rQ1i31i/0XUbb7DChnt5I1BmyclSOw96574RT6neeAdOFulgY4DJCDIz7iA5POPrXZHE3y6ck1pON9e8ZW/JmbpRVdJ32f5o37nT9f1Fh/avii9WIjBisUWAf99cmqUXgLw/ktd2sl/JnPmXkzyt/PH6VvC11pid0unIO21HP8zUX9ma0Wz/a1uo9Bag4/M140sQ3vUX4/5HZGNNbRf9fMlsNL0/TgBYWNrbYGP3MKof0FXKyn0XWpCQ2vhE9Es0B/OkXw1dkHzdf1Fif7u1f6Vk503vP8zRTa2j+RrUoUk4AJPsKxn8ImX/X69rbjpgXOB/KmDwLpRz5s2oyk9S90xzU+0o/zfgP2k/5fxNsggEkYA65qBry2VtrXMIbpgyDNZMvw98OTY82zkc+9xJ/8VXPeKLTwF4TmtLS706OTUr47LW2Bd5JW6DvwM4GaqE6U3yxu36f8El1ZrVpHeIyyLuQhl6ZByKdXg99p2r6Pf3Wn+Grt7DxBepGbqdpglrZRk7sDcTlsdxXY6d4vv9JvodKvvM8S4jGb3ToiWLf7Q+6fqD3ronh7fC7kxxP8ysej0VyEl1411XjS9Ms9HiPSa/fzH/74H8jWJ4z0XWLDSVudX8U6hPLPItutvZotujs3A5HQVlGEXJRcld/MuVeyukelGivI4W1Lwz4k0HSNa8avaW/2f92JVVluH3fcbPXA6E16lJBqe9pbe4tbqJuVVk8vA9ivH6U6lOMLXluEa990WqKovqH2cAX9rcWx5y+zfGB/vLn+VWLe5guVDW08UoIz8jgkfUdvxqHCSV+hoqkXomTUUUVJYKSDkEg+1UrvSdNvWc3unWVyX+8ZoEcn8wau0U1JrZicU9zz/V/hB4M1GQTRabLptyMnztOnaFifpyv5Cmad4F8SaAhPhn4ha1GVBEcGoxrdRfQ55x9BXodFaxxFRdTJ4em+hxHwm0rUNB0C603XpUl1k3ct1cyq27zjIciTPfIAHtjtXb1FLCHkimXAmizg5xvQ9UJ9DgEZ6EA+tTOpRsHuAR7g8g0qvv8AvrqOn7vuPoJRRRWRqFFFFABVa/uls7cyFS7khI416u56KKsEhVZmZVRQWZmOAoAySSegA5zVHREbU7hdVlVltgMWcbDBKnrIR6nt7fWjSK5pbETlbRbl6KKWK3j+0MGlIy2BwD6D6dKcrFWDKcEHINT39xDa2jzXJxGvp1J7Ae5qlbmRolaZQrsMlRzt9s96inJzXMwi18J2WmXyXkI5AlH3l/rV2uHjd43DxsVYdCK6TStUW6Ajmws36N9K9OhiFL3ZbnFWw7j70djUooorrOUKKKKACiijvigDk9ekE9/IjAFFGzB6H1rz3wXbw3XiPxPqRhjLi9FrG23lfKUKcenUdK2vEXiqz0jU2j1KO5jSQkicRFk/Ejp/9Y1zHw913TbbRYVmuojealfSusKsC5JY8levQeleNUU5TTtvd/1959JhXCng6z/wx+983/tp6DRRRUnKFFFFABRRRQBagjUWVxM4BPEaZ9Tyf0FeSGG3Nxoty9vG99fa1LIZioLFU+Xbnrj2r1y7YR2ltACM4818ep6fpivNPFHw7k1eR5LDX7/TyJzcQBMMIGbl9v1NdMHGLs3b+n/mctWMpq6VzvdX17SdHjL6rqNpaKP+esoX9K4+8+Mfgq3Zkj1Y3Ug6JbQtIT9MCm6Z4A8N6bYeXqcMepTE75bnUGEjO3r83Aq/HfeFdGUfZjp0GOALeME/+OiueOGpebB8/VpGEvxksriTZp3hvxFeH1SzIH61zHw98Sa9o11rej6T4VuLiQzm8S3mmWFrdGwAGz7bPzr0j/hKrI4FnaahdLnGYLVsfriuH8WavqGieL9O8Tw6Pc29rPH9guBckRiTJyucZxjrk/3RXtZZRhUjVwfJ8aurveUdV96uvVnJiXyuNXmvZ66dHo/0N+XV/iZMymLQdCtEJ/5bXhkI+u2pBafEW5GZ9d0OzJ/hgtXkx+LYrbEHiq5TGdJsgedw3ysP5CmHw1rVyQb3xPcqB2tIEi/XrXk89GP8v3XOm1+/5GVBoPjSX5bzxkFA5P2ewUHH4mqWpWwgQm/+IdzAV+9maKP9K6A/D/TJ3L6neapqDHr9oumI/IYqZPh34SVw50Gydx3kUsf1NL61Rj/wEhezb6fizzC+1Tw/AW874na45xwtmpmY/kP61y2qah4lvzt8E6940v26K1zZiNCfc5r6TstG0yxAFnp1pBj/AJ5wqv8AIU6/1XTtMTN9e21so/56SBaaxyekYX/ryRLo9W7Hzxonhj43XMiNPrjWiHkmeZSR+AFdxJ8KNS1/VNG1fxh4hebU9NwUazjEYODkc+ua3tS+KugQzfZ9JW81m7PCxWMLPk+m7pWZP4t+IGpOU0XwWliP7+qXIQj/AIDT5sTPVRURWprS7Z2UXhDRlvpb2e1+1XkuN8twxctgYHHTp7Vqs9lp0JLNb2sS+pCAV5VJ4a+JWtjOseMbTSoieYdNgJb/AL6OP51yfjX4Fape2hn0rxbe6jd9Xh1IlVk/3SpOPx/Oo+rc7tUqGl5LWMD1vWviZ4O0ZT9s16y3D+CJ/Mb8lzXAeKfiToHjPTTY6foXiHVUjkWZWtITFyvQ7jXOeFbnw34FuIbPx54EXSbk4VdS2G4gk7Z3HOK+gNAv9K1HT459CntZrRgCptiNv5DpRKMMLJSUW/Pp+BKcqqs3Y8K1TS7fx5YiW3+H0rSQrgtc6qUuFPuD2+grsvC1/wCNtC023tJPCNl9hiG1Vh1DdLj33da9B1fQNO1X5rq3AmH3ZozskX6MK5660fxPpYLaLqMGowDpb364cD0Eg6/jWjxdOvHllZev+Yo0uR31+RfsfGFs4xqVjfaa/T/SIjtz7MM1d+w6Lq7GeAQPKOfNgfa4+pXn865j/hNUsJBB4p0y70hzx5rr5kDfR1rWtodF1iP7Tp8lvITyJrWQBgfXK1m6Cj70bx81qv6+Zqve0TTLc2lanb5bT9Uabv5d8PMH/fQ+YVF9t1S2H/Ew0d3XqZLOQSD/AL4OD+tDQ6zakGx1BJ0HHl3aZz/wIc0xvE9xYnGsaTcxIOs1t++T6kDkCj975S/P9BfD3X5E1vrenzSCP7QsUx/5ZzAxsPbDYrRznpVW11XQtfQJFcWl0cf6t8bh/wABPIpzeH7eMH+z57mxJ5IgkO0/VTkGs3UgnaScX/XoaKpLyZZoqibbWrdmIltb6PsrL5L/AJjIP5U06i0AX+0LO5tfV9nmIPxXP8qtRUvgaZaqrroaFTTyrLHH8p8wZ3MTnP8Ann86zrPUrK9Ki0u4JXY7QiuN+f8Ad6/pVx1ZCm9Su/7mRjd9PWnyzV1YfNF2dxKKDx1oqCwooAJIA5NY13cS6xNJpukSlQrbLy9TpAO8aHvIfX+Ee/RxjfV6Iic1FDZU/wCEi1A2UZJ0i1cG6cdLmQHIhHqqkAse5wO2a6klY0JJCooySeABUNjaQWFnDa2kaxQRLtRF7Cud1iVtf1J9IgfGm2xB1F1ODKTyLdSOeerEdBx1NYNvETstIox1jq92Os5/+EguI9RO5dPhc/ZEI/1x6GYj07KPqe4rYpAAAAoCqAAFUYAA6ADsKWt3baOyNoR5VruFCkhgVJDA8Y65oq/4ft1vpfOiO62Q8TL0dvRD3H+1+XY1dKlKo7IVSrGmrs6e3ZmgjMgIfaNwPrUlIqhFCqAFAwAOAKWvXR5LCiiigAo96KKAPPdY+Sxvi6htsbkqe+Aa86+G/gfS4H0fxRChXUGtWSUjo+48HHqAAK9K8YwyRWmrBRhmhkZPTlTisLwBt/4QvR9gIH2devr3/WvEbcKjS8z6aCU8A3/fj+Cl/mdBRRRQcYUUUUAFG9Y/nfaUX5mDHAIHOM0VFcR2ssEi6ghe02kygEghQOTx6daqFuZXJnfldjjfHHinWotQcaSll9kN0LKS8cliJmXPyDoQvuKu2/gGd1Q6t4o1q9k6ttkWFCfZVHH5mud1ezZPDHhGEnZLd6ks7fRiSD+RFeszSxwxNLM6xxoMs7nAUepNPE1pQt7PTVnJTXN8XkYFr4N0SBQGtDOR3nkZ/wCZrXt9NsbZQtvZ28YH92MCvPNa+L2mjUDpnhDTb7xRqecbLFf3Sn3kxj8sj3qkbP4oeJMtqGp6X4Wsnx+4tF+0Thf977oP4islRr1NakrLzf6Fc0FpBX9D1nKpgZVR6dK5Xx1NoGq+H77S9U1awtxMmFaSZf3bjlWxnPBxXMQ/CrTZQX1zWde1efP3p7wop/4Cv+NbVl8PvClkymDQrPK95VMuT6/OTWtGEMPUjVhN80WmrLqhyhOpFxcdGc18P/ippMXhiC11y6c39pmDMUbS+cq8BgQPwPuM966u08dx36FtO0LW7lezC22g/ma57xrpp8LX9t4u8O2kMQtV8nULaFQiywHAJwBgEcc/Q9jns9O1vTdSsYLy2vrYwTIHVnlVePQ5PBHQjtXqZjhKFVLHUIe7N6r+WXVej3j5adGc2Hc4t0akrOP4ro/8ygfEmvzFltPC0ysOn2m5SMfrVc3Xje8jdRDo2mt2Lu0xH0xxWrca/pNu22TUbUn/AGJQ+P8AvnNRHxPoSnB1SDI/2XP/ALLXmqkl8NP82dNo9Z/kYn/CL67fndrfiy+ZT1hskWBfz5P6VLZfDrw1bv5k1gb2fr5t5K0rfqcfpV9vGPh1ZNr6tCvuUkx+i0jeNPDS5zrNvx/sSf8AxNX++2St6IaVFdTatbaCzh8q0gigiPOyJAi5+gqauUuPiH4TgB36zGSOywTE/wDoFY1x8YPCcL7RJqMx/wCmVjI2f0FR7Go90aKrTWzPRKDwCewGT7CvKb343aIhxp+ieIr44/hstnP4k1i+LvGHi/xr4WvNN8O/D3XoYbsKrXEpIIQMGIGFHJx61ccLNvVWIliYJaHtV9ZwXtrLaX1vHPbvw8UyBlPbkGvNNS+EkNjePqPgLV7rw5fE7vKRi9sx9Cp5A/Or8nxN0TQLGwh8R2esaPOyrG0dxaMRE2Mct6e/6V3GmahZ6rZJeaZdQ3dq4BWWBw68+46fSlarR9A/d1vU80i+InivwYFh+IugvPZA4/tfTR5kePV1HQ/lXpPhfxXonim0FxoWowXaY5VW+dfqvUVbYBkZGAKsMMp5BHoRXA698KvD9/d/b9HNx4e1UHP2vTW2AnOfmj+6fwxWUqdGr05X+AnCpDbVHpksUc0ZjmRZI24KsMg/hXHal8ONDnujeaYJ9Hvuvn2EhjyfdelcnHq3xF8FsRrFlF4t0hP+Xqy+S5RfVkPX8M/Wuw8KfEXw14mYQ2WoJDe/xWlyPKlU+m01i6Nah70HdeRPNCWklqZwh8a6EwDC08Q2S/xL+5uAP/QSauab4y0u6n+y3bS6bejg296nlNn2J4P512tUtT0ux1WDydRtIbmP0lQHH09KI4pS/iR+aLSlH4X95kajoWlap893ZwyuefMUbW+u4c1z2raD4i0yBp/B+tyGSMZWx1D97FJ/shuq1snwi1gc+HtTubFR0t5P30P0weR+BpGuPEdmypcaTBer0MtrOF/8dauiNVS+GSa7P/gifK/ijZ+Rn+DPHNxdh7TxjZJoWrI20Ru/7uX3Vuh/Ou0e+tEhMzXUAiHJcyDH51yd/qyTRGLU/DmpvH3D2wkXPtgmuZvm8JIRI3hbUZnz/q49Pc8/TpSlhYVHdJr0syObl639T0V4tF1WBpdlldxqNxddrY/EV5T4d8O+GtTi8Ua9e2RNlCXSLfK2EABJYc8HpWV4r1mwWyuDo/gfXrK6kiaNLlQLJVJHU84I/CuU8MaH491H4V63bX+o22k6BGrymSdR5lzgZK7uynGM10U6DpQfvNXt/XzMZTUpbHtPgXxDJqvhyxOk2l7qkUESxS3bukas4HRSxy+BjJ9ah1D4o+GdKlubfW5b3TL+A4NncWj+bL6GMLkMD2OaufCMz23w88LW9rp7ra/ZF3yyMEIzzuC9SGJz+NdFq7T/AG6MxaFHftEN0c7yIuwnqBu5H4Vzyqr2jTivv/4JvFyUVZ/gcTp914n8fZ8m1ufDHhluGlmGL68X0Uf8slI79eepr0bStOtNKsIrLT4EgtohhUX+Z9T71Fpf9pOXk1IW8SnhIISW2j/aY4yfoMUut6pb6Pps15dE7UGFReWkc8KijuSeK5q1SVWShHbsv61Kire9IpeJtUltlg0/TmT+1r4mO3DDIjH8UrY/hUc/XApdJ0+HS9Pis7cs6pktI/35XJyzse7E8/p0AqpoenTwSXGoaowfVrwAS7TlYEHIhT/ZB5PqeewrWrflVOPIvmXTi2+dhSEgAsxVVAJLMQAAOpJPQVFd3MFnazXN5NHBbwrvkkkOFUf57dSeBk1H4f0q58UEXeqRTWuhZDQ2cg2PdYIIeUdk9E7nk+g1o0XUfkFWsqa8x+l6dceI7kM2+Lw8FyzYKtfew7iL9W9hXfxosaKkahUUAKqjAAHYU4DAAHAor04QUFZHmyk5u7CiiiqJCiiigAooooA5zx74bHifw7cWSXE1rcY3wzQnBDDkA+oJ6ivA/APj+fR5dJ0bxLZraaVeRkadqWcJIwYqUbPAOQw98V9P1896jY6Tq/gfXfAOoQ+bqiapcRWKKPmhGdyz57KMn3PTvxy1oRlUXN2f6HrYWcvqNWMd1KD+XvJ/i0dXf+LdItLprUXBuboDJhtkMrD646fjWrp1y95aJPJby25cZ8uT7w+tZngzwzYeE9AtdL05BthQB5SPmlbHLE+5rdrhk4bRXzHFT3kwoooqCwrP8Q2h1DQdRsYr+3sbu5gaO3knkCKX4+XnrkZFVvEniXS/Dtt5upXIWRuI4EG+WU+iqOSa43wv4A174heNbfxT49sjp+g2akabpMjYkYEnDyY6Hue/QdBXThqTlJSeyObEVVGPKt2Q+IbXWtUXR01jU9G8PPpBD77e6S4eVsADagPA4zzUbQ6FqtwW1W817xVOPm8lLeUxD6RqAor3nTfDWi6ZJ5lhpdnBJ/fWIbvz61rV2exirW0OJVH1PF7O81ewsli8PeAdTit36RsIrUHHqucj8RVm3/4WJdH934V02yHrd6gH/ROa9foo9hDew/bz2ueWWvhX4gXLF73XtE08HP7u1sjNtH1krTsvh9esQ+reKtVnfuLUJbj9Aa9AorRQitkQ5ye7OSi+H3h4KRc20t4WG1jdTvJuHuM4rg9T8PWHwy106kmmRXngy+ZUuo3i859Pk6CRcgnYeM//AKgfaaxfGdhqOqeGNRsdGntoL24iMavcx70weCCPcZ5wfoa9DAV1Tqezn8EtJJ7W7+TW6f6aGFaHMuZbrYztA1bwjeaxPpOhnTXu4oEuWW3iXaUboQQMHquf94V0ptLY9beH/vgV8ZR2viP4X+L7K9vbKW2ubeTcpPMU6dGUMOCCDj1Gexr7E0DVrTXdGs9T06TzLW6jEiHuPUH3ByCPUV6Od5PHL+SrQlz05Lfz+X3r59jDC4l1rxmrSXQsi0txjEEXHT5BSGztjjNvDx/sCp6K8A7CD7HbYx9nh/74FPWCJMbIkXHTCgYqSigBNoIwQMelLRRQBV1PTrPVLOS01K1hurWQYaKZA6n8DXjuvfAaztr2TU/h3rV74X1E5IjhcvbsemCvYfn9K9sooA+d38WeMvBDrB8R/Dz3NivA1nSE8xCMnBdO34Y+ldz4c8Q6R4ksxdaFqEF7DjLeU3zJ/vL1H4ivTmUMpVgCpGCDyDXnHif4PeG9WvP7S0pZ/D+tA7lvtLbyW3erKPlP6Vz1MNCeq0OiniZx0epern/E/g3w/wCJlJ1nTIJrj+G5QeXMh9Q64Ofrms6eD4geEF26lYR+LdNXgXenjyrtR/tRdG9ePzrS8PeL9E8QSeTp94FvAcNaXCmKdT6FDyfwzXJKjUpao6lVp1VZnO2/h7xf4VZf+EY1z+2NPH/MP1c4dR2CzD29cVqWXxGgtpBB4t0q+8Pz9pLhN8D+6yDgiutpk0cc8LwzoksLjDRuoZWHuDwayk4VP4kfmtGP2Lj8DLdleW19As9lcRXELch4nDA/iKsV51qPw8sPOa68N3174dvjyHsXzET/ALUR+U/hiorDxD4q8KQuvjW0TVrBOmqaXGSVHHMsXUdeo4rCWEvrTd/LqS5OPxo9KorJ8P8AiLSPENqLjRr+C7j7+W3zL7EdRWtXJKLi7MtNPVGRd+HtNvb83d7b/aZf4RKxZV+i9K86+PztcWHhjwvBmK31nVIrabZ8o8sEEqMfhxXrlef/ABo0G81bwxBf6OpfVdFuU1K2QdXMZyV/EZrpw1RurHmf9dDOpFcrsd5BFHBBHDCipFGoRFUYCgDAArL+3XM+tNDCY4rGBgkkjLuaWQjOxewA4yT34pPCXiKw8U6Da6rpkgeGZfmXPzRP/EjDswPFV/EeraX4L0XUdb1F5UtA4llC/MS5wvyj1PFRCNpOMleQ29E09DdmljgheWZ1jjRSzOxwFA6kmuetC+sXkWq3CMtpH81hC4xwR/r2HqQflz0HPU5GbaT3PjWzs7u9tJLHw/KiXKWsp/fXgPKeYB9yPocdW47HNdOASQFHJ4AArop0vY6v4vy/4JUVz69PzCsnxBr1nocMX2nzJru4Oy1soF3T3L+iL6erHgfkDzPijx8ya0PC/gq2TW/FkvARTut7Md3mccccfKO/BwflPefDvwCnh3fqut3T6v4qul/0rUJudv8A0ziHREHAAH/1q7KOGcvemZ1sSo6QK/hvwje6lfx6z4yVA8Tb7LSI33wWvo8h/wCWsvP3iMDnA6Y9CAwMDpRRXekkrI4W23dhRRRTEFFFFABRRRQAVk+K9dtfDXh+91a/JMNsm7av3nboqj3JwK1q8m/aVvp9K8A2mpwRrIllqVvPIrjKkAnGR3G7bQBEur/ELWLc3C3ml6AJkOy3NqbmSLPQtkgbh6ciub8K6ddeFPGEVtq1/JqE+r2xaS9lHzSXCsWYewwen0FGh6/qNl4u0fTNS8RaXq66pBLKyWqhTBIoUgKdxyhDHBIGdufUVoeKmbXr+/0qzAi1LSkivbWbcAfM5O36Ed8+leXiHUmvTX9D3srlRp1HCekZrlbfS+qfyaTO4orz+y+I66nBBb6JoeqatrLxhpba0gPlwnOMvIcKFz3ya6m20Dxtq8KG7k07QUY/MkbG5mA+uAv86mnQnUSktjHES+rVHSqfEt0Sa3rdjosCyX8wUudscajc8jeiqOSaq22neLvEqhraOPw9p79JrhfMuWX2T7q/jmut8PeBtI0e5F46Pf6ljm7uz5jj/d7KPYVL8QvEK+G/C13doSb2QeRaRryzzNwoA746/QV2Rowox5pa2OSnKri6saNLeTsit4W+H+ieH7k3qxy32qt9+/vX82Un2J6fhXXVjeDdPutK8LaZZ6jcS3N7FCPOklcuxc8kbjyQCcD2ArZrpi7pNnNVgoVJRi7pN69/MKKKKZmFFFFABRRRQAUUUUAU9V02y1exks9TtYbq1k+9FKoYH/6/vWN4M8J2/hGO7tNKuJjpc0nnRWsp3eQx+8FbrtPHB6HPPNdLRW0cRUjTdJS919Onr6+ZLhFy5rahRRRWJQUUUUAFFFFABRRRQAUUUUAFc74p8FeH/FC/8TnTIJpgMLcKNkqehDjkYroqKAPK7vwb4s8PqG8N6umt2SDAsdWOJQvAASYc8DoG4qpH4vtbaZbbxFaXmgXh6R3yERtzj5JR8rD34r1+orq2gu4Ghu4Ip4X4aOVAyt9QeKynQhPdGsK04bM4iNlkjSSNleNxlXU5Vh6g96epKsCpII5BHaq1/wDDCzhla48Kaje6BcEhjHA3mW7H/aibIP4YrPlsfHGkj9/pmma/Aufnspzazt7lXyn4DFcksJJfCzqji4v4kZXiDwBomr3JvoEm0nVhyt9pr+RJn/aA+Vx65GT61iPqfxD8H8XVinjHSl6XFmvl3iLz96L+I4HVc1vP43sbFkTxDYatoTsOTf2biPPoHQMCPc4roNP1Cx1GATade2t3GQG3W8yyYB9dpOPoaiSmlarG6/rqVanPWDs/66HN+Ffix4V8RXItEvWsdRztNpfIYZAfTngn6Gu9VgwBUgg9xXHeMfBfh7xjb+X4h02K4lHC3SfJOnT7sg5xx0OR7Vxdp4A8WeECJvBHi2W9t1Of7L1hcxsMj5RICcH8FFc8sNSnrB2fZ/5iftIbq68jrdU+HlqdVm1Tw5qV7oGoTndMbNh5Ux9XjPyk+9cH8QvBl/rEdvoms+JL3XdYuz/otqqLBBbr/FPKqdQozya72Txbrrwi1t/CV+NWZcYkdBbK3qZc421d8L6IdIglnvZ/tms3hD3t4Rje3ZEHaNegHfqfQa0va0/eqvbba/39iOSNR2iael2S2Gm6fp0DvKlpbxWqOwwziNAgJ9ztzXjOu+LvE3xM8UXfhD4Zf6PpUeYb/WjkZXOGKt/CnBAA+ZuegJA3PjJ4k1K5mt/AXg1Hn8S6un79o2x9ltyOdx/hLDv2X/eFeufCjwTaeAfBljo9qiG4Vd91MBzNKfvMf5D0AFdeHpf8vJbsivV+xHZDPhj8OdE+Hmiiy0iLzLqQA3N7KP3s7+pPYcnCjge5yT2dFFdZyhRRRQAUUUUAFFFFABRRRQAVBe2ltfWz297bw3Nu/DRTIHVvqDxU9FAHO6r4K8OanAI7jR7NGHKSwRiKRCOhV1wRXn6/AuyuNXnvNY8Sa1qEM3yvA0gTevZWYckV7FRQB51e/D5tAkh1H4dNDpV5BGI3smz9mukH8LDsfQ/y61JD8SotPHleL9G1PRbleGcwmaBsd1dQcj8PxNeg0Vi6TTvTdvyPSjj4VIKnioc6Wid7SS7Xs012unbpZHn8vxS0q6Bj8NWOp67dH7iW1s6Jn/aZgNo98Gn+H/DOq6rrsHiPxq0X2uD/AI8dNhO6K0z/ABE9Gf37fljvaKPZOTvUd/wQ3j6dKDhhKfJfRtvmlbsnZJX62V3tewUUUVseYFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADXRZEZXUMrAggjII9K5DWvhp4U1VzMdKjsrv8AhubBjbSKfUFMAn6g12NFAHkmp/D/AMbaazP4V8afbIy2fs2vW6zlvYzKA9ZB1T4lac7DVvh9Bfr2l0nUlC8f7EmWP517lRUSpQlui41Jx2Z4hF4u8RSyiJfhz4iWU8bXlhUf99FuPyrU/s/4ga5E8EOnaf4WRwENxc3C30yerIiAJn/eJ6/jXrdFSqFNapFOvUejZx/w/wDh9o/gqGaSxEt1qt0M3mpXT757ls5JZuwz2HH45J7CiitTIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Forearm shaft fractures typically have a rotational mechanism. Panel A) A supinating force accompanies an apex-volar midshaft fracture (blue circular arrow). During reduction, this rotary force is reversed by pronating the thumb and hand towards the deformity (red circular arrow) while stabilizing just proximal to the fracture site (large red arrow). Panel B) A pronating force accompanies an apex-dorsal midshaft fracture (blue circular arrow). During reduction, this rotary force is reversed by supinating the thumb and hand (red circular arrow) while stabilizing just proximal to the fracture site (large red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mehlman CT, Wall EJ. Injuries to the shafts of the radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17266=[""].join("\n");
var outline_f16_55_17266=null;
var title_f16_55_17267="Spinosad: Drug information";
var content_f16_55_17267=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Spinosad: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/9/2196?source=see_link\">",
"    see \"Spinosad: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/54/2915?source=see_link\">",
"    see \"Spinosad: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11404426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Natroba&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11404428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiparasitic Agent, Topical;",
"     </li>",
"     <li>",
"      Pediculocide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11506344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Head lice:",
"     </b>",
"     Topical: Apply sufficient amount to cover dry scalp and completely cover dry hair; 120 mL may be necessary depending on the length of hair. If live lice are seen 7 days after first treatment, repeat with second application.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11506343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/54/2915?source=see_link\">",
"      see \"Spinosad: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Head lice:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;6 months to &lt;4 years (unlabeled use): Apply to dry scalp; may repeat in 7 days if needed (Stough, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;4 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11506345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13156819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natroba&trade;: 0.9% (120 mL) [contains benzyl alcohol, isopropyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11506585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical suspension. For external use only. Shake bottle well. Apply to dry scalp and rub gently until the scalp is thoroughly moistened, then apply to dry hair; completely covering scalp and hair. Leave on for 10 minutes (start timing treatment after the scalp and hair have been completely covered). The hair should then be rinsed thoroughly with warm water. Shampoo may be used immediately after the product is completely rinsed off. If live lice are seen 7 days after the first treatment, repeat with second application. Avoid contact with the eyes. Nit combing is not required, although a fine-tooth comb may be used to remove treated lice and nits.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Spinosad should be a portion of a whole lice removal program, which should include washing or dry cleaning all clothing, hats, bedding and towels recently worn or used by the patient and washing combs, brushes, and hair accessories in hot water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11404430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of head lice (",
"     <i>",
"      Pediculosis capitis",
"     </i>",
"     ) infestation in adults and children &ge;4 years of age",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F11502555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of head lice (",
"     <i>",
"      Pediculosis capitis",
"     </i>",
"     ) infestation in children &ge;6 months and &lt;4 years of age",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11503284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Application site erythema (3%), application site irritation (1%), skin irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Erythema (2%), hyperemia (2%), irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, application site reactions (dryness, exfoliation), dry skin",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11502560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11502561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Benzyl alcohol: Topical suspension contains benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates. Topical suspension is not recommended for use in children &lt;6 months of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For topical use on scalp and scalp hair only; avoid contact with eyes. Wash hands after application.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11503288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11502556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11502557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Human studies did not assess the absorption of benzyl alcohol, an ingredient in the product.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11502558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11502559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Spinosad used topically is not systemically absorbed and will not be present in human milk. The suspension formulation does include benzyl alcohol, which may be systemically absorbed and may be excreted in human milk. Lactating women may choose to pump and discard breast milk for five benzyl alcohol half-lives (8 hours) after use to avoid ingestion of benzyl alcohol by an infant.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Natroba External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (120 mL): $262.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Spinosad External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9% (120 mL): $195.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11506587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor scalp for lice",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11503291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insect paralysis and death is caused by central nervous system excitation and involuntary muscle contractions. Spinosad is thought to be both pediculocidal and ovicidal (Stough, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11503293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Not absorbed topically (not detectable in a pediatric patient plasma sampling study); absorption of the benzyl alcohol was not analyzed in this study.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Frankowski BL and Bocchini JA Jr, &ldquo;Head Lice,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(2):392-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/55/17267/abstract-text/20660553/pubmed\" id=\"20660553\" target=\"_blank\">",
"        20660553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stough D, Shellabarger S, Quiring J, et al, &ldquo;Efficacy and Safety of Spinosad and PermethrinCreme Rinses for PediculosisCapitis (Head Lice),&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(3):e389-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/55/17267/abstract-text/19706558/pubmed\" id=\"19706558\" target=\"_blank\">",
"        19706558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16101 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-A0D016103C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17267=[""].join("\n");
var outline_f16_55_17267=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11404426\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11404428\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11506344\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11506343\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11506345\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13156819\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11506585\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11404430\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11502555\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11503284\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11502560\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11502561\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300078\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11503288\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11502556\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11502557\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11502558\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11502559\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322883\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11506587\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11503291\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11503293\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/9/2196?source=related_link\">",
"      Spinosad: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/54/2915?source=related_link\">",
"      Spinosad: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_55_17268="Second deg vag laceratio repair";
var content_f16_55_17268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Repair of a second degree perineal laceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A first-degree laceration involves the fourchet, the perineal skin, and the vaginal mucous membrane. A second-degree laceration also includes the muscles of the perineal body. The rectal sphincter remains intact.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL. Closure of 2nd degree laceration. In: Obstetrics: Normal &amp; problem pregnancies, 3rd ed, Churchill Livingstone Inc., New York 1996. Copyright &copy; 1996 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17268=[""].join("\n");
var outline_f16_55_17268=null;
var title_f16_55_17269="Cefotetan: Drug information";
var content_f16_55_17269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefotetan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/50/8996?source=see_link\">",
"    see \"Cefotetan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/43/9908?source=see_link\">",
"    see \"Cefotetan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F147623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (Second Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F147596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     I.M., I.V.: 1-6 g/day in divided doses every 12 hours; usual dose: 1-2 g every 12 hours for 5-10 days; 1-2 g may be given every 24 hours for urinary tract infection;",
"     <b>",
"      Note:",
"     </b>",
"     Due to high rates of",
"     <i>",
"      B. fragilis",
"     </i>",
"     group resistance, not recommended for the treatment of community-acquired intra-abdominal infections (Solomkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Orbital cellulitis, odontogenic infections:",
"     </b>",
"     I.V.: 2 g every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"     I.V.: 2 g every 12 hours; used in combination with doxycycline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative prophylaxis:",
"     </b>",
"     I.M., I.V.: 1-2 g 30-60 minutes prior to surgery; when used for cesarean section, dose should be given as soon as umbilical cord is clamped",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urinary tract infection:",
"     </b>",
"     I.M., I.V.: 1-2 g may be given every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F147614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/43/9908?source=see_link\">",
"      see \"Cefotetan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe infections (unlabeled use):",
"     </b>",
"     I.M., I.V.: 20-40 mg/kg/dose every 12 hours (maximum: 6 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative prophylaxis (unlabeled use):",
"     </b>",
"     I.M., I.V.: 40 mg/kg 30-60 minutes prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"     Adolescents: I.V.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F147597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F147598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Dialyzable (5% to 20%); administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     the usual dose every 24 hours on days between dialysis; administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the usual dose on the day of dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or venovenous hemodiafiltration effects: Administer 750 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in  manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g, 10 g [products contain sodium 80 mg (3.5 mEq)/g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F147575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Inject deep I.M. into large muscle mass.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Inject direct I.V. over 3-5 minutes. Infuse intermittent infusion over 30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F147628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, aztreonam, bivalirudin, dexmedetomidine, diltiazem, docetaxel, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), insulin (regular), linezolid, melphalan, meperidine, morphine, paclitaxel, palonesetron, propofol, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Droperidol, pemetrexed, promethazine, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Doxapram, promethazine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F147574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Surgical prophylaxis; intra-abdominal infections and other mixed infections; respiratory tract, skin and skin structure, bone and joint, urinary tract and gynecologic infections as well as septicemia; active against gram-negative enteric bacilli including",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     , and",
"     <i>",
"      Proteus",
"     </i>",
"     ; less active against staphylococci and streptococci than first generation cephalosporins, but active against anaerobes including",
"     <i>",
"      Bacteroides fragilis",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F147630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CefoTEtan may be confused with ceFAZolin, cefOXitin, cefTAZidime, Ceftin&reg;, cefTRIAXone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F147621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Anaphylaxis, urticaria, rash, pruritus, pseudomembranous colitis, nausea, vomiting, eosinophilia, thrombocytosis, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia, prolonged PT, bleeding, BUN increased, creatinine increased, nephrotoxicity, phlebitis, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Seizure, Stevens-Johnson syndrome, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, pancytopenia, agranulocytosis, colitis, superinfection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F147578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefotetan, any component of the formulation, or other cephalosporins; previous cephalosporin-associated hemolytic anemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F147559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Although it contains the methyltetrazolethiol side chain, bleeding has not been a significant problem.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic anemia: Has been associated with a higher risk of hemolytic anemia relative to other cephalosporins (approximately threefold); monitor carefully during use and consider cephalosporin-associated immune anemia in patients who have received cefotetan within 2-3 weeks (either as treatment or prophylaxis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CefoTEtan may enhance the adverse/toxic effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F147589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may cause a disulfiram-like reaction).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6347590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Cefotetan crosses the placenta and produces therapeutic concentrations in the amniotic fluid and cord serum. Cefotetan is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F147602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F147580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Very small amounts of cefotetan are excreted in human milk. The manufacturer recommends caution when giving cefotetan to a breast-feeding mother. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F147581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CefoTEtan Disodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $13.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $27.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (1): $140.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CefoTEtan Disodium-Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g 3.58% (1): $17.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g 2.08% (1): $25.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F147569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal, hepatic, and hematologic function periodically with prolonged therapy. Monitor prothrombin time in patients at risk of prolongation during cephalosporin therapy (nutritionally-deficient, prolonged treatment, renal or hepatic disease). Monitor for signs and symptoms of hemolytic anemia, including hematologic parameters where appropriate.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apacef (BE, FR, LU);",
"     </li>",
"     <li>",
"      Apatef (AU, DE, IT, PT);",
"     </li>",
"     <li>",
"      Ceftenon (AT);",
"     </li>",
"     <li>",
"      Darvilen (DE);",
"     </li>",
"     <li>",
"      Yamatetan (JP, KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F147558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F147577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely to body tissues and fluids including bile, sputum, prostatic, peritoneal; low concentrations enter CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 76% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 1.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as unchanged drug); feces (20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/55/17269/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/55/17269/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/55/17269/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(2):187-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/55/17269/abstract-text/10069359/pubmed\" id=\"10069359\" target=\"_blank\">",
"        10069359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin C, Thomachot L, and Albanese J, &ldquo;Clinical Pharmacokinetics of Cefotetan,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 26(4):248-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/55/17269/abstract-text/8013159/pubmed\" id=\"8013159\" target=\"_blank\">",
"        8013159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/55/17269/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9222 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17269=[""].join("\n");
var outline_f16_55_17269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147623\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147596\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147614\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147597\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147598\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682538\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147571\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147555\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147575\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147628\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147574\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147630\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147621\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147578\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147559\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298991\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147564\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147589\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147567\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6347590\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147602\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147580\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147581\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323048\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147569\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038554\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147558\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147577\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9222\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9222|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/50/8996?source=related_link\">",
"      Cefotetan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/43/9908?source=related_link\">",
"      Cefotetan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_55_17270="Healed varicella pneumonia PA";
var content_f16_55_17270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Healed varicella pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple coarse nodular lung calcifications as sequelae of a previous acute varicella pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17270=[""].join("\n");
var outline_f16_55_17270=null;
var title_f16_55_17271="Coccidioidal meningitis";
var content_f16_55_17271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coccidioidal meningitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17271/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17271/contributors\">",
"     John N Galgiani, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17271/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17271/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17271/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17271/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/55/17271/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioidomycosis is caused by the dimorphic fungi of the genus Coccidioides (C. immitis and C. posadasii), which are endemic in desert regions of the southwestern United States, and Central and South America. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H2#H2\">",
"     \"Primary coccidioidal infection\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary coccidioidal infection\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This infection has protean manifestations, and primary infection is frequently unrecognized. However, disseminated infection can occur. Meningitis is the most lethal complication of coccidioidomycosis and thus is crucial to recognize.",
"   </p>",
"   <p>",
"    Coccidioidal meningitis will be reviewed here. Primary infection, extrapulmonary infection outside of the central nervous system (CNS), laboratory diagnosis, pulmonary sequelae, and infection in immunocompromised hosts are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13751?source=see_link\">",
"     \"Laboratory diagnosis of coccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although precise statistics about the incidence of meningitis due to this fungus are not available, it is estimated that there are more than 150,000 infections with Coccidioides spp annually but are likely fewer than 100 new meningeal infections per year. These estimates would indicate that the proportion of patients with meningitis is less than 0.1 percent of all exposures.",
"   </p>",
"   <p>",
"    It is fortunate that the risk is relatively low since meningitis is the worst complication of coccidioidal infection. If untreated, meningitis is lethal for 95 percent of patients within two years. This contrasts sharply to most non-meningeal infections, which are either self-limited respiratory syndromes or cause chronic focal morbidity within or beyond the lungs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of coccidioidal meningitis has evolved to include oral therapies that have largely supplanted the need to instill antifungal agents directly into the cerebrospinal fluid (CSF). Nonetheless, the management of coccidioidal meningitis remains difficult and often requires the orchestration of several medical subspecialties to optimize the clinical response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two species of Coccidioides have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/1\">",
"     1",
"    </a>",
"    ]. C. immitis is more common in California, whereas C. posadasii is more frequently isolated in Arizona, Texas, and Central and South America. The clinical manifestations associated with these two species are similar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary coccidioidal infection\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of meningitis usually develop within weeks to months of primary infection although occasionally intervals as long as one to two years have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Delays of years are more likely in patients treated initially for primary coccidioidal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/4\">",
"     4",
"    </a>",
"    ]. As with other forms of extrapulmonary dissemination, there may be few or no symptoms associated with the primary respiratory infection, and radiographic examination of the chest is frequently completely normal. Approximately half of patients with meningitis have other lesions resulting from hematogenous dissemination, which are manifest in relation to their specific locations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39734?source=see_link\">",
"     \"Management of pulmonary sequelae and complications of coccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common symptom of coccidioidal meningitis is persistent headache that is present in approximately 75 percent of patients. It should be noted that approximately 20 percent of patients with primary pulmonary infection also complain of headache during their self-limited illness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, judgment is required during early infection to select patients who would benefit from further evaluation of this symptom. Characteristics of headaches that might suggest meningitis in a patient known to have recently developed coccidioidal pneumonia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistence of headache",
"     </li>",
"     <li>",
"      Progressive worsening of headache",
"     </li>",
"     <li>",
"      Unusual severity of the headache",
"     </li>",
"     <li>",
"      Associated nausea and vomiting",
"     </li>",
"     <li>",
"      Blurring of vision",
"     </li>",
"     <li>",
"      Changes in mental status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the lumbar meninges are involved, patients may also complain of lumbosacral back pain.",
"   </p>",
"   <p>",
"    Physical examination findings are frequently absent early in the course of coccidioidal meningitis. Although not emphasized in previous descriptions of coccidioidal meningitis, tremulousness and an intention tremor are often present. Kernig and Brudzinski signs of meningeal irritation are uncommon. Papilledema, indicating increased intracranial pressure and the development of hydrocephalus, is only an occasional presenting symptom in adults but is quite frequent early in children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Papilledema, cranial nerve palsies (resulting from nerve entrapment by basilar meningitis), or evidence of cerebral infarction (resulting from arteritis) are generally observed later in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/8\">",
"     8",
"    </a>",
"    ]. Gait abnormalities and focal neurologic deficits may be seen in a minority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/1\">",
"     1",
"    </a>",
"    ]. Nonspecific laboratory abnormalities may include hyponatremia in association with the syndrome of inappropriate antidiuretic hormone&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND INITIAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs of coccidioidal meningitis are nonspecific and can be produced by a variety of other diseases. Since the onset of symptoms is often subacute or even chronic, management prior to diagnosis is frequently attempted in the outpatient setting with diagnostic procedures scheduled at a pace convenient for the patient and the health care delivery system alike. As a consequence, delays in diagnosis of weeks or even months after the onset of meningeal symptoms are common. Diagnostic delays of this magnitude are likely to continue to occur in standard practice unless the clinician elicits a history of endemic exposure to Coccidioides spp and thus elevates coccidioidal meningitis higher in the differential diagnosis of the patient's illness.",
"   </p>",
"   <p>",
"    The definitive diagnosis of coccidioidal meningitis is supported by isolating Coccidioides species from CSF or other CNS specimens; however most cases are presumptively diagnosed through identifying anti-coccidioidal antibodies in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Routine examination of CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the CSF following a lumbar puncture (LP) is important in diagnosing coccidioidal meningitis, but routine testing is not specific for the diagnosis. Fluid obtained from the lateral ventricle, such as might occur at the time of a ventriculoperitoneal (VP) shunt placement, is often not as helpful as CSF obtained by lumbar or cisternal aspiration and may not be as diagnostically sensitive.",
"   </p>",
"   <p>",
"    Lumbar CSF in coccidioidal meningitis usually has increased numbers of leukocytes, ranging from a few to several hundred cells. Very large numbers of leukocytes in the CSF, such as occur with bacterial meningitis, are distinctly unusual. The majority of cells are typically lymphocytic; however early in the infection, a significant percentage of these leukocytes may be polymorphonuclear leukocytes (PMN), similar to early aseptic meningitis of presumed viral origin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=see_link\">",
"     \"Aseptic meningitis in adults\"",
"    </a>",
"    .) Significant numbers of eosinophils may also occur, but this finding is not specific for coccidioidal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associated with the CSF pleocytosis is a depression of the CSF glucose, occasionally profoundly low, and an elevation of the CSF protein. Typically, protein concentrations range up to 250",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    If protein concentrations in the range of 1.0 to 3.0 grams are obtained, this suggests that the process has been complicated by obstruction to the normal flow of CSF. Experimentally, vasculitic coccidioidal meningitis in rabbits resulted in elevated CSF levels of the inflammation mediator, matrix metalloproteinase (MMP-9) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, Coccidioides organisms may be seen on direct microscopic examination of the CSF; such a finding would be indicative of a high fungal burden of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Specific diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since routine CSF and imaging abnormalities are nonspecific, the diagnosis of coccidioidal meningitis requires serologic or culture findings to secure the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recovering Coccidioides spp from the CSF confirms the diagnosis but has only been possible in approximately 15 percent of initial evaluations. Culturing the sediment of large volumes of CSF improves the diagnostic sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     CSF serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly as specific as recovery of the organism is the detection of complement-fixing (CF) IgG antibodies or immunodiffusion tests for IgM and IgG in CSF. In a few patients without meningitis low titers of such coccidioidal antibodies may be the consequence of parameningeal foci, such as vertebral osteomyelitis or even coccidioidal pneumonia involving posterior segments of the lung adjacent to the vertebral column. CF anticoccidioidal antibodies are not always detectable in early coccidioidal meningitis although such false negatives are less frequent than negative CSF cultures. Serial monitoring of serum coccidioidal IgG level should not be used as a guide for clinical management [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other serologic tests may be performed on CSF but are less useful. Identifying tube precipitin-type antibodies in CSF is not routinely performed but carries the same significance as CF antibodies if found. Antibodies detected by a commercially available enzyme-linked immunoassay (Meridian Diagnostics, Cincinnati, OH) may also be indicative of coccidioidal meningitis, although the documentation of their significance is not as well established. It is not advisable to perform a latex test on CSF because of the problem of false positive test results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13751?source=see_link\">",
"     \"Laboratory diagnosis of coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;On rare occasions, meningeal biopsy is required to establish a histopathologic diagnosis of coccidioidal meningitis. Histopathology may also be useful if there is another focus of disseminated disease, such as a cutaneous lesion in association with a clinical presentation of chronic meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other options",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with symptoms of meningitis and abnormal CSF findings in whom neither antibodies nor fungal growth can be detected from CSF, it may be necessary to infer the diagnosis of coccidioidal meningitis from finding anticoccidioidal antibodies in non-meningeal sources. However, this link is indirect. It is usually valuable to continue to try to corroborate the diagnosis with more direct evidence from repeated CSF analyses in such patients because of the profound implications for subsequent management.",
"   </p>",
"   <p>",
"    On rare occasions, infection with Coccidioides spp is the cause of lymphocytic meningitis in which all testing is unable to establish a diagnosis. In some such circumstances, brain biopsy has proven useful when MRI with gadolinium enhancement has identified lesions that were amenable to a surgical approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) scanning or magnetic resonance imaging (MRI) can identify structural abnormalities in the brain, which are not specific for coccidioidal meningitis. Findings include hydrocephalus, basilar meningitis, and cerebral infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/13\">",
"     13",
"    </a>",
"    ]. Hydrocephalus is the most common complication of coccidioidal meningitis, occurring in up to 30 to 50 percent of patients. Those who have persistent hydrocephalus continue to have CSF abnormalities despite therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/1\">",
"     1",
"    </a>",
"    ]. Vasculitic infarctions are usually due to inflammation of small and middle-sized blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT has been largely supplanted by MRI enhanced with gadolinium due to increased sensitivity, particularly in the setting of vasculitic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/14\">",
"     14",
"    </a>",
"    ]. MRI is more sensitive than CT for meningeal enhancement in the posterior fossa and provides detailed images of the Sylvian aqueduct and the fourth ventricle, which can become obstructed. An uncommon but serious complication is the development of a vertebral artery aneurysm, which may indicate the need to proceed to magnetic resonance angiography (MRA). Spinal arachnoiditis, meningioma-like masses, and cerebral abscesses due to coccidioidomycosis have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment guidelines for coccidioidomycosis were published by the Infectious Diseases Society of America (IDSA) in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/17\">",
"     17",
"    </a>",
"    ]. We agree with these recommendations, a summary of which follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapy with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      is preferred [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. The dose used in reported clinical trials was 400 mg orally once daily. Some clinicians begin therapy with 800 or 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of fluconazole. Other experts administer 400 mg daily as a starting dose but increase the dose if clinical or CSF parameters do not improve [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      in doses of 200 mg twice or three times daily has been reported to be comparably effective [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who respond to azole therapy should continue this treatment for life because relapses upon discontinuing treatment are common and potentially fatal [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/19,22\">",
"       19,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some clinicians also initiate therapy with intrathecal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      based upon their belief that responses are more prompt with this approach. Patients who do not respond to fluconazole or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      are also candidates for intrathecal amphotericin B therapy with or without continuation of azole treatment. The intrathecal dose of amphotericin B normally ranges between 0.01 mg to 1.5 mg per dose administered at intervals ranging from daily to weekly, beginning at a low dose and advancing it until patient intolerance appears [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/23\">",
"       23",
"      </a>",
"      ]. This is administered by direct cisternal injection or less commonly by ventricular injection or cisternal injection via an Ommaya reservoir [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/23\">",
"       23",
"      </a>",
"      ]. Complications of cisternal puncture (bleeding) and the neurotoxicity of amphotericin B make this a difficult therapy to administer for prolonged periods. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link&amp;anchor=H463493101#H463493101\">",
"       \"Pharmacology of amphotericin B\", section on 'Intrathecal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Case reports describe patients with coccidioidal meningitis who progressed while receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      and who subsequently improved during treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. Other similar but unpublished anecdotal experiences have accumulated at referral centers [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/1\">",
"       1",
"      </a>",
"      ]. Voriconazole doses as high as 400 mg orally twice daily have been required as salvage therapy in some patients who had disease progression while taking fluconazole. This experience provides the basis for considering voriconazole as alternative treatment in some patients. Voriconazole may be less well tolerated and produce more untoward reactions than fluconazole, most notably visual disturbances and dermal photosensitivity. We suggest monitoring serum voriconazole trough concentrations in all patients receiving voriconazole for coccidioidal meningitis in order to ensure that adequate concentrations are achieved, and to prevent toxicity from high concentrations. Although there are no guidelines for target voriconazole concentrations, we suggest checking a trough concentration one week into therapy with a goal range of &gt;1",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      and &lt;5.5",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"       \"Pharmacology of azoles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Case reports describe patients with coccidioidal meningitis who were refractory to initial antifungal therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , but who improved during treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/26,28\">",
"       26,28",
"      </a>",
"      ]. Thus, as with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      , posaconazole might also be considered as alternative therapy in selected patients. However, absorption of posaconazole requires oral intake, optimally with a high-fat meal, and absorption can be impaired in patients with gastrointestinal tract disruption (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H9#H9\">",
"       \"Pharmacology of azoles\", section on 'Posaconazole'",
"      </a>",
"      ). When posaconazole is used for this indication, it should be dosed at 400 mg orally twice daily.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (Ambisome) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       amphotericin B lipid complex",
"      </a>",
"      (Abelcet) have been shown to be beneficial in experimental coccidioidal meningitis and appear to be equally effective, but their clinical utility has not yet been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/29-31\">",
"       29-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is no evidence that echinocandins are useful in the treatment of coccidioidal meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Because of the potential teratogenic effects of azoles on fetal bone formation during the first trimester of pregnancy, intrathecal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate is the recommended therapy during this period [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Management of hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocephalus nearly always requires a shunt for decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17271/abstract/35\">",
"     35",
"    </a>",
"    ]. Development of hydrocephalus may occur regardless of the therapy being used and does not in itself dictate switching to alternative therapy. Shunts themselves can be associated with a variety of complications; patients can develop recurrent distal obstruction, intraventricular foraminal obstruction, and shunt failure. Recurrence of headache, nausea, vomiting, gait disturbance, or mental status changes should lead to prompt imaging of the brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Monitoring treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once therapy is initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or possibly another azole antifungal, response will usually first be noted by amelioration of symptoms. This is frequently gradual and may take several weeks before the improvement is convincing to observers. However, patients subjectively often note improvement earlier. Patient adherence can be problematic over time and lack of medication compliance can lead to serious consequences; patients must be counseled that treatment is lifelong.",
"   </p>",
"   <p>",
"    Lumbar puncture findings also improve but do so even more slowly. Thus, in patients who are continuing to gradually improve symptomatically, follow-up LPs can reasonably be delayed for weeks. CSF leukocytosis generally improves, although low numbers of leukocytes often persist for many months or even years in patients that otherwise appear to be doing well. Normalization of the CSF glucose seems to more reliably reflect clinical improvement.",
"   </p>",
"   <p>",
"    Because focal neurologic complications may emerge during treatment, especially within the first two years, it is useful to perform MRI of both the head and spinal cord at baseline and in follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coccidioidomycosis is caused by the dimorphic fungi of the genus Coccidioides (C. immitis and C. posadasii), which are endemic in desert regions of the southwestern United States, and Central and South America. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coccidioidomycosis has protean manifestations, and primary infection is frequently unrecognized. However, disseminated infection can occur. Meningitis is the most lethal complication of coccidioidomycosis and thus is crucial to recognize. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If untreated, meningitis is lethal for 95 percent of patients within two years. This contrasts sharply to most non-meningeal infections, which are either self-limited respiratory syndromes or cause chronic focal morbidity within or beyond the lungs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptom of coccidioidal meningitis is persistent headache that is present in approximately 75 percent of patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms and signs of coccidioidal meningitis are nonspecific and can be produced by a variety of other diseases. Furthermore, the onset of symptoms is often subacute or even chronic. As a consequence, delays in diagnosis of weeks or even months after the onset of meningeal symptoms are common. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis and initial assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definitive diagnosis of coccidioidal meningitis is supported by isolating Coccidioides species from CSF or other CNS specimens; however most cases are presumptively diagnosed through identifying anti-coccidioidal antibodies in the CSF. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis and initial assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CSF usually reveals a lymphocytic pleocytosis with elevated protein and low glucose concentrations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Routine examination of CSF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      is preferred. The dose used in reported clinical trials was 400",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Some clinicians begin therapy with 800 or 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of fluconazole. Other experts administer 400 mg daily as a starting dose but increase the dose if clinical or CSF parameters do not improve. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who respond to azole therapy should continue this treatment for life because relapses upon discontinuing treatment are common and potentially fatal. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some clinicians also initiate therapy with intrathecal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      based upon their belief that responses are more prompt with this approach. Patients who do not respond to fluconazole or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      are also candidates for intrathecal amphotericin B therapy with or without continuation of azole treatment. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hydrocephalus nearly always requires a shunt for decompression. Development of hydrocephalus may occur regardless of the therapy being used and does not in itself dictate switching to alternative therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management of hydrocephalus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once therapy is initiated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      or possibly another azole antifungal, response will usually first be noted by amelioration of symptoms. This is frequently gradual and may take several weeks before the improvement is convincing to observers. However, patients subjectively often note improvement earlier. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Monitoring treatment response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/1\">",
"      Johnson RH, Einstein HE. Coccidioidal meningitis. Clin Infect Dis 2006; 42:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/2\">",
"      Vincent T, Galgiani JN, Huppert M, Salkin D. The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clin Infect Dis 1993; 16:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/3\">",
"      Almoujahed MO, Johnson LB, Gehring R, Khatib R. Coccidioidal meningitis: incidental diagnosis 3 y after ventriculo-peritoneal shunt placement for hydrocephalus. Scand J Infect Dis 2002; 34:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/4\">",
"      Ampel NM, Giblin A, Mourani JP, Galgiani JN. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clin Infect Dis 2009; 48:172.",
"     </a>",
"    </li>",
"    <li>",
"     Lundergan LL, Kerrick SS, Galgiani JN. Coccidioidomycosis at a university outpatient clinic: A clinical description. In: Coccidioidomycosis. Proceedings of the Fourth International Conference, Einstein HE, Catanzaro A (Eds), National Foundation for Infectious Diseases, Washington 1985. p.47.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/6\">",
"      Harrison HR, Galgiani JN, Reynolds AF Jr, et al. Amphotericin B and imidazole therapy for coccidioidal meningitis in children. Pediatr Infect Dis 1983; 2:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/7\">",
"      Saitoh A, Homans J, Kovacs A. Fluconazole treatment of coccidioidal meningitis in children: two case reports and a review of the literature. Pediatr Infect Dis J 2000; 19:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/8\">",
"      Williams PL, Johnson R, Pappagianis D, et al. Vasculitic and encephalitic complications associated with Coccidioides immitis infection of the central nervous system in humans: report of 10 cases and review. Clin Infect Dis 1992; 14:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/9\">",
"      Webb M, Ziauddin A, Okusa MD. Coccidioidomycosis meningitis and syndrome of inappropriate antidiuretic hormone. Am J Med Sci 2002; 324:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/10\">",
"      Ismail Y, Arsura EL. Eosinophilic meningitis associated with coccidioidomycosis. West J Med 1993; 158:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/11\">",
"      Lo Re V 3rd, Gluckman SJ. Eosinophilic meningitis. Am J Med 2003; 114:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/12\">",
"      Williams PL, Leib SL, Kamberi P, et al. Levels of matrix metalloproteinase-9 within cerebrospinal fluid in a rabbit model of coccidioidal meningitis and vasculitis. J Infect Dis 2002; 186:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/13\">",
"      Arsura EL, Johnson R, Penrose J, et al. Neuroimaging as a guide to predict outcomes for patients with coccidioidal meningitis. Clin Infect Dis 2005; 40:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/14\">",
"      Erly WK, Bellon RJ, Seeger JF, Carmody RF. MR imaging of acute coccidioidal meningitis. AJNR Am J Neuroradiol 1999; 20:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/15\">",
"      Komotar RJ, Clatterbuck RE, Komotar JR. Coccidioidomycosis of the brain, mimicking en plaque meningioma. J Neurol Neurosurg Psychiatry 2003; 74:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/16\">",
"      Ba&ntilde;uelos AF, Williams PL, Johnson RH, et al. Central nervous system abscesses due to Coccidioides species. Clin Infect Dis 1996; 22:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/17\">",
"      Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/18\">",
"      Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med 1993; 119:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/19\">",
"      Benson, C, Kaplan, J, Masur, H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America Clin Infect Dis 2005; 40:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/20\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/21\">",
"      Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990; 112:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/22\">",
"      Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996; 124:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/23\">",
"      Stevens DA, Shatsky SA. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin Respir Infect 2001; 16:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/24\">",
"      Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003; 36:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/25\">",
"      Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother 2004; 48:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/26\">",
"      Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011; 53:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/27\">",
"      Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/28\">",
"      Schein R, Homans J, Larsen RA, Neely M. Posaconazole for chronic refractory coccidioidal meningitis. Clin Infect Dis 2011; 53:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/29\">",
"      Clemons KV, Sobel RA, Williams PL, et al. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2002; 46:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/30\">",
"      Capilla J, Clemons KV, Sobel RA, Stevens DA. Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother 2007; 60:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/31\">",
"      Clemons KV, Capilla J, Sobel RA, et al. Comparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2009; 53:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/32\">",
"      Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol 2007; 45:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/33\">",
"      Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J 1992; 11:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/34\">",
"      Bercovitch RS, Catanzaro A, Schwartz BS, et al. Coccidioidomycosis during pregnancy: a review and recommendations for management. Clin Infect Dis 2011; 53:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17271/abstract/35\">",
"      Romeo JH, Rice LB, McQuarrie IG. Hydrocephalus in coccidioidal meningitis: case report and review of the literature. Neurosurgery 2000; 47:773.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2445 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17271=[""].join("\n");
var outline_f16_55_17271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS AND INITIAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Routine examination of CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Specific diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - CSF serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Management of hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monitoring treatment response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=related_link\">",
"      Coccidioidomycosis in compromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13751?source=related_link\">",
"      Laboratory diagnosis of coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39734?source=related_link\">",
"      Management of pulmonary sequelae and complications of coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26807?source=related_link\">",
"      Manifestations and treatment of extrapulmonary coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_55_17272="Monitoring the HIV-infected patient on antituberculous medications";
var content_f16_55_17272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Monitoring the HIV-infected patient on antituberculous medications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17272/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17272/contributors\">",
"     Timothy R Sterling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17272/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17272/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17272/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17272/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/55/17272/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the treatment of tuberculosis (TB) in the HIV-infected patient is complex and needs to address the patient&rsquo;s requirement for antiretroviral therapy (ART), potential drug reactions, and complications related to the immune reconstitution inflammatory syndrome (IRIS). Follow-up should be designed to monitor both bacteriologic and clinical efficacy of the therapeutic regimen.",
"   </p>",
"   <p>",
"    This topic will cover the appropriate follow-up of HIV-infected patients with TB including directly observed therapy, the clinical response to treatment, adverse events related to treatment, duration of treatment, and prognosis.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis and treatment of susceptible TB in the HIV-infected patient are discussed elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    ). Treatment of multidrug-resistant tuberculosis in HIV-infected patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIRECTLY OBSERVED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directly observed therapy (DOT) is the most effective way to maximize adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/1\">",
"     1",
"    </a>",
"    ] and is recommended by most TB experts and the World Health Organization (WHO) for all TB patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In some programs, patients are observed taking their medications Monday through Friday and are given their doses to take over the weekend for greater patient convenience.",
"   </p>",
"   <p>",
"    Although DOT programs require a significant commitment of resources, they are very effective in decreasing rates of primary and acquired drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. In developing countries where TB and HIV are endemic, DOT is associated with lower TB relapse rates and a higher percentage of patients who complete their full duration of TB therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age, sex, education, race, and socioeconomic status do not correlate with adherence, whereas psychiatric disease, substance abuse, and alcoholism are each correlated with poor compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/1\">",
"     1",
"    </a>",
"    ]. General issues related to adherence to TB therapy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10341?source=see_link\">",
"     \"Adherence to tuberculosis treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons with tuberculosis (TB) and HIV infection generally respond well to therapy if the diagnosis is made promptly and standard therapy instituted. Fever usually resolves within one month while the chest radiograph is typically improved at two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bacteriologic efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the HIV-infected patient with pulmonary TB, sputum collections are also important in monitoring the response to therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sputum should be collected every two weeks in patients with positive acid-fast bacillus (AFB) smears until a negative smear is documented to get an early assessment of treatment efficacy and transmission risk.",
"     </li>",
"     <li>",
"      In patients with smear-negative disease at baseline, monthly collections are adequate.",
"     </li>",
"     <li>",
"      After the sputum culture has converted to negative, at least one sputum should be collected at the completion of therapy to confirm that the patient has remained culture-negative [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL DETERIORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical deterioration in an HIV-infected patient with TB may be related to poor adherence, emergence of tuberculosis (TB) drug resistance, an intercurrent opportunistic infection, or the immune reconstitution inflammatory syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Predictors of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HIV-infected persons, low CD4+ lymphocyte count is a key risk factor for relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Among HIV-seronegative persons, a positive culture after two months of treatment is a predictor of subsequent relapse; this may also be true among HIV-infected persons, but it has been less well studied. Patients who do not convert to a negative sputum culture within two months should be reevaluated with repeat drug sensitivity studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If drug resistance is demonstrated, the regimen should be modified according to the report.",
"     </li>",
"     <li>",
"      As in HIV seronegative patients with TB, a single drug should never be added to a failing regimen, as this may lead to acquired resistance to the new drug. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"       \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A poor treatment response can be related to inadequate adherence or low drug concentrations, particularly if diarrhea and malabsorption are present [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. One study of 36 HIV-infected patients with TB demonstrated that low maximum concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    were common, even in the absence of gastrointestinal symptomatology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/15\">",
"     15",
"    </a>",
"    ]. For this reason, monitoring of serum drug levels may be useful in patients who do not respond clinically to a directly observed, seemingly appropriate regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study conducted among South African miners in a high-risk environment showed that recurrent TB rates (more than two years after the initial episode) were 24 percent in HIV-positive men and 4 percent in HIV-negative men. Most of these clinical recurrences were suspected to be due to reinfection. Rates of recurrent TB were higher than rates of initial infection in the same population, suggesting that persons with an initial episode of TB represent a susceptible population at high risk for a second infection with a new strain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recent studies using DNA fingerprinting have quantified the risk of recurrent tuberculosis in HIV infection. A study in Malawi of 584 culture-positive episodes of TB demonstrated that recurrent tuberculosis was more common in HIV-infected patients than in HIV-seronegative patients; reinfections accounted for 1 of 16 recurrences among HIV-negative patients and 12 of 23 in HIV-positive individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some TB endemic countries, recurrences of TB in HIV-infected patients are due to exogenous reinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intercurrent opportunistic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an HIV-infected patient on appropriate TB therapy whose sputum smear becomes negative, new clinical findings such as fever, cough or weight loss, or new radiographic abnormalities usually indicate the development of a nontuberculous process, such as Pneumocystis jirovecii pneumonia (PCP) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immune reconstitution inflammatory syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative explanation for transient clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic deterioration despite appropriate antituberculous chemotherapy can also indicate the onset of the &ldquo;immune reconstitution inflammatory syndrome&rdquo; (IRIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IRIS usually occurs in immunosuppressed patients who were recently initiated on antituberculosis medications and potent ART. This phenomenon presumably results from partial reconstitution of the host immune response and a transient increase in inflammation. Among patients with TB, IRIS has been described in 8 to 43 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/20,22,24,25\">",
"     20,22,24,25",
"    </a>",
"    ]. The risk is increased in patients with an initial CD4 count below",
"    <span class=\"nowrap\">",
"     100/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/24\">",
"     24",
"    </a>",
"    ] and in patients with a significant reduction in viral load and a larger increase in CD4 count [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link&amp;anchor=H9#H9\">",
"     \"Immune reconstitution inflammatory syndrome\", section on 'IRIS associated with mycobacterial infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paradoxical responses are self-limited and therefore do not require alteration or interruption of the antituberculous or antiretroviral regimens. The addition of nonsteroidal antiinflammatory drugs or a short course of corticosteroids has been recommended if paradoxical responses cause significant symptoms. However, such treatment should be undertaken only after a thorough evaluation to exclude other potential causes of clinical deterioration (eg, lymphoma, TB treatment failure, or drug-resistant TB).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DRUG-RELATED SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drugs used to treat TB are each associated with adverse side effects, mainly hepatic and neurologic. Management of these issues is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIDS patients have a higher rate of complications from TB therapy than patients without AIDS. In one study, for example, 18 percent of patients had some side effect (most often rash or hepatitis), including 12 percent of those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, the complication rate is less than 5 percent in non-HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of hepatotoxicity is increased in the setting of alcoholism and chronic liver disease (eg, hepatitis B or C virus infection), which are common comorbidities in HIV-infected patients, due to shared modes of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serial monitoring with liver function tests is indicated due to the potential for drug-induced liver injury, especially in patients with possible preexisting liver impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Patients should be also advised regarding symptoms and signs of hepatitis, including right upper quadrant pain, nausea, vomiting, jaundice, pruritus, or dark urine when they are prescribed TB medications. They should also be instructed to promptly seek medical attention if these symptoms occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    may develop peripheral neuropathy. The risk of this adverse event is higher in HIV-infected patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    , which is associated with mitochondrial toxicity, and may require substitution of this nucleoside analog with another antiretroviral medication (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ) when feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Visual abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced visual abnormalities can occur in patients taking TB medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ), which must be distinguished from infectious etiologies, such as cytomegalovirus (CMV) retinitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ethambutol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuropathy (usually manifested as a change in visual acuity or red-green color blindness) is the most important manifestation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    toxicity. Patients should be questioned regarding blurred vision or scotomata if on ethambutol. Testing for visual acuity and color discrimination should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=see_link\">",
"     \"Ethambutol: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Rifabutin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blurred vision in an HIV-infected patient may also be related to uveitis, which can occur on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    and may be manifested as &ldquo;floaters&rdquo; or reduced visual acuity; this clinical entity is diagnosed with slit lamp examination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     CMV retinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with advanced AIDS, floaters and decreased visual acuity can also be the primary manifestation of CMV retinitis. An urgent ophthalmologic evaluation for a retinal examination is warranted since untreated infection can lead to permanent blindness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=see_link\">",
"     \"Treatment of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     THERAPEUTIC DRUG MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug therapeutic monitoring is not routinely recommended. However, drug concentrations may be considered in the following scenarios [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Slow response to therapy (eg, positive smears or cultures after two months of therapy)",
"     </li>",
"     <li>",
"      Documented or suspected drug-resistant TB",
"     </li>",
"     <li>",
"      Potential drug-drug interactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study evaluated the pharmacokinetics of induction TB therapy in 225 patients from Botswana (69 percent HIV-seropositive) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/33\">",
"     33",
"    </a>",
"    ]. After adjustment for HIV infection and CD4 cell counts, patients with low",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    levels were three times more likely than patients with normal pyrazinamide levels to have poor treatment outcomes (adjusted risk ratio, 3.38; 95% CI 1.84-6.22).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Standard duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to various guideline committees, the standard duration of therapy for drug-susceptible TB, regardless of HIV status, should be six months; this includes two months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH), a rifamycin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    followed by isoniazid and a rifamycin for four additional months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some experts have suggested that a longer duration of therapy may be needed. A 2012 meta-analysis was performed to evaluate the impact of treatment duration, dosing schedule of rifamycin, and the use of antiretroviral therapy on treatment outcomes in HIV-infected patients with active tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. After screening more than 5000 citations, six randomized trials and 21 cohort studies were included. The meta-analysis showed the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse was more common with regimens employing only two months of rifamycin (adjusted risk ratio, 5.0; 95% CI 1.9-13.2) compared with regimens using rifamycin for at least eight months. The risk of relapse was lower among patients on regimens with &gt;9 months than among patients on regimens with six months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      (pooled risk difference, -9.1 percent; 95% CI -16.5 to -1.8 percent).",
"     </li>",
"     <li>",
"      Compared with daily therapy in the initial phase, thrice-weekly therapy was associated with higher rates of treatment failure (adjusted risk ratio, 4.0; 95% CI 1.5-10.4) and relapse (adjusted risk ratio, 4.8; 95% CI 1.8-12.8).",
"     </li>",
"     <li>",
"      The authors of this meta-analysis also acknowledged the paucity of well-designed and adequately powered randomized trials of",
"      <span class=\"nowrap\">",
"       HIV/TB",
"      </span>",
"      coinfection treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized controlled trials comparing six and nine months of treatment in HIV-infected patients with pulmonary TB are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     When to prolong therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of TB therapy is longer in specific clinical situations, regardless of HIV status [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/4,36\">",
"     4,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those patients with cavitary disease and positive sputum cultures after two months of treatment, the duration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      treatment should be extended by three months for a total of nine months of treatment.",
"     </li>",
"     <li>",
"      For patients with bone, joint, or central nervous system (CNS) disease, many experts recommend 9 to 12 months of therapy.",
"     </li>",
"     <li>",
"      For all other patients with extrapulmonary disease, the recommended treatment is two months of four-drug therapy followed by four months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of therapy is also generally longer in patients with drug-resistant TB. HIV-infected patients with MDR TB should be treated for 24 months after conversion of sputum culture to negative [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/2\">",
"     2",
"    </a>",
"    ]. After the cessation of therapy, patients should be examined every four months for an additional 24 months to monitor for evidence of relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adjuvant corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in HIV-seronegative patients, adjuvant corticosteroids should also be given to patients with CNS or pericardial disease because it has been associated with improved outcomes (",
"    <a class=\"graphic graphic_table graphicRef55736 \" href=\"UTD.htm?11/58/12205\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ISOLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients are highly susceptible to tuberculosis, and outbreaks can develop rapidly on in-hospital AIDS wards [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Measures to control outbreaks include respiratory isolation in negative-pressure rooms, ultraviolet lighting of hallways and patient rooms, and the use of particulate-respirator face masks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=see_link\">",
"     \"Tuberculosis transmission and control\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is little consensus as to the optimal duration of isolation. It is common to discontinue isolation after two weeks of appropriate therapy, with evidence of clinical response, including negative sputum smears.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV infection and drug-sensitive TB generally respond well to therapy. In a series from before the ART era, only 4 of 82 patients (5 percent) with HIV and drug-sensitive TB who were treated with a standard antituberculous regimen failed therapy; all of the failures occurred in patients who were noncompliant with therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/40\">",
"     40",
"    </a>",
"    ]. Most deaths occur in the first month after therapy, and are attributable to a delay in diagnosis and treatment.",
"   </p>",
"   <p>",
"    The outcomes are worse in patients with MDR TB [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/38,41,42\">",
"     38,41,42",
"    </a>",
"    ]. The mortality rate may be as high as 82 percent within 20 weeks in patients with MDR-TB who do not receive early therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Impact of ART on mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral therapy has significantly decreased mortality related to TB; this is most evident in resource-limited settings where TB is endemic. In a prospective study in Thailand of 290 HIV-infected TB patients with known clinical outcomes, death during TB treatment occurred in 5 of 71 (7 percent) who received ART and 94 of 219 (43 percent) who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Impact of cotrimoxazole prophylaxis on mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high incidence of opportunistic infection among HIV-1-infected patients with tuberculosis in Africa and, consequently, high mortality. After tuberculosis, the most common opportunistic infections in Africa include salmonellosis, toxoplasmosis, and bacterial pneumonia.",
"   </p>",
"   <p>",
"    Several studies suggest that cotrimoxazole prophylaxis significantly decreases morbidity and mortality among HIV-infected patients in resource-limited settings with TB [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. For example, in a study of 771 HIV-seropositive patients with sputum-positive TB (median CD4 cell count 317",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    in Abidjan, patients were randomly assigned to one daily tablet of cotrimoxazole (n = 386) or placebo (n = 385) one month after the start of a standard six-month tuberculosis regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/45\">",
"     45",
"    </a>",
"    ]. None of the patients were taking ART.",
"   </p>",
"   <p>",
"    A 46 percent reduction in risk of death and a 43 percent reduction in risk of hospitalization were seen in the recipients taking cotrimoxazole. There were also significantly fewer admissions for septicemia and bacterial enteritis in the cotrimoxazole group than in the placebo group. Although the clinical benefit of cotrimoxazole was highest among those with severe immunosuppression (CD4 cell count &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ),",
"    </span>",
"    significant declines in mortality were also seen in patients with CD4 cell counts &lt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    Despite these data to suggest benefit, cotrimoxazole is not routinely administered in many developing countries due to lack of infrastructure, resources, and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17272/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persons with tuberculosis (TB) and HIV infection generally respond well to therapy if the diagnosis is made promptly and standard therapy instituted. Fever usually resolves within one month while the chest radiograph may take longer to improve. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sputum should be collected every two weeks in patients with positive acid-fast bacillus (AFB) smears until a negative smear is documented to get an early assessment of treatment efficacy and transmission risk. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical deterioration in an HIV-infected patient with TB may be related to poor adherence, emergence of TB drug resistance, an intercurrent opportunistic infection, or the immune reconstitution inflammatory syndrome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical deterioration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AIDS patients have a higher rate of complications from TB therapy than patients without AIDS. Common complications include hepatotoxicity, peripheral neuropathy, and ophthalmologic toxicity. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Drug-related side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug therapeutic monitoring is not routinely recommended, but may be considered in certain clinical scenarios (eg, ongoing smear-positive sputums after two months of appropriate therapy). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Therapeutic drug monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We are in agreement with various guideline committees which favor duration of therapy for drug-susceptible TB at least six months, regardless of HIV status; this includes two months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      (INH), a rifamycin (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      followed by isoniazid and a rifamycin for four additional months. The duration of TB therapy is longer (nine months or more) in specific clinical situations, regardless of HIV status, including cavitary disease, in patients who are slow to clear, and for those with bone, joint, or central nervous system (CNS) disease. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiretroviral therapy has significantly decreased mortality related to TB; this is most evident in resource-limited settings where TB is endemic. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/1\">",
"      Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/2\">",
"      Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/3\">",
"      Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med 1993; 328:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/4\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/5\">",
"      Dye C, Watt CJ, Bleed DM, et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/6\">",
"      Ntshanga SP, Rustomjee R, Mabaso ML. Evaluation of directly observed therapy for tuberculosis in KwaZulu-Natal, South Africa. Trans R Soc Trop Med Hyg 2009; 103:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/7\">",
"      Anuwatnonthakate A, Limsomboon P, Nateniyom S, et al. Directly observed therapy and improved tuberculosis treatment outcomes in Thailand. PLoS One 2008; 3:e3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/8\">",
"      Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. Clin Infect Dis 1992; 15:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/9\">",
"      Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/10\">",
"      Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/11\">",
"      Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/12\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/13\">",
"      Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/14\">",
"      Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/15\">",
"      Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 2005; 41:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/16\">",
"      Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clin Lab Med 1996; 16:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/17\">",
"      Glynn JR, Murray J, Bester A, et al. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J Infect Dis 2010; 201:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/18\">",
"      Crampin AC, Mwaungulu JN, Mwaungulu FD, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010; 24:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/19\">",
"      Narayanan S, Swaminathan S, Supply P, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis 2010; 201:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/20\">",
"      Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/21\">",
"      Fishman JE, Saraf-Lavi E, Narita M, et al. Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000; 174:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/22\">",
"      Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/23\">",
"      Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/24\">",
"      Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/25\">",
"      Navas E, Mart&iacute;n-D&aacute;vila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/26\">",
"      Dutt AK, Stead WW. Present chemotherapy for tuberculosis. J Infect Dis 1982; 146:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/27\">",
"      Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/28\">",
"      Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/29\">",
"      Singanayagam A, Sridhar S, Dhariwal J, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med 2012; 185:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/30\">",
"      Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS 2010; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/31\">",
"      Chaknis MJ, Brooks SE, Mitchell KT, Marcus DM. Inflammatory opacities of the vitreous in rifabutin-associated uveitis. Am J Ophthalmol 1996; 122:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/32\">",
"      Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/33\">",
"      Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/34\">",
"      Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/35\">",
"      Ahmad Khan F, Minion J, Al-Motairi A, et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis 2012; 55:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/36\">",
"      CDC. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep 2003; 52(RR-11):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/37\">",
"      Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/38\">",
"      Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for Preventing the Transmission of Mycobacterium tuberculosisin Health-Care Settings, 2005 MMWR Morb Mortal Wkly Rep 2005; 54:1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/40\">",
"      Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994; 150:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/41\">",
"      Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/42\">",
"      Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/43\">",
"      Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007; 13:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/44\">",
"      Onyebujoh PC, Ribeiro I, Whalen CC. Treatment Options for HIV-Associated Tuberculosis. J Infect Dis 2007; 196 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/45\">",
"      Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, C&ocirc;te d'Ivoire: a randomised controlled trial. Lancet 1999; 353:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17272/abstract/46\">",
"      Mwaungulu FB, Floyd S, Crampin AC, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004; 82:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8030 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17272=[""].join("\n");
var outline_f16_55_17272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIRECTLY OBSERVED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adherence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bacteriologic efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL DETERIORATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Predictors of relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intercurrent opportunistic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DRUG-RELATED SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Visual abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ethambutol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Rifabutin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - CMV retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      THERAPEUTIC DRUG MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Standard duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      When to prolong therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adjuvant corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ISOLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Impact of ART on mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Impact of cotrimoxazole prophylaxis on mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8030|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/58/12205\" title=\"table 1\">",
"      Dosing antituberculous therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10341?source=related_link\">",
"      Adherence to tuberculosis treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5978?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=related_link\">",
"      Ethambutol: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=related_link\">",
"      Isoniazid hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13337?source=related_link\">",
"      Treatment of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=related_link\">",
"      Tuberculosis transmission and control",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_55_17273="Peyronie's disease: Diagnosis and medical management";
var content_f16_55_17273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peyronie's disease: Diagnosis and medical management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17273/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17273/contributors\">",
"     William O Brant, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17273/contributors\">",
"     Anthony J Bella, MD, FRCSC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17273/contributors\">",
"     Tom F Lue, MD, ScD (Hon), FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17273/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17273/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17273/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/55/17273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peyronie's disease (PD) is an acquired, localized fibrotic disorder of the tunica albuginea resulting in penile deformity, mass, pain, and in some men, erectile dysfunction (ED). The disorder is named after Francois Gigot de la Peyronie, surgeon to King Louis XIV, who in 1743 described &ldquo;rosary beads&rdquo; of scar tissue extending the full length of the dorsal penis in a treatise on ejaculatory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PD can resolve spontaneously in a minority of cases while others have stable disease. However, nearly half of patients will have worsening within one year. PD can be a psychologically and physically disabling disorder, leading to a lower quality of life. Diagnosis is generally straightforward, based on history and physical examination. Ultrasound can also be used to confirm fibrotic plaque.",
"   </p>",
"   <p>",
"    The efficacy of medical management for PD is limited. Treatment options typically include oral or intralesional drug therapy. In most cases, medical management should be initiated once the diagnosis of PD is made. Surgical management may be considered for patients who have penile deformity compromising sexual function and whose PD has persisted for more than 12 months, regardless of previous medical therapy.",
"   </p>",
"   <p>",
"    The diagnosis and medical management of PD will be reviewed here. Surgical management of PD and general issues relating to male sexual dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42007?source=see_link\">",
"     \"Surgical management of Peyronie's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians, including urologists, have the misconception that Peyronie&rsquo;s disease (PD) is a rare condition, based on previous case reports documenting prevalence of &le;1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Contemporary estimates are several-fold higher, perhaps partly due to the introduction of PDE-5 inhibitors for erectile dysfunction leading to improved general awareness among patients and clinicians.",
"   </p>",
"   <p>",
"    The current prevalence of PD is approximately 5 percent in men. Rates range from 3 percent in a community-based survey of 8000 men (mean age 57.8) to 16 percent among 488 men undergoing evaluation for ED (mean age 52.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In 534 men undergoing routine prostate screening (without a specific urologic complaint), the prevalence of PD was 8.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/6\">",
"     6",
"    </a>",
"    ]. The mean age of those with PD was 68.2 years compared to 61.8 years of those without PD. The true prevalence of PD may be underestimated as men might be reluctant to report a condition to their clinician that they consider embarrassing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    older men may accept the condition as a by-product of aging. In addition, men who do not engage in sexual intercourse, such as those with erectile dysfunction, may not be aware there is a problem, as they may not have deformities of the flaccid penis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying pathogenesis of Peyronie&rsquo;s disease (PD) is unknown but is likely multifactorial with an interplay between genetic predisposition, trauma, and tissue ischemia. The underlying lesion of PD is a fibrous plaque(s) that contains excessive collagen, an altered framework of reduced and fragmented elastic fibers, and fibroblastic proliferation that alters penile anatomy. The fibrous plaque causes focal inelasticity and can compromise erectile function. Plaques may be fibrous, contain areas of calcification, or are completely ossified. Most authorities postulate that PD results from repeated minor, and usually unrecognized, blunt trauma to the penis during intercourse.",
"   </p>",
"   <p>",
"    PD is thought to be due to a localized aberration of the wound healing process. For susceptible individuals, bleeding within the tunica albuginea, trapping of fibrin and inflammatory cells, and overexpression of matrix proteins secondary to upregulation of cytokines and growth factors in the local environment lead to plaque formation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/7\">",
"     7",
"    </a>",
"    ]. Excess fibrin deposition in response to microvascular injury and upregulation of transforming growth factor-1 results in one or more areas of plaque formation (",
"    <a class=\"graphic graphic_figure graphicRef61965 \" href=\"UTD.htm?10/5/10324\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of PD has been observed in 2 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/9\">",
"     9",
"    </a>",
"    ]. Twenty-one percent of patients with PD may also have Dupuytren's contracture [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/10\">",
"     10",
"    </a>",
"    ]. Patterns of gene expression in families with PD and Dupuytren's disease are similar, particularly in regard to collagen degradation, ossification, and myofibroblast differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genital",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perineal injuries, radical prostatectomy, plantar fascial contractures, tympanosclerosis, urethral instrumentation, Paget's disease, gout, and lipomas have been associated, albeit weakly, with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Hypertension, smoking, hyperlipidemia, and diabetes have been proposed as risk factors, but they are more likely related to underlying erectile dysfunction, as current research does not show a relation between these factors and severity of penile curvature [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/13\">",
"     13",
"    </a>",
"    ]. An association with vascular comorbidities is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/5,6,14\">",
"     5,6,14",
"    </a>",
"    ], as is the role of overt trauma such as penile fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although historical data suggested that the natural history of PD is often one of spontaneous resolution with conservative management, contemporary studies have shown that this is incorrect. Untreated PD resolves in only 12 percent of men, with 40 to 48 percent of men demonstrating worsening of curvature at 12 months, while curvature remains stable in the remaining men [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/16\">",
"     16",
"    </a>",
"    ]. The mean change was 15 degrees in those in whom curvature improved, while the mean change was 22 degrees in those in whom curvature worsened.",
"   </p>",
"   <p>",
"    The disease state may often be divided into an acute (or inflammatory) phase and a chronic phase. During the former, there may be penile pain, even when flaccid, and there are often dynamic changes of penile malformation. During the latter, pain resolves and the malformation stabilizes in its characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting symptoms of Peyronie&rsquo;s disease (PD) include penile pain, nodule, induration, curvature, deformity, or shortening during erection, as well as sexual dysfunction.",
"   </p>",
"   <p>",
"    Penile pain occurs primarily during erection, and usually resolves within 12 to 24 months of PD onset (94 percent of 246 men who did not receive medical or surgical treatment reported complete resolution of pain, mean 18 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PD deformities are varied but may manifest as curvature, indentation, palpable plaque or nodule, hour-glass narrowing, penile shortening (with or without curvature), or in combination. PD is most evident during erection, as tunical compliance is compromised and the paired corpora cavernosa are unable to expand normally. In a review of 307 men with PD, 46 percent had dorsal curvature, 29 percent lateral, and 9 percent ventral, with the remaining being a combination of curvatures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe or complex curvature and compromised penile rigidity may make penetrative intercourse impossible. Erectile dysfunction is present in 20 to 50 percent of men with PD, and occurs due to deformity preventing coitus, flail penis (cavernous fibrosis or vascular compromise), performance anxiety (psychological), or impaired erections due to venoocclusive dysfunction. Patient and partner quality of life are significantly impacted, as men with PD are at increased risk of depression, lowered self-esteem, and relationship difficulties (especially maintenance of intimacy or dating), in addition to body-image issues and pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis is usually apparent from patient history and penile examination. Patients can be given a preliminary diagnosis of Peyronie&rsquo;s disease (PD) when they present with classic symptoms of the disease: penile nodules (plaques), curvature,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain. Possible associated disorders (eg, Dupuytren's contractures or vascular disease) and inciting events (eg, trauma or genitourinary instrumentation) should be evaluated. It is important to define the psychological effect of PD on the patient and partner, as well as determine the extent of associated erectile dysfunction.",
"   </p>",
"   <p>",
"    Objectively, clinicians may measure penile length, plaque size, and penile curvature. In classical PD, a well-defined plaque or induration is palpable on physical examination, even if the patient is unaware. Among men with PD affecting the dorsal side of the penis, two thirds will have associated plaque (",
"    <a class=\"graphic graphic_figure graphicRef76294 \" href=\"UTD.htm?21/50/22310\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/18\">",
"     18",
"    </a>",
"    ]. Lateral or ventral plaques are less common, but when present, can result in more coital difficulties (",
"    <a class=\"graphic graphic_figure graphicRef74188 \" href=\"UTD.htm?1/16/1295\">",
"     figure 3",
"    </a>",
"    ). Plaques located primarily in the penile septum, or equally distributed on both the ventral and dorsal aspects of the penis, may cause penile shortening without angulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/19\">",
"     19",
"    </a>",
"    ]. Abnormal tissue may extend beyond the palpable lesion or even into the corporal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/20\">",
"     20",
"    </a>",
"    ]. It is often helpful to have the patient take photographs of the erect penis at home to characterize the deformity. If the patient cannot or will not do this, office pharmacoerection can be performed.",
"   </p>",
"   <p>",
"    If the diagnosis of PD is uncertain after history and physical examination, imaging may be helpful. Various imaging modalities have been used to diagnose PD, including ultrasound, plain radiography, computerized tomography, and magnetic resonance. Ultrasound has the highest sensitivity for plaques in the tunica albuginea compared to other methods [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/21\">",
"     21",
"    </a>",
"    ]. Ultrasonography has additional advantages due to its easy availability, low risk, and ability to image and quantify both calcified and soft tissue elements of PD as well as assess vascular status if a reconstructive procedure is being considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically the diagnosis of PD is clinically apparent, but infrequently it can present similarly to developmental penile deformities including congenital ventral curvature, chordee without hypospadias, or curvature associated with epispadias. A chordee is a curved erection of the penis usually due to a congenital lack of distensibility of the corpus cavernosum urethrae or discrepant size between the dorsal and ventral aspects of the tunica albuginea during development. A chordee can also be caused by gonorrheal infection, subsequent inflammation, and scar tissue formation. In contrast, PD occurs due to acquired",
"    <span class=\"nowrap\">",
"     lesions/plaques",
"    </span>",
"    of the tunica albuginea.",
"   </p>",
"   <p>",
"    Although rare, other conditions such as sclerosing lymphangitis or rare neoplasms (epithelioid or angiosarcomas) have been reportedly confused with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR UROLOGY REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As Peyronie&rsquo;s disease (PD) is an uncommon condition and most primary care clinicians have limited experience in managing PD, the primary care clinician should refer the patient to a urologist when the diagnosis of PD is established, or in any patient with a penile deformity. The urologist can coordinate both medical and surgical therapy for PD. Surgical management may be considered for patients who have penile deformity compromising sexual function and whose PD has persisted for more than 12 months, regardless of previous medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16664?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgical treatment of erectile dysfunction\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the management of Peyronie&rsquo;s disease (PD) include observation, medical, or surgical therapy, depending upon the severity of the disease. There are few trials examining the efficacy of the available treatment options. Most studies are hampered by low patient numbers, lack of control groups or reproducibility,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the inability to distinguish efficacy from spontaneous improvement of the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/24\">",
"     24",
"    </a>",
"    ]. Critical appraisal of contemporary literature identifies widespread use of inappropriate clinical endpoints, especially improvement in penile pain, as pain resolves spontaneously in the vast majority of patients. Improvement or resolution of penile deformity (curvature measured after an erection elicited by intracavernous injection) remains the gold standard by which therapies should be measured, while rigorous measurement of plaque size as a secondary endpoint may also be useful. It is important to note, however, that a reduction in plaque size has not been shown to correlate with reduction in curvature [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Critical analysis of non-surgical approaches indicates that there is no mode of treatment able to relieve all symptoms for men with PD. Nonetheless, early medical intervention while the disease is still evolving is more likely to have therapeutic effect compared with intervention when the disease is stable or even calcified. Thus, the need for early diagnosis and consideration of treatment of PD is important.",
"   </p>",
"   <p>",
"    We suggest initiating medical management in PD patients without a penile deformity causing sexual dysfunction and whose PD has persisted for less than 12 months, regardless of previous medical therapy. We suggest using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    as first-line oral therapy with moderate to severe curvature (&gt;30 degrees). In patients who do not have a good response (ie, decrease in penile deformity), intralesional injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or interferon alpha-2b may also be of benefit, and can be used in conjunction with pentoxifylline. In one report, pentoxifylline was found to decrease the size of plaque calcification if taken for several months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Watchful waiting is an appropriate option for select patients with PD. We suggest observation for men with stable, mild curvature (&le;30 degrees) who have satisfactory erectile function, although large observational studies and randomized trials are lacking in this patient population. Such patients who undergo observation should be told that PD may progress with worsening curvature or formation of new penile plaques in the future. If mild curvature worsens or causes sexual dysfunction, medical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical management should be considered. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for urology referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral therapy is indicated in men with moderate to severe curvature (30 degrees or more). We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    for first-line oral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pentoxifylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    is not known. Pentoxifylline blocks transforming growth factor (TGF)-beta 1-mediated inflammation, prevents deposition of collagen type I, and acts as a non-specific PDE inhibitor. In a rat model, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and pentoxifylline reduced the plaque size in tunical fibrosis induced by injection of TGF beta-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/28\">",
"     28",
"    </a>",
"    ]. This agent has been previously used in humans for a variety of inflammatory and fibrotic conditions.",
"   </p>",
"   <p>",
"    There are very few studies evaluating the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    in the treatment of PD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In a six-month, blinded trial of pentoxifylline (400 mg po bid) versus placebo in 228 patients with PD for &lt; 12 months, mean reductions in penile curvature were significantly better in the pentoxifylline group (-22, -20, and -40 degrees compared with baseline in those with dorsal, lateral, and ventral curvature, respectively) compared with an increase in curvature of +31, +22, and +27 degrees, respectively, in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/30\">",
"     30",
"    </a>",
"    ]. Total plaque volumes, erectile function, and peak systolic velocity of blood flow through the cavernous arteries improved significantly for the pentoxifylline group compared to the placebo group. Pentoxifylline was safe and well-tolerated in this study. Further investigations are required to optimize patient response, including optimum dosing and duration of treatment, as well as use in combination with intralesional treatments.",
"   </p>",
"   <p>",
"    Encouraged by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    's observed suppression of collagen production in Peyronie's cells in tissue culture [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/31\">",
"     31",
"    </a>",
"    ], as well as its efficacy in other human fibrotic disorders, we have been offering patients treatment with pentoxifylline (400 mg po tid) as a treatment option for PD since 2002. The earliest meaningful improvement in degree of curvature may take four months or more. The patient may be reassessed in four to five month intervals. If interval improvement is observed, pentoxifylline may be continued up to two years.",
"   </p>",
"   <p>",
"    An article comparing (non-randomized or blinded)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    to vitamin E demonstrated significant",
"    <span class=\"nowrap\">",
"     improvement/stability",
"    </span>",
"    in ultrasonographic calcifications (92 versus 44 percent) and decreased subjective worsening of the curvature (25 versus 78 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E is a potent antioxidant that is thought to reduce collagen deposition within the injured tunica albuginea. Although Vitamin E is a widely used agent for PD in the US, there is little evidence to support its superiority over placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, double blind trial of 236 men with PD, Vitamin E did not significantly improve penile curvature or plaque size compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of Vitamin E alone or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      (n = 236), there was no significant improvement in penile curvature or plaque size compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, vitamin E was effective in men with mild curvature when used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    . In a randomized trial report of 45 men with mild curvature (&lt;30 degrees) and &lt;6 months from PD onset, there was improvement in plaque size with colchicine (1",
"    <span class=\"nowrap\">",
"     mg/twice",
"    </span>",
"    daily) and Vitamin E (600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in two divided doses) combination treatment compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the lack of efficacy as monotherapy in randomized trials, Vitamin E is not a recommended treatment option for PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Potassium para-aminobenzoate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium para-aminobenzoate (Potaba) is an antifibrotic agent that has been used in a variety of disease states. It is thought to increase tissue levels of monoamine oxidase, thereby decreasing levels of serotonin, which are thought to contribute to scar formation. Although potassium para-aminobenzoate has been available for decades, very few studies have examined its efficacy in the treatment of PD.",
"   </p>",
"   <p>",
"    In a 12-month trial, in which 103 men with PD were randomly assigned to potassium para-aminobenzoate (3 g four",
"    <span class=\"nowrap\">",
"     times/day",
"    </span>",
"    for one year) versus placebo, a greater proportion of patients in the active treatment group achieved the primary outcome, defined as a reduction in plaque size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction in penile curvature of at least 30 percent (74 versus 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the data were not analyzed by intention to treat, and therefore it is unclear if potassium para-aminobenzoate protects against PD progression. Further studies are warranted.",
"   </p>",
"   <p>",
"    Current evidence does not support potassium para-aminobenzoate for first-line therapy of PD. Potassium para-aminobenzoate carries a significant cost, requires the patient to ingest up to 24 tablets daily, and is known for its low tolerability due to gastrointestinal side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon basic science and animal model investigations of PD, colchine inhibits collagen synthesis and subsequent fibrosis. Although observational studies demonstrated improvement in penile pain and curvature [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], a randomized, placebo-controlled trial (n = 78) did not demonstrate any difference in plaque size or penile curvature between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    (0.5 to 2.5 mg daily) and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/38\">",
"     38",
"    </a>",
"    ]. Colchicine was effective in men with mild curvature when used in combination with vitamin E [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Vitamin E'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Gastrointestinal side effects are relatively common. Additionally,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    may cause bone marrow suppression. Due to the side effect profile and lack of efficacy, colchicine is not commonly used to treat PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in the treatment of PD has not been shown in controlled trials to date. It is unlikely that an adequate tamoxifen concentration can be attained in the Peyronie's plaque via oral administration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/3\">",
"     3",
"    </a>",
"    ]. In a randomized, double-blind trial of tamoxifen versus placebo (n = 25), there was no difference in correction of curvature (46 versus 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Carnitine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    , an acetyle coenzyme-A inhibitor, has shown mixed results in comparison to other medications or placebo, as illustrated by the following blinded randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (n = 48), the improvement in curvature was greater in the carnitine group (15.9 versus 8.4 degrees) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/40\">",
"       40",
"      </a>",
"      ]. It is unclear if this difference represents a meaningful clinical effect.",
"     </li>",
"     <li>",
"      In another trial of men with advanced PD (n = 60) treated with intralesional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      significantly reduced penile curvature (11.8 versus 1.9 degrees), plaque size (7.6 versus 1.3 mm(2)), and need for surgery while increasing the International Index of Erectile Function score, compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      alone or in combination with Vitamin E (n = 236), there was no significant improvement in penile curvature or plaque size compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Intralesional drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional drug injections are generally safe and well-tolerated (",
"    <a class=\"graphic graphic_figure graphicRef54678 \" href=\"UTD.htm?10/15/10485\">",
"     figure 4",
"    </a>",
"    ). There are three intralesional drug treatments that have shown efficacy in randomized trials:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , interferon alpha-2b, and collagenase.",
"   </p>",
"   <p>",
"    There is currently no clinical role for the use of corticosteroid injections into Peyronie's plaques, as little supportive data exist, and therapy carries a risk of tissue atrophy or obliteration of native penile tissue planes which can make surgical correction more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/3,42\">",
"     3,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Verapamil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is thought to influence fibroblast metabolism by increasing collagenase activity and concurrently decreasing collagen production [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/42,44-46\">",
"     42,44-46",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/47\">",
"     47",
"    </a>",
"    ] trials have shown improvement in symptoms and penile",
"    <span class=\"nowrap\">",
"     plaque/curvature",
"    </span>",
"    with intralesional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    therapy. In a systematic review including four prospective studies of patients with mild PD (including only one small randomized, placebo-controlled trial), verapamil showed some benefit in penile curvature, plaque size, and penile pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/42\">",
"     42",
"    </a>",
"    ]. Verapamil injection is safe, well-tolerated, and commonly used as part of non-surgical PD management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Interferon alpha-2b",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited clinical evidence suggests that interferon alpha-2b treatment may be efficacious for mild to moderate PD. The interferons (IFN) are low molecular weight proteins that are known to inhibit the proliferation of fibroblasts, increase collagenase activity, and decrease collagen production [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/42\">",
"     42",
"    </a>",
"    ]. In a non-randomized trial (n = 117), where investigators were not blinded to treatment arm compared with placebo, men treated with interferon alpha-2b had greater improvement in curvature and plaque size [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/48\">",
"     48",
"    </a>",
"    ]. Interferon injections appear safe, with a primary side-effect of flu-like symptoms in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Collagenase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collagenase, a purified bacterial enzyme targeting collagen for breakdown, has shown some efficacy in improving plaque size and curvature in small, observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/49\">",
"     49",
"    </a>",
"    ]. In a randomized trial of collagenase versus placebo in 49 men, there was a small, but significant improvement in curvature (maximal change of 15 to 20 degrees) in the collagenase group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/50\">",
"     50",
"    </a>",
"    ]. The treatment effect was mostly limited to patients with mild curvature (&lt;30 degrees, plaque size &lt;2 cm). Treatment was well-tolerated.",
"   </p>",
"   <p>",
"    According to a preliminary report in a manufacturer&rsquo;s press release, two larger randomized trials including men with higher degrees of curvature found that collagenase was superior to placebo but also caused more adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/51\">",
"     51",
"    </a>",
"    ]. A phase 2b randomized trial compared collagenase with placebo (saline) and included both penile &ldquo;modeling&rdquo; and non-modeling arms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/52\">",
"     52",
"    </a>",
"    ]. &ldquo;Modeling,&rdquo; in this context, consisted of forcible bending of the penis in a direction opposite that of the bend. Subjects in the modeling arm who received collagenase demonstrated significant reduction in curvature and improvement in subjective bother; there was no difference between treatment and placebo for subjects who did not undergo modeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , superoxide dismutase) is not currently recommended for the treatment of PD outside of clinical trials. In a randomized trial, topical verapamil gel was better than placebo in eliminating pain on erection, decreasing plaque size (84.7 versus 55 percent), decreasing curvature (61.1 versus 43.6 percent), and improving erection quality in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/53\">",
"     53",
"    </a>",
"    ]. However, it is uncertain whether topical therapy has an effect on penile plaques, as topically (transdermal) administered verapamil gel has not been shown to penetrate into the tunica albuginea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized, placebo controlled, crossover series in 39 men, liposomal recombinant human superoxide dismutase did not demonstrate significant effects upon plaque size or penile curvature, although decreased penile pain was observed over the eight week treatment course [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OTHER TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile traction, iontophoresis, extracorporeal shock wave therapy (ESWT), and radiation therapy are other treatment approaches to Peyronie&rsquo;s disease (PD), but none have been shown to be conclusively effective in randomized trials. Well-designed studies are needed to document a treatment effect, should it exist, prior to widespread use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Penile traction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile traction therapy, usually in conjunction with medical management, shows some efficacy with a good safety profile in pilot studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In a study of ten men with PD, nine of whom had failed medical therapy, traction therapy for two to eight hours a day for six months led to reduced curvature in all men (10 to 45 degrees), stretched flaccid penile length increased (0.5 to 2.0 cm), and erect girth increased (0.5 to 1.0 cm). There were no adverse events including skin changes, erectile dysfunction, or hypoesthesia. These results suggest traction therapy may become a non-surgical option for PD. Further studies have demonstrated that traction can play an important role in combination therapy (with oral agents and injection therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/59\">",
"     59",
"    </a>",
"    ], as well as significantly improve patient outcomes after reconstructive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Iontophoresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have investigated the effect of electromotive drug administration, also known as iontophoresis. Theoretically, electrokinetic transport of charged ionic molecules may enhance the delivery of transdermal medications to the target tissues, in this case the diseased tunica albuginea, thereby improving local penetration without systemic side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/61\">",
"     61",
"    </a>",
"    ]. Increased levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    were present after iontophoresis in surgically retrieved tunica albuginea specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial of iontophoresis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    (5 mg) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (8 mg) compared to iontophoresis with 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    in 96 men, there was objective improvement in plaque size and curvature in the verapamil group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/62\">",
"     62",
"    </a>",
"    ]. However, in another trial of iontophoresis with verapamil in 42 men with PD, there was no improvement in penile curvature compared to iontophoresis with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/63\">",
"     63",
"    </a>",
"    ]. Further trials are needed, especially since it is unclear whether the electric current itself may be beneficial for wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iontophoresis is well-tolerated, with the most common side effect being temporary erythema at the electrode site. If iontophoresis continues to prove efficacious, widespread acceptance of iontophoresis likely would occur since it can readily be performed at home [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Extracorporeal shock wave therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This modality remains an investigational treatment due to lack of well-designed trials with long-term follow-up. There are also concerns about the potential side-effects including penile fibrosis, secondary PD scarring, and development of erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited clinical trial data evaluating the efficacy of ESWT for the treatment of PD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. An exploratory meta-analysis of predominantly observational studies determined that ESWT may be somewhat effective in improving penile pain and sexual dysfunction; however, there was insufficient evidence to determine its effect on penile plaque size and curvature [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/66\">",
"     66",
"    </a>",
"    ]. The meta-analysis was limited by several factors, including lack of prospective studies, no blinding in any of the studies, and use of non-standardized outcome measures.",
"   </p>",
"   <p>",
"    In a subsequent randomized trial comparing ESWT versus placebo in 100 patients who had not previously received PD-related treatment, there was a statistically significant decrease in mean plaque size (-0.6 versus +1.4 mm2) and curvature (-1.4 versus +1.8 degrees), which is of uncertain clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy for the treatment of PD has yielded mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Although radiation therapy may reduce pain and penile curvature, it may also compromise erectile function, especially in the aging male [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17273/abstract/69\">",
"     69",
"    </a>",
"    ]. Well-designed trials are required, as no prospective, randomized, placebo-controlled studies have been published. There is insufficient evidence to recommend radiation therapy at this time, particularly since secondary malignancy risks have not been quantified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The underlying pathogenesis of Peyronie&rsquo;s disease (PD) is unknown and most likely represents a combination of factors including chronic minor injury and genetic susceptibility. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presenting symptoms of PD are penile pain, induration, curvature,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sexual dysfunction. Patient and partner quality of life are significantly impacted, as men with PD are at increased risk of depression, relationship difficulties, and body-image issues. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is usually apparent from patient history and penile examination. On exam, clinicians may observe a penile plaque and penile curvature or deformity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis and assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When primary care clinicians have limited experience in managing PD, the primary care clinician should refer the patient to a urologist once the diagnosis of PD is established, or in any patient with a penile deformity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for urology referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not have penile deformity compromising sexual function and whose PD has persisted for less than 12 months, we suggest medical management rather than surgical management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Medical management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42007?source=see_link\">",
"       \"Surgical management of Peyronie's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with stable, mild curvature (&le;30 degrees) who have satisfactory erectile function, we suggest observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If mild curvature worsens or causes sexual dysfunction, we suggest medical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical management (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Observation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the initial medical management of men with moderate to severe PD (&gt;30 degrees), we suggest oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An alternative option is intralesional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , which may also be used concurrently with pentoxifylline. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/1\">",
"      Hauck EW, Weidner W. Fran&ccedil;ois de la Peyronie and the disease named after him. Lancet 2001; 357:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/2\">",
"      Lindsay MB, Schain DM, Grambsch P, et al. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/3\">",
"      Greenfield JM, Levine LA. Peyronie's disease: etiology, epidemiology and medical treatment. Urol Clin North Am 2005; 32:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/4\">",
"      Schwarzer U, Sommer F, Klotz T, et al. The prevalence of Peyronie's disease: results of a large survey. BJU Int 2001; 88:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/5\">",
"      Kadioglu A, Oktar T, Kandirali E, et al. Incidentally diagnosed Peyronie's disease in men presenting with erectile dysfunction. Int J Impot Res 2004; 16:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/6\">",
"      Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/7\">",
"      Lue TF. Peyronie's disease: an anatomically-based hypothesis and beyond. Int J Impot Res 2002; 14:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/8\">",
"      Haag SM, Hauck EW, Szardening-Kirchner C, et al. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007; 51:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/9\">",
"      Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease (CME). J Sex Med 2007; 4:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/10\">",
"      Carrieri MP, Serraino D, Palmiotto F, et al. A case-control study on risk factors for Peyronie's disease. J Clin Epidemiol 1998; 51:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/11\">",
"      Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004; 64:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/12\">",
"      Gholami SS, Gonzalez-Cadavid NF, Lin CS, et al. Peyronie's disease: a review. J Urol 2003; 169:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/13\">",
"      Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie's disease: a case-control study. BJU Int 2006; 97:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/14\">",
"      Usta MF, Bivalacqua TJ, Jabren GW, et al. Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease. J Urol 2004; 171:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/15\">",
"      Zargooshi J. Trauma as the cause of Peyronie's disease: penile fracture as a model of trauma. J Urol 2004; 172:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/16\">",
"      Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006; 175:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/17\">",
"      Kadioglu A, Tefekli A, Erol B, et al. A retrospective review of 307 men with Peyronie's disease. J Urol 2002; 168:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/18\">",
"      Pryor JP, Ralph DJ. Clinical presentations of Peyronie's disease. Int J Impot Res 2002; 14:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/19\">",
"      Bella AJ, Sener A, Foell K, Brock GB. Nonpalpable scarring of the penile septum as a cause of erectile dysfunction: an atypical form of Peyronie's disease. J Sex Med 2007; 4:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/20\">",
"      Brant WO, Bella AJ, Garcia MM, et al. Isolated septal fibrosis or hematoma--atypical Peyronie's disease? J Urol 2007; 177:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/21\">",
"      Andresen R, Wegner HE, Miller K, Banzer D. Imaging modalities in Peyronie's disease. An intrapersonal comparison of ultrasound sonography, X-ray in mammography technique, computerized tomography, and nuclear magnetic resonance in 20 patients. Eur Urol 1998; 34:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/22\">",
"      Ung JO, Padera RF, O'Leary MP. Angiosarcoma of the penis masquerading as a Peyronie's plaque. J Urol 2002; 167:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/23\">",
"      Hauck EW, Schmelz HU, Diemer T, et al. Epithelioid sarcoma of the penis--a rare differential diagnosis of Peyronie's disease. Int J Impot Res 2003; 15:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/24\">",
"      Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006; 49:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/25\">",
"      Ohebshalom M, Mulhall J, Guhring P, Parker M. Measurement of penile curvature in Peyronie's disease patients: comparison of three methods. J Sex Med 2007; 4:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/26\">",
"      Hashimoto K, Hisasue S, Kato R, et al. Outcome analysis for conservative management of Peyronie's disease. Int J Urol 2006; 13:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/27\">",
"      Smith JF, Shindel AW, Huang YC, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Androl 2011; 13:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/28\">",
"      Valente EG, Vernet D, Ferrini MG, et al. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/29\">",
"      Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nat Clin Pract Urol 2006; 3:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/30\">",
"      Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int 2010; 106:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/31\">",
"      Garcia MM, Bella AJ, Lin GT, et al. The effect of pentoxyfylline on cultured human tunical fibroblasts harvested from patients with Peyronie's disease. Can J Urol 2006; 13:3099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/32\">",
"      Pryor JP, Farrell CR. Controlled clinical trial of vitamin E in Peyronie's disease. Prg Reprod Biol Med 1983; 9:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/33\">",
"      Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007; 178:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/34\">",
"      Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003; 91:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/35\">",
"      Weidner W, Hauck EW, Schnitker J, Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005; 47:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/36\">",
"      Akkus E, Carrier S, Rehman J, et al. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/37\">",
"      Kadioglu A, Tefekli A, K&ouml;ksal T, et al. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/38\">",
"      Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004; 16:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/39\">",
"      Teloken C, Rhoden EL, Grazziotin TM, et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999; 162:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/40\">",
"      Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001; 88:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/41\">",
"      Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002; 89:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/42\">",
"      Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease. Eur Urol 2007; 51:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/43\">",
"      Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990; 49:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/44\">",
"      Nicolai M, Cipollone G, Iantorno R, et al. Intralesional verapamil injection versus placebo in Peyronie's disease. J Urol 1998; 159:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/45\">",
"      Steiger M, Ohlig W, Ludwig G. Verapamil versus placebo als injektionstherapie der induratio penis plastica: langzeitergebnisse einer doppel-blind-studie. Urologie A 1999; 38:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/46\">",
"      Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998; 51:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/47\">",
"      Shirazi M, Haghpanah AR, Badiee M, et al. Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009; 41:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/48\">",
"      Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/49\">",
"      Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008; 5:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/50\">",
"      Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 1993; 149:56.",
"     </a>",
"    </li>",
"    <li>",
"     file://ir.auxilium.com/phoenix.zhtml?c=142125&amp;p=irol-newsArticle&amp;ID=1701869&amp;highlight= (Accessed on June 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/52\">",
"      Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol 2012; 187:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/53\">",
"      Fitch WP 3rd, Easterling WJ, Talbert RL, et al. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med 2007; 4:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/54\">",
"      Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/55\">",
"      Riedl CR, Sternig P, Gall&eacute; G, et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol 2005; 48:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/56\">",
"      Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med 2008; 5:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/57\">",
"      Levine LA, Newell MM. FastSize Medical Extender for the treatment of Peyronie's disease. Expert Rev Med Devices 2008; 5:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/58\">",
"      Gontero P, Di Marco M, Giubilei G, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med 2009; 6:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/59\">",
"      Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. J Sex Med 2012; 9:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/60\">",
"      Rybak J, Papagiannopoulos D, Levine L. A retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie's disease: measured lengths and patient perceptions. J Sex Med 2012; 9:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/61\">",
"      Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003; 169:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/62\">",
"      Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004; 171:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/63\">",
"      Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. J Urol 2007; 177:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/64\">",
"      Ojingwa JC, Isseroff RR. Electrical stimulation of wound healing. J Invest Dermatol 2003; 121:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/65\">",
"      M&uuml;ller A, Akin-Olugbade Y, Deveci S, et al. The impact of shock wave therapy at varied energy and dose levels on functional and structural changes in erectile tissue. Eur Urol 2008; 53:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/66\">",
"      Hauck EW, Mueller UO, Bschleipfer T, et al. Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol 2004; 171:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/67\">",
"      Hatzichristodoulou G, Meisner C, Liske P, et al. Efficacy of extracorporeal shock wave therapy (ESWT) in patients with Peyronie's disease (PD)-first results of a prospective, randomized, placebo-controlled, single-blind study. J Urol 2006; 175(Suppl 4):320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/68\">",
"      Palmieri A, Imbimbo C, Longo N, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009; 56:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/69\">",
"      Incrocci L, Hop WC, Slob AK. Current sexual functioning in 106 patients with Peyronie's disease treated with radiotherapy 9 years earlier. Urology 2000; 56:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17273/abstract/70\">",
"      Niewald M, Wenzlawowicz KV, Fleckenstein J, et al. Results of radiotherapy for Peyronie's disease. Int J Radiat Oncol Biol Phys 2006; 64:258.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6882 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-8B28454533-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17273=[""].join("\n");
var outline_f16_55_17273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS AND ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR UROLOGY REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pentoxifylline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Potassium para-aminobenzoate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Colchicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Carnitine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Intralesional drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Verapamil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Interferon alpha-2b",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Collagenase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OTHER TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Penile traction therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Iontophoresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Extracorporeal shock wave therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6882\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6882|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/5/10324\" title=\"figure 1\">",
"      Peyronies disease plaque cross section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/50/22310\" title=\"figure 2\">",
"      Peyronies disease deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/16/1295\" title=\"figure 3\">",
"      Lateral curvature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/15/10485\" title=\"figure 4\">",
"      Intralesional drug inject",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42007?source=related_link\">",
"      Surgical management of Peyronie's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16664?source=related_link\">",
"      Surgical treatment of erectile dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_55_17274="Post-remission therapy for acute myeloid leukemia in younger adults";
var content_f16_55_17274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-remission therapy for acute myeloid leukemia in younger adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17274/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17274/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17274/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/55/17274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/55/17274/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/55/17274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sixty to 80 percent of adult patients with newly diagnosed acute myeloid leukemia (AML) will attain a complete remission (CR) with intensive induction chemotherapy. However, without additional cytotoxic therapy, virtually all of these patients will relapse within a median of four to eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, patients who receive post-remission therapy may expect four-year survival rates as high as 40 percent in young and middle-aged adults.",
"   </p>",
"   <p>",
"    Post-remission therapy aims to destroy leukemia cells that survived induction chemotherapy but are undetectable by conventional studies. There are three basic options for post-remission therapy (in order of increasing intensity): consolidation chemotherapy, autologous hematopoietic cell transplantation (HCT), or allogeneic HCT. The choice among these approaches for an individual patient depends upon a number of factors including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expected rate of relapse with consolidation chemotherapy alone (influenced strongly by the tumor karyotype)",
"     </li>",
"     <li>",
"      Expected morbidity and mortality associated with treatment options (as determined by patient characteristics such as age and comorbidities)",
"     </li>",
"     <li>",
"      Salvage treatments available for the treatment of relapsed disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach minimizes exposure to potentially toxic therapies in patients expected to respond well to conventional chemotherapy while providing maximum antitumor activity for patients with more difficult-to-treat disease.",
"   </p>",
"   <p>",
"    Post-remission therapy for AML in younger adults will be reviewed here. Induction therapy is presented separately, as are the treatment of relapsed disease and the management of complications related to AML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link\">",
"     \"Treatment of relapsed or refractory acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with acute myeloid leukemia (AML), treatment regimens and outcomes may differ between younger and older adults. Although there is no clear dividing line between younger and older adults when dealing with AML, in most studies, \"older adults\" was defined as over age 60. The treatment of older adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is strongly recommended that every case of newly diagnosed AML undergo cytogenetic and molecular analysis before starting induction therapy since specific cytogenetic abnormalities in AML have considerable prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Full knowledge of the karyotype determined by metaphase cytogenetics is an essential part of treatment planning and monitoring of the leukemic clone. More recently, information about the genotype based on molecular studies has demonstrated prognostic significance that can be used to guide treatment decisions as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H8#H8\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Karyotype'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Stratification by genetic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;As more details about the genetic abnormalities found in AML have been realized, risk stratification schemas have undergone multiple revisions. We prefer the following system for risk classification based upon karyotype and molecular studies (",
"    <a class=\"graphic graphic_table graphicRef71278 \" href=\"UTD.htm?21/40/22156\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Favorable risk (approximately 25 percent):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      t(8;21); RUNX1-RUNX1T1",
"     </li>",
"     <li>",
"      inv(16), t(16;16), CBFB-MYH11, whether alone or in conjunction with other abnormalities",
"     </li>",
"     <li>",
"      Normal cytogenetics displaying mutations in both alleles of the nucleophosmin 1 (NPM1) gene but lacking coexistent FMS-like tyrosine kinase 3 gene producing internal transmembrane duplications (FLT3-ITD) mutations",
"     </li>",
"     <li>",
"      Normal cytogenetics displaying mutations in the",
"      <span class=\"nowrap\">",
"       CCAAT/enhancer",
"      </span>",
"      binding protein alpha (CEBPA) gene",
"     </li>",
"     <li>",
"      t(15;17) which identifies acute promyelocytic leukemia (APL), is also favorable, but APL is now considered separately from other forms of AML. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intermediate risk (approximately 65 percent):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal cytogenetics, except for those described in favorable risk subgroup",
"     </li>",
"     <li>",
"      Normal cytogenetics with NPM1 mutations and FLT3-ITD mutations",
"     </li>",
"     <li>",
"      Normal cytogenetics with wild-type NPM1 and FLT3-ITD",
"     </li>",
"     <li>",
"      t(9;11), MLLT3-MLL",
"     </li>",
"     <li>",
"      Other cytogenetic abnormalities not described as either favorable or unfavorable",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfavorable risk (approximately 10 percent):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      3(q21q26) abnormalities, RPN1-EVI1",
"     </li>",
"     <li>",
"      del(5q), del(7q), t(6;9), other 11q23 abnormalities, 17p abnormalities, or complex aberrant karyotypes described as at least 3 unrelated abnormalities excluding cases with t(8;21), inv(16), and t(15;17)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prognostic factors in AML including more details on karyotype analysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H8#H8\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Karyotype'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incorporating other genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in other genes (eg, c-KIT) as well as high levels of expression of particular genes and microRNA signatures appear to confer prognostic significance in adult patients with AML. We are currently beginning to understand how to incorporate these into the risk stratification schema described above. Examples of how these might be incorporated in the future include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with favorable risk disease who also harbor c-KIT mutations may do as poorly as patients with intermediate risk disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High expression of the transcripts of particular genes (eg, ERG, BAALC, EVI-1) have been associated with poorer survival [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The therapeutic implications for these mutational analyses are unclear at this time. These and other prognostic factors such as age and white blood cell count at diagnosis are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FAVORABLE RISK DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the optimal dose, schedule, and number of cycles is unknown, consolidation chemotherapy with high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (HDAC) appears to provide the best survival for most patients with favorable risk disease with the least amount of toxicity. This approach results in overall survival rates at four years of 60 to 75 percent. A randomized trial indicated a disease-free survival benefit when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     gemtuzumab ozogamicin",
"    </a>",
"    was incorporated into treatment for patients with core-binding factor AML [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Administration of consolidation HDAC'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chemotherapy versus transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many prospective studies have investigated the use of various post-remission therapies in patients with favorable risk disease including chemotherapy alone, autologous hematopoietic cell transplantation (HCT), allogeneic HCT, and maintenance therapy. Randomized trials of allogeneic HCT have not been feasible for patients with AML. Instead, investigators have relied on a \"genetic randomization\" in which patients are assigned to treatment with or without allogeneic HCT based upon the presence or absence of an HLA-matched sibling donor. Patients without an HLA-matched sibling are assigned to treatment with either chemotherapy alone or autologous HCT, depending upon the trial design. Results are then evaluated by an intention-to-treat analysis for \"donor\" and \"no donor\" (available) treatment groups. As with randomized trials, not all patients in the \"donor\" group ultimately receive an allogeneic HCT, but they would still be included in the \"donor\" group for the statistical analysis.",
"   </p>",
"   <p>",
"    Three large meta-analyses of these studies performed using data from over 4000 patients with AML in first complete remission examined the effect of donor availability and cytogenetic risk category on disease free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. There were 480 patients with favorable risk disease analyzed. In this group, the availability of an HLA-matched sibling did not result in superior disease-free or overall survival, implying no benefit from allogeneic HCT in this risk group. The estimated risk of relapse after consolidation chemotherapy is approximately 35 percent or less in this population. With such a relatively low risk of relapse, the high rate of treatment-related mortality associated with allogeneic HCT (approximately 20 percent) likely negates the effect of a possible small decrease in relapse rate on disease-free or overall survival. A randomized trial also demonstrated that consolidation chemotherapy results in superior survival rates when compared with lower dose maintenance therapy given over an extended period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For young patients with newly diagnosed AML demonstrating favorable cytogenetics, we recommend post-remission therapy with consolidation chemotherapy rather than either autologous HCT or allogeneic HCT. Post-remission chemotherapy is used in this patient population instead of HCT to avoid the unnecessary risks of acute and chronic morbidity and mortality associated with HCT in a considerable number of patients who may be cured with consolidation chemotherapy alone. HCT is then reserved for use at the time of relapse, if necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link&amp;anchor=H21584407#H21584407\">",
"     \"Treatment of relapsed or refractory acute myeloid leukemia\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (HDAC) has been the consolidation chemotherapy of choice in these patients for over a decade. Attempts to improve on survival rates attained with HDAC by substituting other agents with different mechanisms of action have not been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/2,15-18\">",
"     2,15-18",
"    </a>",
"    ]. Alternating courses of other two-drug combinations have been tested and provide survival rates equivalent to HDAC consolidation therapy. This was shown in a randomized study of 473 patients &lt;60 years of age, in which the use of three consolidation courses of HDAC (3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    given as above) was equally as effective as three courses of sequential multiagent chemotherapy (one course each of HDAC,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"      etoposide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"     ,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     diaziquone/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"      mitoxantrone",
"     </a>",
"     ),",
"    </span>",
"    with less overall toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dose of cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     Cytarabine",
"    </a>",
"    is one of the most effective agents available for the treatment of AML and is a key component of induction therapy. High dose cytarabine produces high intracellular drug concentrations, which saturate the deaminating metabolic enzyme pathway, leading to increased levels of the active agent ara-cytidine triphosphate. In this way, HDAC can often effectively eliminate minimal residual disease that survived induction with cytarabine containing regimens.",
"   </p>",
"   <p>",
"    Consolidation chemotherapy with HDAC produces superior survival rates than those seen with lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    . This was principally demonstrated in a randomized trial of consolidation therapy in 596 patients using 4 courses of cytarabine at low (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) or intermediate doses (400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) as continuous IV infusions for 5 days or at high doses (HDAC: 3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 12 hours on days 1, 3, and 5) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients &lt;60 years old who received HDAC had the following significant outcomes when compared with patients who received intermediate or low dose cytarabine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher rates of four-year disease-free survival (44 percent versus 29 and 24 percent, respectively)",
"     </li>",
"     <li>",
"      Improved four-year overall survival rates (52 percent versus 40 and 35 percent, respectively)",
"     </li>",
"     <li>",
"      Fewer relapses more than two years after attaining complete remission (44 versus 29 and 24 percent, respectively)",
"     </li>",
"     <li>",
"      Greater toxicity (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Toxicities'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While it is clear that higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    are preferable to lower doses, the ideal dose remains unknown and there is likely a dose above which additional cytarabine is not a benefit. A cytarabine dose of 3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    given over three hours is frequently used primarily because it was the dose used for adults younger than 60 years in the study described above. Cytarabine 2",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for five days has demonstrated similar rates of disease-free and overall survival, but has not been compared directly with the 3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    dose in a prospective trial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, results from a randomized trial indicate that cytarabine 3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for six days was not superior to cytarabine 1",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for six days when each was combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    for a first consolidation course followed in some cases by an autologous or allogeneic transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Number of cycles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal number of post-remission chemotherapy cycles is not known, but patients who receive at least three cycles appear to do better than those who receive fewer.",
"   </p>",
"   <p>",
"    As an example, a total of 50 patients with AML and t(8;21)(q22;q22) from four successive CALGB studies were assigned (but not randomized) to receive either one (29 patients) or &ge;3 cycles (21 patients) of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (HDAC) as postinduction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/22\">",
"     22",
"    </a>",
"    ]. When compared with those receiving a single cycle of HDAC, patients treated with &ge;3 cycles of HDAC demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A lower rate of relapse &mdash; 19 versus 62 percent",
"     </li>",
"     <li>",
"      Longer median relapse-free survival &mdash; &gt;35 versus 10.5 months",
"     </li>",
"     <li>",
"      A higher estimated rate of five-year overall survival &mdash; 76 versus 44 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar report using data from AML patients with inv(16) or t(16;16) found that repetitive HDAC therapy decreases the likelihood of relapse compared with consolidation regimens including less HDAC [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/23\">",
"     23",
"    </a>",
"    ]. However, there was no significant difference in overall survival, likely due to a high success rate using salvage treatment with hematopoietic cell transplantation in relapsing patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Administration of consolidation HDAC",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically give three courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    3",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    administered over three hours twice per day on days 1, 3, and 5 for a total of six doses per course [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients older than 60 years typically receive 2",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and those older than 70 years 1.5",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    The initial course is begun after confirmation of a complete remission and resolution of all toxicities from induction therapy. Sequential courses are administered no sooner than every 28 days or 1 week after marrow recovery as documented by an absolute neutrophil count &ge;1000 and platelets &ge;100,000 without transfusion.",
"   </p>",
"   <p>",
"    Saline or steroid eye drops should be administered to both eyes four times daily until 24 hours after completion of the HDAC infusion to prevent chemical conjunctivitis due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    in the tears. Cerebellar evaluations for dysdiadochokinesis or past-pointing should be performed at least every 12 hours during therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H13#H13\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Monitoring during treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H14#H14\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;This regimen is usually administered as an inpatient and requires close monitoring for toxicities. Even within the context of a clinical trial, only approximately 56 percent of patients under age 60 were able to complete 4 courses of this regimen. Treatment related mortality, mostly due to infection, is approximately 5 percent. Common major side effects of HDAC include pancytopenia, infection (62 percent), central nervous system toxicity (13 percent), hyperbilirubinemia (11 percent), and fatigue (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of particular importance, serious central nervous system toxicities (eg, somnolence and confusion, and rarely seizures, cerebral dysfunction, and acute cerebellar syndrome) can be seen in approximately 12 percent of patients overall. This percentage rises to approximately 30 percent in patients over the age of 60, 40 percent of whom may be left with permanent disability. If cerebellar toxicity occurs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    should be discontinued. The clinical situation can be confusing if patients are also receiving anti-emetics or other drugs that can have CNS effects. It is unclear whether patients should be rechallenged with HDAC in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INTERMEDIATE RISK DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-remission therapy options for patients with intermediate risk disease include consolidation chemotherapy with high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (HDAC) as given for favorable risk disease, HDAC followed by autologous hematopoietic cell transplantation (HCT), or allogeneic HCT alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consolidation chemotherapy with high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (HDAC) is nonmyeloablative and has a low treatment related mortality rate (approximately 5 percent). Rates of four-year disease-free survival among patients with intermediate risk disease are approximately 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/24\">",
"       24",
"      </a>",
"      ]. Common major side effects include pancytopenia, infection, central nervous system toxicity, and hyperbilirubinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Toxicities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autologous HCT allows the use of myeloablative chemotherapy and is not associated with graft-versus-host disease, but does not provide the graft-versus-leukemia effect seen with allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/25-32\">",
"       25-32",
"      </a>",
"      ]. Treatment-related morbidity and mortality are relatively low (&le;6 percent) but relapse rates are high (30 to 50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/33-37\">",
"       33-37",
"      </a>",
"      ]. Rates of four-year disease-free survival are approximately 45 percent and are in the same range as those in patients who receive intensive but nonablative consolidation chemotherapy (eg, HDAC) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Allogeneic HCT targets cancer cells both by administering myeloablative chemotherapy and by harnessing a graft-versus-leukemia effect. Treatment-related mortality is high (approximately 20 percent) as is morbidity associated with graft-versus-host disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/12\">",
"       12",
"      </a>",
"      ]. Rates of four-year disease-free survival are approximately 48 percent overall; patients younger than 35 or 40 years have superior results [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/12,38\">",
"       12,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=see_link\">",
"       \"Quality of life following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three large meta-analyses of prospective studies comparing these post-remission therapies for patients with AML, subdivided by karyotypes, have been performed using data from over 4000 patients with AML in first complete remission [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. There were 603 patients with intermediate risk disease analyzed. In an intention-to-treat analysis, patients \"genetically assigned\" to matched related donor HCT (ie, those who had an HLA-matched sibling) had superior rates of four-year disease-free survival. While overall survival did not reach statistical significance in the first meta-analysis, combination of the data from these three meta-analyses demonstrated a benefit in overall survival implying that allogeneic HCT was beneficial for patients in this risk group overall. Such results were particularly noticeable for patients younger than age 35 years who tolerate the morbidity from HCT better.",
"   </p>",
"   <p>",
"    However, controversy remains as to whether allogeneic transplantation is of benefit in patients with normal karyotypes that demonstrate certain gene mutations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects with a normal karyotype, NPM1 mutations, wild-type FLT3, and low levels of ERG appear to have an especially favorable prognosis, with an estimated two-year progression-free survival of 60 to 70 percent after induction treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      followed by high dose cytarabine or autologous hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/7,40\">",
"       7,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from \"donor\" versus \"no donor\" analyses demonstrate that a subgroup of cytogenetically normal AML defined by the favorable molecular genotype with NPM1 gene mutations but no FLT3-ITD mutations have outcomes similar to those patients with favorable karyotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/40\">",
"       40",
"      </a>",
"      ]. Such patients derive no benefit from allogeneic HCT compared with chemotherapy alone. For another favorable genotype defined by CEBPA gene mutations, direct data are not available but circumstantial evidence would suggest that they are unlikely to benefit from allogeneic HCT as post remission therapy in first complete remission either.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a subset of patients with intermediate risk karyotypes may not require an allogeneic HCT, but these observations require confirmation in additional studies. Given the controversy surrounding this group of patients, patients should be encouraged to participate in clinical trials. Outside of a clinical trial, any of the above approaches may be offered. The choice of post-remission therapy for an individual with intermediate risk disease depends upon the patient's age and comorbidities. Age and comorbidities are host factors that define the mortality risk of the transplant and which can be taken into account in relation to the risk of relapse of the disease. As an example, young patients (eg, &lt;40 years old) with few comorbidities may choose allogeneic HCT rather than autologous HCT or HDAC. This preference places a strong emphasis on the survival benefit seen on meta-analysis and a lesser emphasis on the high rate of treatment related mortality and morbidity. A post-remission treatment calculator has been proposed that incorporates age, percentage of CD34 positive blasts, FLT3-ITD mutant-to-wild-type ratio, cytogenetic risk, and disease status to predict probability of survival with these therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/41\">",
"     41",
"    </a>",
"    ]. However, FLT3-ITD mutant-to-wild-type ratio is not widely available and measures of CD34 positive blasts may have variability among institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/42\">",
"     42",
"    </a>",
"    ]. As such, we await validation of this calculator in other cohorts prior to its widespread application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     UNFAVORABLE RISK DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unfavorable karyotypes, as defined above, do poorly when treated with consolidation chemotherapy alone after attainment of a complete remission; rates of five-year overall survival with this approach are 15 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/2,4,12,24\">",
"     2,4,12,24",
"    </a>",
"    ]. In contrast, treatment with allogeneic hematopoietic cell transplantation (HCT) provides an additional graft-versus-leukemia (GVL) effect together with myeloablative chemotherapy, resulting in superior survival rates of approximately 40 percent at four years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The strong GVL response in AML is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rates of AML relapse are much higher in patients who have received identical twin (syngeneic) transplants compared with HLA-identical sibling transplants administered with identical cytotoxic treatment (eg, 52 versus 16 percent in one series) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/43\">",
"       43",
"      </a>",
"      ]; this difference relates to the allogeneic graft-versus-leukemia effect.",
"     </li>",
"     <li>",
"      Patients who relapse after an allogeneic HCT may benefit from donor lymphocyte infusion (DLI). As an example, remission was achieved with DLI in 29 percent in one study of 23 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, the beneficial GVL response is closely associated with acute and chronic graft-versus-host disease (GVHD), while intensive myeloablative chemotherapy is associated with life-threatening cytopenias. Both are major causes of morbidity and mortality following allogeneic HCT. GVHD can be reduced by T-cell depletion from the donor marrow, generally at the risk of increased rates of graft failure and leukemia relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Myeloablative allogeneic transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prospective studies have evaluated different post-remission strategies in patients with unfavorable risk disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/25,45-49\">",
"     25,45-49",
"    </a>",
"    ]. As mentioned above, investigators have relied on a \"genetic randomization\" in which patients are assigned to treatment with or without allogeneic HCT based upon the presence or absence of an HLA-matched sibling donor. The strength of evidence provided by these observational studies is limited by a lack of true randomization. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Chemotherapy versus transplantation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Three large meta-analyses of these observational studies performed using data from patients with AML in first complete remission examined the effect of patient age, donor availability and cytogenetic risk category on disease free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Patients with unfavorable risk disease who had an HLA-matched sibling donor had the following significant outcomes when compared with patients assigned to treatment with chemotherapy with or without autologous HCT, when analyzed in an intention-to-treat fashion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Superior rates of four-year overall survival (40 versus 30 percent)",
"     </li>",
"     <li>",
"      Improved rates of disease-free survival at four years (33 versus 17 percent)",
"     </li>",
"     <li>",
"      Fewer relapses at four years (39 versus 77 percent)",
"     </li>",
"     <li>",
"      Higher treatment-related mortality (28 versus 6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further analysis using age cutoffs of either 35 or 40 years found that younger patients have a lower treatment related mortality and as a result the benefits of allogeneic HCT become more pronounced. For patients with unfavorable risk cytogenetics, we recommend allogeneic HCT rather than autologous HCT or consolidation chemotherapy alone. If a related or unrelated donor were not available or if the patient were not a candidate for transplantation, then enrollment in a clinical trial is advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Conditioning regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic HCT should be delivered shortly after attainment of an initial complete remission. Postremission consolidation therapy with standard or high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    is not associated with improved outcome, compared with proceeding directly to allogeneic transplantation following successful induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ideal conditioning (preparative) regimen is unknown and clinical practice differs by institution according to experience. Possible options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       Busulfan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       Melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      , and total body irradiation (TBI) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      plus TBI [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced intensity regimens using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/53\">",
"       53",
"      </a>",
"      ] or the combination of busulfan, fludarabine, and antithymocyte globulin [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/54\">",
"       54",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Nonmyeloablative HCT'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Choice of donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the prospective trials evaluating allogeneic HCT in first complete remission included in the meta-analyses mentioned above used HLA-matched related donors since this criterion was used as the method for treatment stratification. However, only 25 to 30 percent of potential recipients have HLA-matched siblings who can serve as donors. With the advent of molecular typing techniques, morbidity and mortality associated with the use of HLA-matched unrelated donors has declined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients without an HLA-matched sibling, the following donors may be considered since they are expected to result in similar outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/53,55-66\">",
"     53,55-66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Matched unrelated donor",
"     </li>",
"     <li>",
"      Single antigen mismatched related donor",
"     </li>",
"     <li>",
"      Umbilical cord blood transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allogeneic HCT using a matched unrelated donor (MUD) is an option for younger adults who lack a sibling donor. The likelihood of finding a MUD in the National Bone Marrow Donor Registry is related in part to the ethnic background of the patient compared with the volunteer donor pool. It also depends on the number of allelic mismatches between donor and recipient that one wishes to allow (eg, a full",
"    <span class=\"nowrap\">",
"     10/10",
"    </span>",
"    match or",
"    <span class=\"nowrap\">",
"     9/10",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     8/10",
"    </span>",
"    with mismatches). The overall match rate is approximately 50 percent for Caucasians but only 10 percent for minorities who are both underrepresented in the donor pool and more polymorphic with respect to HLA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the relative immaturity of the immune system in umbilical cord samples, stem cells from this source allow the crossing of immunologic barriers that would otherwise be prohibitive. As a result, the degree of HLA-disparity that is tolerable is much greater, making this approach more feasible for members of minorities. In addition, cord blood has already been collected and cryopreserved before the time a match is identified, thereby greatly reducing the time required for accessing the donor and completing the transplant procedure; however, there is less clinical follow-up with cord blood transplantations and long term follow-up will be necessary to determine whether they truly provide equivalent results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/60,68\">",
"     60,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another option which would significantly increase donor availability is to use T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype, sometimes called partially-matched family member transplants or haploidentical transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/54,69,70\">",
"     54,69,70",
"    </a>",
"    ]. This method should be considered as investigational as only limited data in selected patients are available and this procedure is associated with severe and prolonged immunodeficiency after transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nonmyeloablative HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because myeloablative allogeneic HCT may lead to significant early morbidity and mortality in patients of higher age and those with other medical conditions (comorbidities), nonmyeloablative HCT has been developed as an alternative strategy. Thus, older patients who are not candidates for myeloablative allogeneic HCT may be candidates for a nonmyeloablative HCT. This procedure relies less on the dose intensity of the pretransplant cytotoxic regimen and heavily upon the graft-versus-leukemia response [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/53,71-76\">",
"     53,71-76",
"    </a>",
"    ]. It seems likely that a durable remission must first be achieved before this is a feasible option.",
"   </p>",
"   <p>",
"    Published experience on this approach involves small nonrandomized trials with limited follow-up and a single randomized trial that was closed early due to poor accrual. These limitations imply that, for a thorough assessment of the clinical value of nonmyeloablative HCT, more mature data and a better understanding of patient comorbidities are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/77\">",
"     77",
"    </a>",
"    ]. There is wide variation in the specific preparative regimens used in these trials, and some may be more effective than others.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an unblinded German phase III trial, 195 younger adults (age 18 to 60 years) with intermediate-risk or high-risk AML in first complete remission who had an available HLA-matched sibling or matched unrelated donor (9 of 10 or 10 of 10) were randomly assigned to receive reduced intensity conditioning (RIC) or myeloablative conditioning, each followed by allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/78\">",
"       78",
"      </a>",
"      ]. RIC consisted of four doses of 2 Gy total body irradiation (TBI) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      . Myeloablative conditioning consisted of six doses of 2 Gy TBI plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . The trial closed early due to poor accrual and thus has limited statistical power. At a median follow-up of 27 months, when compared with standard myeloablative conditioning, RIC was associated with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A similar estimated incidence of non-relapse mortality (13 versus 22 percent; HR 0.62, 95% CI 0.30-1.31) at three years",
"     </li>",
"     <li>",
"      A similar estimated incidence of relapse (28 versus 26 percent; HR 1.10, 95% CI 0.63-1.90) at three years",
"     </li>",
"     <li>",
"      A lower rate of in-hospital mortality (0 versus 9 percent)",
"     </li>",
"     <li>",
"      A similar time to neutrophil (19 versus 17 days) and platelet (18 days) engraftment",
"     </li>",
"     <li>",
"      A lower rate of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      mucositis (54 versus 83 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of the Center for International Blood and Marrow Transplant Research database included 545 patients older than age 40 with AML in first complete remission (CR) who underwent reduced-intensity or non-myeloablative conditioning followed by related or unrelated donor HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/79\">",
"       79",
"      </a>",
"      ]. Patients were divided into four groups by age: 40 to 54, 55 to 59, 60 to 64, and older than 64 years. There was no statistically significant difference in the two-year rates for non-relapse mortality (22 to 34 percent), disease relapse (33 to 37 percent), and survival (34 to 50 percent) among the age groups.",
"     </li>",
"     <li>",
"      A prospective study employed non-myeloablative conditioning using 2 Gy total body radiation with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      in 122 patients with AML, most of whom were considered ineligible for conventional allogeneic HCT because of older age or comorbidities [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/75\">",
"       75",
"      </a>",
"      ]. The median age was 58 years (range: 17 to 74). At a median follow-up of 44 months, rates of overall survival were 51 and 61 percent for patients transplanted in first or second CR, respectively, and 28 percent for those beyond CR2 at the time of HCT. Two-year incidences of non-relapse mortality were 10 and 22 percent for those with related or unrelated donors, respectively.",
"     </li>",
"     <li>",
"      Reduced-intensity conditioning with a",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"        fludarabine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"        melphalan",
"       </a>",
"      </span>",
"      regimen incorporating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      was utilized in 76 patients with high-risk AML or MDS, 42 of whom were in first, second, or third CR [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/74\">",
"       74",
"      </a>",
"      ]. Median age was 52 years (range: 18 to 71 years). Estimated three-year disease-free survival was 42 percent for those in CR at the time of HCT. One-year transplant-related mortality was 19 percent.",
"     </li>",
"     <li>",
"      A French cooperative study explored the role of nonmyeloablative allo-HCT in 33 patients with high-risk AML in first CR [",
"      <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/71\">",
"       71",
"      </a>",
"      ]. The median age was 52 years (range: 26 to 60). All patients received two courses of consolidation chemotherapy followed by non-myeloablative allo-HCT. Thirteen patients also received high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      and an autologous HCT just prior to their allo-HCT. At a median follow-up of 18 months after allo-HCT, estimated two-year overall and leukemia-free survivals were 79 and 76 percent, respectively, with a cumulative treatment-related mortality of 9 percent. The occurrence of chronic graft-versus-host disease was associated with a significantly lower relapse rate (zero versus 44 percent) and a significantly better overall survival (95 versus 61 percent), suggesting the presence of a graft-versus-leukemia effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that reduced-intensity or nonmyeloablative conditioning followed by related or unrelated donor HCT is feasible in a subset of patients who are not candidates for myeloablative HCT. This approach may be preferable to consolidation chemotherapy alone in patients with intermediate or unfavorable risk disease in first CR. This is supported by a single center prospective trial that compared outcomes with a reduced intensity conditioning regimen versus consolidation chemotherapy in 95 patients with intermediate risk (80 percent) or unfavorable risk AML in first CR [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/80\">",
"     80",
"    </a>",
"    ]. All patients were considered to be candidates for reduced intensity conditioning, and \"genetic randomization\" was used to assign treatment with or without allogeneic HCT based upon the presence or absence of an HLA-matched sibling donor. At a median follow-up of 4.8 years, patients with an HLA-matched sibling donor had significantly higher estimated rates of leukemia-free survival at seven years (60 versus 23 percent). Treatment-related mortality for those who underwent reduced-intensity conditioning was 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If feasible, we suggest the use of a reduced intensity or nonmyeloablative conditioning followed by related or unrelated donor HCT rather than consolidation chemotherapy for older patients with intermediate or unfavorable risk AML who are not candidates for myeloablative allogeneic HCT. Ideally this treatment should be performed within the context of a clinical trial to allow for the collection of additional data regarding its safety and efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POST-CONSOLIDATION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of post-remission therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up.",
"   </p>",
"   <p>",
"    Maintenance therapy alone, using relatively nonmyelosuppressive doses of cytotoxic drugs following remission induction, has no proven benefit in the cure of AML. For patients under 60 years of age, consolidation therapy results in significantly longer survival than maintenance therapy alone. Clinical trials are investigating the use of agents such as interleukin 2 or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    as a maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/55/17274/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Monitoring for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to patient surveillance is to schedule patient visits every one to two months for the first two years when the disease is most likely to relapse, and then every three to six months for up to five years post consolidation. At these visits we perform a complete blood count including platelets, white blood cell differential, and review of the peripheral blood smear. Bone marrow biopsy and aspirate is not routinely performed, but is indicated if the peripheral smear demonstrates abnormalities or if cytopenias develop.",
"   </p>",
"   <p>",
"    The use of minimal residual disease monitoring in patients with AML is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link&amp;anchor=H14#H14\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\", section on 'Use in non-APL AML'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the patient with AML who has relapsed after attainment of a complete remission is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link\">",
"     \"Treatment of relapsed or refractory acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Monitoring for treatment complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long term treatment complications differ based upon the post-remission treatment strategy used. Immunizations and general health maintenance guidelines are recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended treatment of acute myeloid leukemia (AML) in the younger adult includes the following three major components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pre-treatment cytogenetics and molecular genetics &mdash; Metaphase cytogenetics and molecular analyses should be performed prior to initiation of therapy, since specific cytogenetic abnormalities and acquired genetic mutations help determine prognosis and thus treatment interventions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Remission induction &mdash; The first goal of treatment is attainment of a complete remission with rapid restoration of normal bone marrow function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postremission therapy &mdash; Remission consolidation therapy following attainment of complete remission comprises one or more courses of chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As more details about the genetic abnormalities found in AML have been realized, risk stratification schemas have undergone multiple revisions. It is likely that these will change further as we learn more about the effect of gene mutations and microRNA expression, especially in patients with cytogenetically normal AML. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Risk stratification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Postremission therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with favorable cytogenetics (ie, t(8;21), inv(16), or t(16;16)), we recommend consolidation treatment with three or more courses of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , rather than standard dose cytarabine, alternative chemotherapeutic agents, or early hematopoietic cell transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Favorable risk disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with intermediate risk cytogenetics, including a normal karyotype, selection of treatment (eg, chemotherapy versus transplantation) should be based on individual patient features (eg, age, initial white blood cell count, ease of remission induction, comorbidities, and evidence for minimal residual disease), patient preference, donor availability, and access to specific clinical trials. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Intermediate risk disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unfavorable-risk cytogenetics, we recommend allogeneic hematopoietic cell transplantation in first remission for appropriate candidates over conventional chemotherapy or autologous hematopoietic cell transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Availability of a matched donor is the prerequisite, and HLA typing of the patient should be done at diagnosis so that a donor search is not delayed. Registry data suggest that there is no advantage to giving one or more cycles of consolidation therapy after achievement of a CR and prior to allogeneic transplantation as long as the transplant is not delayed more than several weeks after remission induction. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Unfavorable risk disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/1\">",
"      Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988; 6:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/2\">",
"      Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58:4173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/3\">",
"      Mr&oacute;zek K, Prior TW, Edwards C, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2001; 19:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/4\">",
"      Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/5\">",
"      D&ouml;hner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/6\">",
"      Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24:3904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/7\">",
"      Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007; 25:3337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/8\">",
"      Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008; 111:4329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/9\">",
"      Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008; 111:5371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/10\">",
"      Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/11\">",
"      Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005; 103:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/12\">",
"      Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109:3658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/13\">",
"      Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/14\">",
"      Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/15\">",
"      Rees JK, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Br J Haematol 1996; 94:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/16\">",
"      Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006; 107:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/17\">",
"      Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 2011; 117:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/18\">",
"      Thomas X, Elhamri M, Raffoux E, et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 2011; 118:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/19\">",
"      Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 2005; 105:3420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/20\">",
"      Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/21\">",
"      Schaich M, R&ouml;llig C, Soucek S, et al. Cytarabine dose of 36 g/m&sup2; compared with 12 g/m&sup2; within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 2011; 29:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/22\">",
"      Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999; 17:3767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/23\">",
"      Byrd JC, Ruppert AS, Mr&oacute;zek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004; 22:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/24\">",
"      Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/25\">",
"      Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/26\">",
"      Ball ED, Rybka WB. Autologous bone marrow transplantation for adult acute leukemia. Hematol Oncol Clin North Am 1993; 7:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/27\">",
"      Linker CA, Ries CA, Damon LE, et al. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant 1998; 22:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/28\">",
"      Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/29\">",
"      L&ouml;wenberg B. Post-remission treatment of acute myelogenous leukemia. N Engl J Med 1995; 332:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/30\">",
"      Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/31\">",
"      Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leuc&eacute;mies Aigu&euml;s My&eacute;loblastiques (GOELAM). Blood 1997; 90:2978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/32\">",
"      Gorin NC, Labopin M, Pichard P, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Haematol 2000; 110:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/33\">",
"      Lazarus HM, P&eacute;rez WS, Klein JP, et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006; 132:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/34\">",
"      Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/35\">",
"      Tsimberidou AM, Stavroyianni N, Viniou N, et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003; 97:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/36\">",
"      Nathan PC, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 2004; 96:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/37\">",
"      Loh YS, Koh LP, Tai BC, et al. Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. Leuk Lymphoma 2007; 48:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/38\">",
"      Farag SS, Ruppert AS, Mr&oacute;zek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005; 23:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/39\">",
"      Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011; 118:6037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/40\">",
"      Schlenk RF, D&ouml;hner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/41\">",
"      Pfirrmann M, Ehninger G, Thiede C, et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 2012; 13:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/42\">",
"      Ferrara F. Renaissance of autologous stem cell transplantation for AML? Lancet Oncol 2012; 13:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/43\">",
"      Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/44\">",
"      Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/45\">",
"      Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol 1998; 102:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/46\">",
"      Frassoni F, Labopin M, Gluckman E, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996; 17:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/47\">",
"      Blaise D, Maraninchi D, Michallet M, et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001; 97:3669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/48\">",
"      Greinix HT, Nachbaur D, Krieger O, et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 2002; 117:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/49\">",
"      Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/50\">",
"      Tallman MS, Rowlings PA, Milone G, et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000; 96:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/51\">",
"      Murata M, Nishida T, Haneda M, et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. Br J Haematol 1999; 105:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/52\">",
"      Bacigalupo A, Vitale V, Corv&ograve; R, et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000; 108:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/53\">",
"      Ringd&eacute;n O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:4570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/54\">",
"      Lee KH, Lee JH, Lee JH, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 2011; 118:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/55\">",
"      Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/56\">",
"      Valcarcel D, Kan F, Wang T, et al. One antigen HLA-mismatched related and 8/8 allele matched unrelated donors are associated with similar survival after hematopoietic cell transplantation for acute leukemia (abstract). Blood 2008; 112:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/57\">",
"      Appelbaum FR. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. Hematology Am Soc Hematol Educ Program 2008; :412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/58\">",
"      Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/59\">",
"      Schetelig J, Bornh&auml;user M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26:5183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/60\">",
"      Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood 2009; 113:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/61\">",
"      Basara N, Schulze A, Wedding U, et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/62\">",
"      Walter RB, Pagel JM, Gooley TA, et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 2010; 24:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/63\">",
"      Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010; 116:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/64\">",
"      Schlenk RF, D&ouml;hner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010; 28:4642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/65\">",
"      Huang XJ, Zhu HH, Chang YJ, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012; 119:5584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/66\">",
"      Brunstein CG, Eapen M, Ahn KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012; 119:5591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/67\">",
"      Mori M, Beatty PG, Graves M, et al. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997; 64:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/68\">",
"      Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/69\">",
"      Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/70\">",
"      Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112:3574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/71\">",
"      Blaise DP, Michel Boiron J, Faucher C, et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/72\">",
"      Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102:3052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/73\">",
"      Stelljes M, Bornhauser M, Kroger M, et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood 2005; 106:3314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/74\">",
"      Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23:9387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/75\">",
"      Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/76\">",
"      Nelson RP Jr, Yu M, Schwartz JE, et al. Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transplant 2010; 45:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/77\">",
"      Grigg AP, Szer J, Beresford J, et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999; 107:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/78\">",
"      Bornh&auml;user M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012; 13:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/79\">",
"      McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/80\">",
"      Mohty M, de Lavallade H, Ladaique P, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005; 19:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/81\">",
"      Mohty M, de Lavallade H, El-Cheikh J, et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison. Leukemia 2009; 23:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/55/17274/abstract/82\">",
"      Buyse M, Squifflet P, Lange BJ, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 2011; 117:7007.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4533 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17274=[""].join("\n");
var outline_f16_55_17274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Stratification by genetic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incorporating other genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FAVORABLE RISK DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chemotherapy versus transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dose of cytarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Number of cycles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Administration of consolidation HDAC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Toxicities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INTERMEDIATE RISK DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      UNFAVORABLE RISK DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Myeloablative allogeneic transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Conditioning regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Choice of donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nonmyeloablative HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POST-CONSOLIDATION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Monitoring for relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Monitoring for treatment complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Postremission therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4533\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4533|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/40/22156\" title=\"table 1\">",
"      Karyotype risk AML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=related_link\">",
"      Quality of life following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=related_link\">",
"      Treatment of relapsed or refractory acute myeloid leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_55_17275="Criteria avoidant personality";
var content_f16_55_17275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for avoidant personality disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Four or more of the following plus general criteria for personality disorder:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Avoids occupational activities that involve significant interpersonal contact because of fears of criticism, disapproval, or rejection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Is unwilling to get involved with people unless certain of being liked",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Shows restraint within intimate relationships because of the fear of being shamed or ridiculed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Is preoccupied with being criticized or rejected in social situations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Is inhibited in new interpersonal situations because of feelings of inadequacy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Views self as socially inept, personally unappealing, or inferior to others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Is unusually reluctant to take personal risks or to engage in any new activities because they may prove embarrassing",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17275=[""].join("\n");
var outline_f16_55_17275=null;
var title_f16_55_17276="ACC AHA ESC RFA accessory path";
var content_f16_55_17276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Radiofrequency catheter ablation (RFA) of accessory pathways",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that RFA of accessory pathways should be performed in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; Patients",
"with symptomatic atrioventricular (AV) reentrant tachycardia that is",
"drug resistant or the patient is drug intolerant or does not desire",
"long-term drug therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &bull;&nbsp; Patients with atrial fibrillation (or other atrial tachyarrhythmia) and a rapid ventricular response via the accessory pathway when the tachycardia is drug resistant or the patient is drug intolerant or does not desire long-term drug therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of benefit from RFA of accessory pathways should be performed in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; Patients",
"with AV reentrant tachycardia or atrial fibrillation with rapid",
"ventricular rates identified during electrophysiological study of",
"another arrhythmia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &bull;&nbsp; Asymptomatic patients with ventricular preexcitation whose livelihood or profession, important activities, insurability, or mental well being or the public safety would be affected by spontaneous tachyarrhythmias or the presence of the ECG abnormality.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; Patients with atrial fibrillation and a controlled ventricular response via the accessory pathway.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients with a family history of sudden cardiac death.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence that RFA of accessory pathways is not useful and may be harmful in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; Patients who have accessory pathway-related arrhythmias that are responsive to drug therapy, well tolerated, and preferred by the patient to ablation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Zipes, DP, DiMarco, JP, Gillette, PC, et al. ACC/AHA Guidelines for Clinical Intracardiac Electrophysiological and Catheter Ablation Procedures. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 1995; 26:555.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17276=[""].join("\n");
var outline_f16_55_17276=null;
var title_f16_55_17277="Accidental loss of FB";
var content_f16_55_17277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Potential complications of foreign body extraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 300px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    1. Foreign body becomes wedged distally, leading to postobstructive atelectasis 2. Loss of the foreign body complicated by 3. Obstruction of the contralateral mainstem bronchus or central airway, potentially causing asphyxia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17277=[""].join("\n");
var outline_f16_55_17277=null;
var title_f16_55_17278="Contents: Infections and infestations";
var content_f16_55_17278=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Infections and infestations",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Infections and infestations",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Bacterial infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33365\">",
"           Botryomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12825\">",
"           Cellulitis and erysipelas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29286\">",
"           Cutaneous manifestations of gonorrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21034\">",
"           Cutaneous manifestations of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/43/11959\">",
"           Erythrasma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21846\">",
"           Impetigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/362\">",
"           Necrotizing soft tissue infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/8/43142\">",
"           Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43831\">",
"           Skin abscesses, furuncles, and carbuncles",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bites/Stings/Infestations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/23/39286\">",
"           Bedbugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/34/43556\">",
"           Chigger bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/0/43016\">",
"           Jellyfish stings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25849\">",
"           Pediculosis capitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24339\">",
"           Pediculosis corporis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1511\">",
"           Pediculosis pubis and pediculosis ciliaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/2/28712\">",
"           Scabies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fungal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30648\">",
"           Candidal intertrigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7082\">",
"           Dermatophyte (tinea) infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5258\">",
"           Onychomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/47/31481\">",
"           Overview of Candida infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3320\">",
"           Tinea versicolor",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/33/538\">",
"           Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29098\">",
"           Fever and rash in the immunocompetent patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23097\">",
"           Gianotti-Crosti syndrome (papular acrodermatitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20152\">",
"           Skin lesions in the returning traveler",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31687\">",
"           Soft tissue infections following water exposure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/20/2378\">",
"           Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/38/23144\">",
"           Condylomata acuminata (anogenital warts)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/7/8312\">",
"           Condylomata acuminata (anogenital warts) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/40/26249\">",
"           Cutaneous warts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/10/9386\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/50/24359\">",
"           HIV-associated eosinophilic folliculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6842\">",
"           Molluscum contagiosum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21751\">",
"           Prevention of genital herpes virus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/32/7690\">",
"           Treatment of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36488\">",
"           Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33096\">",
"           Treatment of herpes zoster in the immunocompetent host",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-3950AACA4A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_55_17278=[""].join("\n");
var outline_f16_55_17278=null;
var title_f16_55_17279="Standarized height score by age at transplant";
var content_f16_55_17279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Standarized height score (Z score) by age at transplant from the NAPRTCS registry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 376px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Height Z score: the number of standard deviations from the mean height for age; NAPRTCS: North American Pediatric Renal Trials and Collaborative Studies.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2010 Annual Transplant Report. Available at: https://web.emmes.com/study/ped/annlrept/annlrept.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_55_17279=[""].join("\n");
var outline_f16_55_17279=null;
